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ABSTRACT 
 
Membranoproliferative glomerulonephritis (MPGN) is an uncommon cause of 
glomerular injury that mainly occurs in children and young adults. 
MPGN is currently classified in immune complex-mediated MPGN (IC-MPGN), 
characterized by activation of the complement classic pathway, and C3 Glomerulopathy 
(C3G), with predominant complement alternative pathway (AP) activation. C3G is 
further classified in Dense Deposit Disease (DDD) and C3 glomerulonephritis (C3GN). 
The first part of the thesis describes a large cohort of patients with IC-MPGN (n=96), 
DDD (n=26) and C3GN (n=77). Data obtained from genetic and biochemical analysis 
were correlated with histological and clinical parameters. We found that the majority of 
patients across the three histology groups (from 70 to 85 %) showed low C3 and normal 
C4. About 18% of patients carried likely pathogenic variants (LPVs) in complement 
genes, mainly in CFH regulatory gene and in C3 and CFB, encoding the two convertase 
components. Interestingly, two LPVs in THBD gene, were identified in two patients 
with C3G. C3NeF, an autoantibody stabilizing AP convertase, resulted abundant in 
DDD patients (79%) but was also present in patients with IC-MPGN (40%) or C3GN 
(39%).  
To classify IC-MPGN and C3G patients based on the underlying pathogenesis, a three-
step algorithm based on histological, genetic and biochemical data was used to classify 
patients in 4 clusters identifying 4 different pathogenetic patterns. 
In the second part of the thesis, copy number variation (CNV) studies, disclosed 
abnormal CNVs both in IC-MPGN and C3G. Interestingly, we describe, for the first 
time, genomic rearrangements involving the CFHR4 gene. Finally, Western Blot studies 
 in DDD patients showed the presence of abnormal FHR molecular pattern in patients 
with normal CNVs and without CFHR LPVs. 
In conclusion, the present study increased our understanding in IC-MPGN and C3G and 
provided new insights in the pathogenetic mechanisms underlying these complex 
glomerular diseases. 
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INTRODUCTION 
 
1. THE ROLE OF COMPLEMENT IN DENSE DEPOSIT DISEASE, C3 
GLOMERULONEPHRITIS AND IMMUNE COMPLEX-MEDIATED. 
1.1  The complement system 
The complement cascade is an immune-surveillance system that protects from pathogen 
invasion and participates in physiological processes to maintain tissue homeostasis. It 
consists of a series of proteins that are mostly synthesized in the liver, and exist in the 
plasma and on cell surfaces as inactive precursors then activated in a cascading manner. 
Complement system normally operates at a low steady state level of activation and is 
tightly controlled at each level by multiple complement regulators and inhibitors that 
discriminate between self and non-self surfaces. However, an inadequate balance 
between complement regulators and inhibitors have a pathologic role in several 
glomerular diseases15,16.  
Complement cascade can be initiated by three major activation pathways, the alternative 
(AP), the classical (CP), or the lectin (LP) pathway (Fig.1). The AP is spontaneously 
and continuously activated17. The CP is initiated by generation of antigen/antibodies 
complexes or by virus and Gram-negative bacteria18. The LP is triggered by 
carbohydrates on microbial or altered host surfaces19-21. The resulting activation from 
each pathway generates the C3 convertases, the first proteolytic complexes of the 
cascade (AP convertase, C3bBb, and CP and LP convertase, C4bC2a) that can cleave 
the component 3 (C3) into C3a and C3b. C3a acts as an anaphylatoxin. C3b covalently 
binds to surface membranes, e.g. intact host cells, microbial membranes and modified 
host surfaces (apoptotic cells or damaged tissues). On healthy host cells C3b can be 
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inactivated to generate iC3b by the protease Factor I (FI), in presence of complement 
regulators with factor I cofactor activity which include Factor H (FH), membrane 
cofactor protein (MCP/CD46), and Complement receptor 1 (CR1/CD35). 
Thrombomodulin (THBD), an ubiquitous transmembrane endothelial-cell glycoprotein, 
binds C3b and, in presence of FH,  facilitates FI-mediated C3b inactivation22. 
In contrast, on microbial or apoptotic cells, complement regulators are not present and 
therefore complement activation is not controlled. C3b can generate, in presence of 
Factor B (FB) and Factor D (FD), additional C3 convertase, thereby amplifying the 
deposition of C3b through “the amplification loop”. The AP C3 convertase is stabilized 
by properdin (FP). Accumulation of C3b favors the generation of C5convertases (AP 
convertase, C3bBbC3b, and CP and LP convertase, C4bC2aC3b), the second 
proteolytic complexes of complement cascade, that process the C5 into the potent 
anaphylatoxin C5a and C5b. C5b recruits complement components C6, C7, C8 and 
multiple molecules of C9 to the surface to assemble the terminal complex C5b-9 (TCC) 
which can be soluble (sC5b-9) when formed in the fluid-phase or inserted into a 
membrane (membrane attack complex; MAC) leading to pore formation and cell lysis23-
25. 
On healthy host cells each step of complement system is also controlled by soluble or 
membrane regulators. Among soluble proteins C1 inhibitor (C1-INH) and C4b-binding 
protein(C4BP) regulate the CP and LP, while FH and FI control AP. Factor H, besides 
its cofactor activity for FI-mediated cleavage of C3b to iC3b, accelerates the decay of 
the AP C3 convertase, C3bBb. Vitronectin (VN; also known as S Protein) and Clusterin 
(Cl) bind soluble nascent C5b-7/8/9 complexes, blocking their incorporation into cell 
membranes and forming soluble complexes commonly indicated as "SC5b-9"26. 
Membrane proteins include the convertase regulators represented by CR1, MCP and 
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decay accelerating factor (DAF) and the terminal pathway regulator CD59 (or protectin) 
that binds C5b-8 complexes, inhibiting the recruitment of C9, thus preventing MAC 
formation.  
Furthermore, interactions between complement and coagulation systems have been 
proposed although the molecular pathway of this interplay is still unclear. Some 
coagulation factors have effects on complement system. Factor (F) Xa, FXIa and 
plasmin may cleave both C3 and C5 causing subsequent generation of C3a and C5a. 
Kallikrein cleaves selectively the C5. Factor XIIa activates C1q and thereby the 
complement CP while C1-INH inhibits the endogenous coagulation pathway 
(Kallikrein, Factor XIIa) and also classical and lectin complement pathways (CP:C1qrs; 
LP: MBL)27-29.  
The anaphylatoxins, C3a and C5a, are chemoattractants for neutrophils and other 
leukocytes in the site of inflammation and exhibit potent proinflammatory properties. 
These include smooth muscle contraction, increased capillary permeability and release 
of histamine from basophils and mast cells30. These effects are mediated by binding to 
their specific receptors, C3aR and C5aR. The activity of anaphylatoxins is abolished by 
carboxypeptidase N,  which cleaves the carboxy-terminal arginine residue of C3a and 
C5a, generating desarginated forms termed C3a(desArg) and C5a (desArg). The 
biological activity of these forms is significantly reduced in comparison that of their 
full-length forms31. C3a and C5a are also inactivated by thrombin activatable 
fibrinolysis inhibitor (TAFI), a plasma procarboxypeptidase B activated both by 
thrombin and thrombomodulin22, 32, 33. 
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Figure1. Schematic representation of Complement System activation taken from 
Ricklin et al. (2017)7. 
Complement system can be initiated by three pathways. The classical pathway 
(CP) is activated when C1q (part of the penta-molecular complex C1qr2s2 of the 
first complement component C1) recognizes antibodies bound to their 
corresponding antigens with consequent activation of the proteases C1r and C1s. 
The latter cleaves C4 into C4a and C4b that covalently binds to surfaces close to 
site of activation. C1s also cleaves C2 in C2a and C2b. C4b on surfaces binds 
C2a, generating the C3 convertase of classical pathway (C4bC2a). The lectin 
pathway (LP) begins after the interaction between Mannan-Binding Lectin 
(MBL) and mannose residues of bacterial surfaces acting serine proteases 
(MASP1 and MASP2) that, similarly to C1s, cleaves C4 and C2 producing C3 
convertase, C4bC2a. LP can be also activated by ficolins and collectins. The  
alternative pathway (AP) is spontaneously and continuously activated by C3 
hydrolysis to form C3H2O that binds the Factor B protease (FB). Bound FB is 
cleaved by Factor D (FD) producing the AP convertase C3 H2O convertase, 
C3H2OBb. C3H2OBb cleaves the C3 into the anaphylatoxin C3a and in the opsonin 
C3b. Surface-bound C3b can generate, in presence of FB and FD, additional C3 
convertase, amplifying the deposition of C3b through “the amplification loop”.  
AP C3 convertase is stabilized by properdin, FP. Increased deposited C3b 
produced by the amplification loop, is bound by C3 convertases C4b2b and 
C3bBb to form larger complexes called C5 convertases, C4b2bC3b 
andC3bBbC3b. These proteolytic complexes process the C5 into C5a (a strong 
anaphylatoxin) and C5b. The latter recruits other complement component (C6, 
C7, C8 and C9) to the surface to assembly the terminal C5b-9 complex or  the 
membrane attack complex (MAC). MAC forms pores causing cell lysis.  
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1.2  The renal glomerulus 
The main function of the kidney is to filter the blood and concentrate metabolic waste to 
produce the urine. Production of urine is made in the nephron, the functional unit of the 
kidney. An average of 1 million up to 2.5 million of nephrons are contained in an adult 
human kidney34 and contribute to filter about 140 liters of primary urine to produce 
about 1 liter of urine per day. Each nephron extends through the kidney cortex and 
medulla areas and is composed of the renal corpuscle, glomerular tubule and collecting 
tubules (Fig.2).  
 
 
 
 
The glomerulus is an intertwined group of capillaries surrounded by a cup-like sac 
called Bowman's capsule. Together the glomerulus and Bowman's capsule are known as 
the renal corpuscle. The area between glomerular capillaries and Bowman's capsule is 
Figure 2. Image representing the nephron, the functional unit of kidney. 
Image taken from UNC kidney Center website. 
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called Bowman's space and has the role to collect the primary urinary filtrate produced 
by the glomerular filtration barrier (GFB). 
The GFB is composed by Glomerular Endothelial Cells (GECs), the glomerular 
basement membrane (GBM) and podocytes (Fig.3). 
 
 
 
 
 
1.2.1 Glomerular Endothelial Cells 
During filtration, blood enters the afferent arteriole and flows into the glomerular 
capillaries characterized by transcellular pores, known as fenestrae,  that are in the order 
of 60-100nm of diameter. These pores comprise 20-50% of the endothelial surface and 
Figure 3. Image modified from Jefferson et al. (2008)12 representing the 
glomerular structure. 
Bowman's capsule 
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allow water and small solutes to pass into the Bowman's space, retaining large proteins 
as albumin35,36. Numerous studies demonstrated that the filtration capability of 
glomerular endothelium is due to its negatively charged surface. Indeed, the luminal 
side of glomerular capillaries and fenestrated surfaces are covered by a layer of 
negatively charged glycoproteins, called glycocalyx37,38. In addition, the absorption of 
plasma components in the  glycocalyx, creates a larger coat called endothelial surface 
layer (ESL)39. Reduced ESL depth and loss of negative charges on endothelial cells 
caused by enzymatic destruction of ESL components, results in increased albumin 
excretion. This demonstrates the important role of ESL in glomerular filtration40, 41, and 
is confirmed in animal models42,43. 
 
1.2.2 Glomerular basement membrane 
Glomerular basement membrane (GBM) is the extracellular matrix, situated between 
the fenestrated endothelial cells and podocytes. Although proteomic studies revealed the 
presence of 144 proteins in human glomerular extracellular matrix (GBM included)44,45 
the most abundant macromolecules are type IV collagenα3α4α5, laminin-β2, nidogen 
and the heparan sulfate proteoglycan agrin. Together, these produce a lattice with size- 
and charge-selective properties. In addition, GBM may contain pro-angiogenic ligands 
and secreted factors that play a role in the communication between GECs and 
podocytes. Adhesive interactions of GECs and GBM favor the adhesion of podocytes to 
GBM giving a stabilization of filtration barrier. 
The GBM proteins are important in glomerular development, morphology and function 
so that mutations in genes that encode these proteins cause human kidney diseases.  
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Alport syndrome (AS) is a genetic disorder, characterized by hematuria, proteinuria and 
progression to end-stage renal disease (ESRD) determined by an incomplete maturation 
of GBM. These patients have mutations in the genes of COL4A3, COL4A4 and COL4A5 
encoding the type IV collagen subunitsα3, α4, α5, respectively. During the development 
of GBM, the α1α1α2 type IV collagen is substituted by α3α4α5 type IV collagen 
complex that gives long-term stability to the GBM46,47,48. In the GBM of AS patients, all 
three α3, α4, α5 subunits of collagen IV are absent although only one of these chains 
result mutated, while the α1 and α2 chains are strongly expressed across  the entire 
GBM. Abnormalities in the GBM are also responsible for Goodpasture's disease, 
an autoimmune condition characterized by pulmonary alveolar hemorrhage and anti-
GBM antibodies that target the α3 subunit of type IV collagen located in the renal 
glomerulus and causing progressing glomerulonephritis49. 
Mutations in the gene LAMB2, encoding the laminin-β2, a protein expressed in the 
GBM to anchor and differentiate podocyte foot processes, causes Pierson syndrome50. 
Loss of membrane integrity causes proteinuria leading to ESRD often with an early-
onset. Since laminin β2 is also present in nervous system and in the ocular connective 
tissue, mutations in LAMB2 cause also blindness and neurodevelopment problems51.  
Nidogens, (also known as entactins), are two glycoproteins found in the GBM and are 
encoded by two different genes. Since Nidogen-1 binds to both laminin-γ1 and type IV 
collagen, it has been hypothesized that it acts as a bridge to connect the laminin to type 
IV collagen. However, mutant nidogen-1 and nidogen-2 mice showed normal basement 
membranes52, 53 though double nidogen knockout mice resulted in perinatal lethality54.  
These findings indicate that nidogens confer extra stability to GBM under unusual 
stress, but they are not essential for their initial formation55.  
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Heparan sulfate proteoglycans (HSPGs) are characterized by a sulfated 
glycosaminoglycan side chains bound to a protein core. Agrin is the most abundant 
HSPG in the GBM56and through its glycosaminoglycan chains gives a negative charge 
to GBM suggesting a role in the charge selectivity of GFB and interactions with 
adjacent cells. In addition, heparan sulfate side chains may bind and sequester growth 
factors, as the VEGF produced by podocytes. However, in Agrn knockout mice, a 
reduction of GBM anionic charge was detected but with normal function of the GBM. 
In addition, the in-vivo treatment with heparanase to destroy heparan sulfate side chains 
did not cause proteinuria57. These findings indicate that agrin and the negative charge of 
the GBM are not so crucial in the charge selectivity of GFB58. 
 
1.2.3  Podocytes 
Podocytes (or visceral epithelial cells) are the most abundant glomerular cells and 
express an elaborate octopus-like cytoarchitecture, specialized in the blood 
ultrafiltration. On the basis of structure and function characteristics, podocytes are 
composed of a main body, major processes and foot processes (FPs). The main body 
contain the nucleus and other organellus such as Golgi apparatus, rough endoplasmic 
reticulum, mitochondria and lysosomes. Podocyte cell bodies with their FPs cover the 
outer side of GBM, facing the Bowman's capsule and the primary urine59. The cell body 
is separated from the GBM by a subpodocyte space that confer dynamic properties 
which modulate capillary permeability and influence the response to inflammation60. 
FPs of adjacent podocytes interdigitate, leaving between them the filtration fissures that 
are bridged by intercellular junctions that constitute a structure called slit diaphragm 
(SD; Fig.3). Foot processes are characterized by an highly regulated actin cytoskeletal 
network while SD is composed by several molecules, including nephrin, CD2 
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associated protein (CD2AP), protocadherin Fat 1( FAT1), tight junction protein 1 (also 
known as ZO-1), P-cadherin, Podocin and Kin of IRRE-like protein 1-2 ( also known as 
Neph 1-3, respectively), some of them are important for SD integrity61. Nephrin is a 
transmembrane protein that by its extracellular domain forms homodimers with nephrin 
from an adjacent podocyte or heterodimers with neph-1. These interactions  are 
important to maintain the permeability characteristics of the SD62,63 . In addition, 
nephrin, through its intracellular domain, interacts with podocin and other regulatory 
proteins to promote actin polymerization64. Inactivating mutations in the genes encoding 
for nephrin and podocin (NPHS1 and NPHS2) cause congenital nephropathy 
characterized by collapse of FPs and the absence of SDs, an hallmark of podocyte injury 
correlated with proteinuria65,66. 
Podocytes with glomerular basement membrane and endothelial fenestrated cells form 
the glomerular filtration barrier promoting the filtration of small solutes, electrolytes 
and cationic molecules and limiting the passage of macromolecules and cationic 
molecules64, 67. 
Podocytes have also the important role to promote the proliferation, survival and the 
development of endothelial cells through the production of pro-angiogenic factors as 
VEGF, Angpt 1 and SDF168. 
The majority of cases of glomerular proteinuria are accompanied by a shape change of 
podocytes, called foot processes effacement (FPE). This consists of the retraction of 
foot processes into the cell bodies. Proposed mechanisms causing FPE involve slit 
diaphragm loss69, podocyte cytoskeleton disruption70,71 or abnormal podocyte-GBM 
interactions72,73. Since experimental models with proteinuria in absence of FPE and vice 
versa have been reported63,74-78 it has been hypothesized that foot processes effacement 
alone do not cause proteinuria but may represent a consequence of podocyte injury12. 
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1.2.4 The Mesangium 
The mesangium, an important component of glomerular structure, has the main role to 
provide structural and functional support to the GBM.  On the capillary lumen side the 
mesangium is in direct contact with glomerular endothelial cells and is composed by 
mesangial cells (MCs) and extracellular matrix. Mesangial cells are separated from 
podocytes by GBM and, like smooth muscle cells, have a contractile activity  that may 
be responsible for glomerular distensibility in response to pressure79, 80. 
Mesangial cells generate their own extracellular matrix, which is hypothesized to give 
support for glomerular capillaries. The mesangial extracellular matrix is composed by 
collagens type I, III, IV and V, laminin, fibronectin, heparan sulfate proteoglycans  and 
chondroitin sulfate proteoglycans. Mesangial cells have been reported to synthesize 
growth factors (like interleukin IL-1, platelet-derived growth factor PDGF, insulin-like 
growth factor IGF), cytokines (including transforming growth factor-β, TGF-β), 
adhesion molecules, chemokines, and vasoactive factors (as angiotensin-II). 
Experimental data showed that the survival of MCs depends precisely on PDGF81,82 
while mesangial matrix expansion, typical of diabetic glomerusclerosis, appeared to be 
under TGF-β control83. 
Mesangial cell proliferation and matrix expansion are typically associated with several 
diseases such as IgA nephropathy, diabetic nephropathy, mesangioproliferative 
glomerulonephritis, and systemic diseases such as lupus nephritis. Indeed, mesangial 
matrix expansion, cause a reduced glomerular capillaries area, and may eventually 
obstruct the lumen capillary (Fig.4)84,36,85. 
Introduction 
 
 
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Images modified from Reidy et al. (2014)11. 
Comparison of glomerulus organization between the 
healthy glomerulus (on the left) and glomerulus with 
Diabetic kidney Disease (DKD; on right). The latter is 
characterized by mesangial expansion, collagen deposition, 
GBM thickening, podocyte loss and hyperthrophy, 
podocyte foot processes effacement and albuminuria.    
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1.3  Diagnosis and pathogenesis of C3 glomerulopathy and IC-MPGN 
Membranoproliferative glomerulonephritis (MPGN) is a kidney disorder that mainly 
affects children and young adults but can occur at any age. The clinical presentation and 
course are variable with patients presenting with asymptomatic hematuria and 
proteinuria, hypertension, nephritic or nephrotic syndrome, chronic kidney disease or a 
rapid progressive glomerulonephritis. Primary idiopathic MPGN is rare with a 
prevalence of 6 cases per 100,000 European people. The pathogenesis of primary 
MPGN is ill defined. Hypocomplementemia is a very common finding. Secondary 
MPGN is most often due to autoimmune diseases, chronic infections and 
malignancies86. 
MPGN diagnosis requires a kidney biopsy. The typical features of glomerular injury on 
light microscopy (LM) includes an increase in mesangial cellularity and matrix with 
thickening of the peripheral capillary walls by subendothelial immune deposits and/or 
intramembranous dense deposits and mesangial interposition into the capillary walls87. 
Traditionally, MPGN classification was based on Electron Microscopy studies (EM). 
The most common variant was the MPGN type I, characterized by the predominant 
presence of subendothelial deposits. MPGN type II (also known Dense Deposit Disease, 
DDD) indicated the presence of highly electron dense deposits within (i.e. 
intramembranous) the basement membrane. The term MPGN type III was used to 
describe cases with both subendothelial and subepithelial deposits1,88. 
The current MPGN classification is based on Immunofluorescence studies (IF) and 
distinguishes immune-complex mediated MPGN (IC-MPGN) from C3 Glomerulopathy 
(C3G). IC-MPGN is characterized by glomerular C3 and significant immunoglobulin 
deposition including IgG, IgM, IgA and C1q. Association between IC-MPGN and 
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complement classical pathway activation is based on the presence of chronic 
antigenemia, with antigen-antibody immune complexes caused by chronic viral and 
bacterial infections (as hepatitis C, hepatitis B and endocarditis), elevated levels of 
circulating immune-complexes due to autoimmune diseases (as lupus erythematosus, 
Sjögren’s syndrome and rheumatoid arthritis) or paraproteinemias due to monoclonal 
gammopathies13, although in some IC-MPGN cases an underlying cause cannot be 
identified3.  
 
In C3 Glomerulopathy, IF pattern is typically characterized by dominant C3 staining 
with no or scanty immunoglobulins. Dominant C3 is defined as "C3c intensity ≥ 2 
orders of magnitude more than other immune-reactant on a 0 to 3 scale"89 (Fig.5). 
Electron microscopy (EM) provides different appearances allowing a C3G 
subclassification in Dense Deposit Disease  (DDD, with dense osmiophilic mesangial 
and intramembranous electron dense deposits) and C3 glomerulonephritis (C3GN, with 
light dense, amorphous mesangial, subendothelial, subepithelial electron deposits)90 
(Fig.6).  
Acquired partial lipodystrophy (APL) and extracellular retinal deposits (drusen) have 
been reported both in DDD and C3GN91-93. 
 
 
 
Figure 5. Immunofluorescence microscopy images modified from Houet al. 
(2014)5. Biopsy from a patient with C3 Glomerulopathy (Dense Deposit 
Disease) showing 3+ glomerular capillary wall and mesangial C3 staining 
(panel A) with 1+ of IgG (panel B).  
DDD  DDD  
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A distinct form of C3GN is represented by CFHR5 Nephropathy, identified in two large 
families with reported ancestry from the Troodos mountains of Cyprus. Patients present 
with renal failure, C3 glomerulonephritis, synpharyngitic macroscopic hematuria, 
persistent microscopic hematuria and show an internal duplication in the gene of Factor 
H-related 5 (CFHR5)94. 
 
Hyperactivation of the complement alternative pathway (AP) appears to be a primary 
cause of C3G2, and may be caused by both acquired and genetic factors. Indeed, the C3 
nephritic factor (C3NeF), an autoantibody that stabilizes the C3 convertase, is present in 
around 80% and 45% of  DDD and C3GN patients, respectively2,95. Anti-factor B and 
anti-factor H autoantibodies have been also reported in a few cases96-100.  Rare 
functional variants (var) in genes coding the AP complement regulators Factor H (CFH) 
Figure 6. Electron microscopy images modified from Noris and 
Remuzzi, (2015)3. 
The image of panel A shows the presence of osmiophilic wavy dense 
deposits in the GBM and also in the mesangium (arrows) of glomeruli 
from a patient with DDD. In panel B, the arrows indicate 
intramembranous and subendothelial deposits in glomeruli from a 
patient with C3GN. 
DDD  C3GN 
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and Factor I (CFI) and gain of function var in the genes encoding the two components 
of the AP C3 convertase, complement C3 (C3) and  Factor B (CFB) have been 
reported4,95,101,102 (Fig.7).  
However, publications suggest that this new classification is not all-encompassing and 
that complement AP dysregulation may also play a role in the pathogenesis of IC-
MPGN. Indeed, genetic or acquired abnormalities leading to dysregulation of the AP 
have been found both in C3G and IC-MPGN patients, suggesting the presence of still 
unknown commonalities underlying the AP dysregulation in patients with DDD, C3GN 
and IC-MPGN95, 103. 
 
 
 
 
 
Figure 7. Images modified from Sethi et al. (2012)13 representing  the schematic 
model of normal glomerular capillary wall (upper panel) and the complement 
activation with consequent glomerular damage in immune complex-mediated 
MPGN (IC-MPGN; left panel) and C3 Glomerulopathy (C3G; right panel). 
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1.4 Genetic drivers of C3G and IC-MPGN 
1.4.1  Complement gene variants 
The fact that familial forms have been reported both in C3G and IC-MPGN104 indicates 
that genetic abnormalities may play a role in determining predisposition to these 
diseases. Absence of FH in plasma in association with type I and II MPGN has been 
reported in humans105-109, in mutant CFH deficient pigs110 and in Cfh−/− mice111.  
FH is a plasma protein produced mostly by the liver that plays a central role in the 
regulation of the AP of complement both in fluid phase and on cellular surfaces by 
binding to C3b, destabilizing the AP convertase, C3bBb. In fluid phase this interaction 
results in dissociation of C3bBb and in irreversible inactivation of C3b to iC3b by 
Factor I. On cell surfaces FH competes with Factor B (FB) to bind to C3b−targeted 
surfaces and also favors the degradation of bound−C3b by cofactor activity. Both in 
patients and in pigs, FH deficiency was due to homozygous (ho) or compound 
heterozygous (he) CFH  rare functional variants 105-109 that determine block of protein 
secretion, or secreted proteins that have severely reduced cofactor and decay 
accelerating activity. Absence of FH in plasma causes sustained activation of the AP of 
complement reflected by consumption of C3 and accumulation of C3 degradation 
products and is associated with an early onset. However, heterozygous CFH var and 
normal FH levels have been reported in MPGN I and C3G patients95, 103. Recently, rare 
functional variants in other complement regulatory genes CFI, MCP and gain of 
function var in the genes C3 and CFB have been identified in a large cohort of patients 
with primary IC-MPGN and C3G4,95,101-103. Low frequency of rare functional variants 
has been reported in the gene encoding thrombomodulin (THBD), an anticoagulant 
glycoprotein that also accelerates FI-mediated C3b inactivation103. Of interest, 
prevalence of var was similarly distributed in IC-MPGN (16%) and C3G (20%) 
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underlining the common AP dysregulation implicated both in the pathogenesis of some 
cases of IC-MPGN and C3G. 
Among C3 variants, functional studies have been reported only for two of them. 
Martìnez-Barricarte et al. demonstrated the two aminoacid deletion of C3 (∆923-
924AspGly), found  in heterozygosity in a DDD pedigree, is a gain of function variant 
causing an uncontrolled C3 activation in the fluid phase. By functional studies they 
proved that mutant C3, the predominant circulating C3 protein in the patients, generated 
an active C3 convertase that cleaved wild-type C3 and that was resistant to decay by 
FH. Moreover, mutant C3b was resistant to proteolysis by FI in presence of FH.  
Altogether these abnormalities caused a continuous activation and consumption of C3 
produced by the normal allele indicating that fluid-phase complement dysregulation can 
be caused not only by abnormalities in AP regulatory proteins, like FH, but also by 
components of the AP C3 convertase generating a convertase resistant to FH-
inactivation101. In 2016, Chauvet et al, characterized a C3 missense mutation (p.I734T), 
present in heterozygosity in two related C3GN individuals with normal C3 levels, 
generating a functional C3 convertase normally regulated by FH. Assays using 
recombinant proteins showed a decreased binding of mutant C3 to complement receptor 
1 (CR1), a regulator highly expressed on podocytes. By cellular models of complement 
activation the authors demonstrated that serum from patients caused an high deposition 
of C3 fragments on glomerular endothelial cells (GEnC) and podocytes indicating that 
this C3 variant causes a cell surface AP dysregulation, and evidencing podocytes as 
targets of complement in C3GN112.  
Rare variants in the gene encoding CFB have been described in a familial case of 
C3GN113 and in IC-MPGN patients103 although their functional effects are still 
unknown.  
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Common single nucleotide polymorphisms (SNPs) have been studied in IC-MPGN and 
C3G. Among CFH SNPs, the p.Y402H (c.1204T>C; rs1061170), that has been shown 
to be a susceptibility factor for age−related macular degeneration114,  is reported to be 
over-represented in DDD compared with controls95,115,116 while the p.V62I (c.184G>A; 
rs800292) resulted protective in patients with C3G (including DDD and C3GN)103. 
Functional studies revealed that the H402 may determine lower binding of FH to 
glycosamminoglycans (GAGs) and, as a consequence, lower protection of cell  surfaces 
from complement attack114,117,118 while the I62 increases binding affinity for C3b and 
enhances cofactor activity with the resulting reduction of AP activation. 
Association studies revealed that the CFH-H1 haplotype including FH-H402 ( c.-331C, 
c.184G, c.1204C, c.2016A and c.2808G) is associated with DDD while the CFH-H2 
(331C, c.184A, c.1204T, c.2016A and c.2808G) haplotype is decreased in DDD  
supporting the protective effect of the FH-I62 variant (Table 1)14, 119. 
Servais et al. in 2012 identified one at-risk MCP haplotype (named MCPaaggt: c.-652A, 
c. -366A, c.944-78G, c.1082+638G, c.*783T) for C3GN and MPGN I. Recently, 
Iatropoulos et al. observed an higher frequency of MCP c.-366A and the c.*783T 
variants in patients with IC-MPGN compared with controls. Likewise, the allele c.-
366A resulted significantly over expressed in DDD compared with controls.  
These results highlight that common variants in MCP, which is expressed on endothelial 
and mesangial cells and participates in the generation of the C3 metabolite iC3b, 
influence the glomerular pattern of patients presenting fluid-phase activation of 
complement95. 
For the first time Iatropoulos et al., reported a significant association between C3G 
patients and the THBD A473 allele103. THBD is an anticoagulant glycoprotein 
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expressed by glomerular endothelial cells that binds C3b and FH enhancing FI-mediated 
C3b inactivation22. Increased thrombomodulin expression was found in kidney biopsy 
of MPGN patients probably as a protective response to neutralize the complement 
hyperactivation occuring on MPGN glomerular cells120,121. 
Finally, two SNPs in C3 (C3p.R102G and C3 p.P314L), are associated with DDD116. 
Alternative complement activity assay in genotyped controls showed that the presence 
of the risk allele C3 p.G102 or p.L314 increased the complement activity in comparison 
of C3 p.R102 or p.P314, respectively.   In addition, the C3 p.L314 risk allele showed a 
synergic effect with the above described FH risk alleles p.H402 and p.V62 indicating a 
complotype associated with DDD116. These data are consistent with the functional 
studies reporting that FH bound C3b102G with less efficiency in comparison to 
C3b102R and that FI cofactor activity to inactivate C3b102G was decreased resulting in 
an overall increased AP activity of C3b102G122. 
Haplotype 
c. -331C>T 
rs3753394 
 
c.184G>A  
(p.Val62Ile) 
rs800292 
c.1204T>C 
(p.Tyr402His) 
rs1061170 
c.2016A>G 
(p.Gln672Gln) 
rs3753396 
c.2808G>T 
(p.Glu936Asp) 
rs1065489 
CONTROLS 
Frequency 
n=317 
DDD 
Frequency 
n= 16 
H1 C G C A G 0.257 0.47 
H2 C A T A G 0.203 0.12 
H3 T G T G T 0.207 0.16 
H4a C G T A G 0.139 0.09 
H4b T G T A G 0.070 0.06 
H5 T G C A G 0.037 - 
H6 C G T A G 0.021 0.06 
H7 T G T A G 0.016 - 
H8 C G T G T 0.015 - 
 
 
 
 
Table 1. Haplotypes of CFH and association with DDD. (Data from de Còrdoba and 
Goicoechea, 200814). H1 haplotype (in red) is associated with DDD while H2 haplotype 
(green) is less present in DDD than in controls suggesting a protective effect. 
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1.4.2  Genomic rearrangements in RCA cluster 
In the regulator of complement activation (RCA) gene cluster on chromosome 1, 
downstream of CFH, are located five factor H-related genes (CFHRs). This genomic 
segment is characterized by several large regions of sequence similarity (Fig 8).  
 
 
 
 
CFHR genes derive from CFH gene by tandem duplication events and encode the five 
Factor H-related proteins (FHRs)123. These proteins, organized in short consensus 
repeats (SCRs), are mainly produced in the liver and, with the exception of FHR4, 
circulate in plasma in glycosylated isoforms. The two N-terminal domains of all five 
FHRs proteins share an high degree of sequence (36-94%) while the C-terminal 
domains show an high sequence homology with the C-terminal of FH (36-100%)124 
(Fig.9). Factor H, through its C-terminal domains (SCR 18-20) and SCR7 binds 
complement C3b, heparin, glomerular basement membrane (GBM), bacterial ligands 
a 
b 
c 
Figure 8.  Regulator of complement activation (RCA) gene cluster. Images 
modified from de Cordoba, Immunobiology, 20128. The RCA gene cluster is 
located on chromosome 1 (panel a) and the five CFHR genes are downstream of 
CFH (panel b). The coloured boxes in panel c indicate the sequence repeats, 
labelled with the same letter (i.e., B, B’, B"). The vertical lines represent the exon 
position of CFH and CFHRs genes.  
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and glycosaminoglycans (GAGs) while its N-terminal region has a complement 
regulatory function through cofactor and decay accelerating activities.  
 
 
 
 
The homology between C-terminal domain of FH and FHR proteins suggests that FHRs 
can similarly bind surface ligands as FH but since they lack the N-terminal complement 
regulatory domains of FH do not have a similar direct complement regulatory activity.  
Nevertheless some in vitro studies reported factor I cofactor activity for FHR3 and 
FHR4125 and FHR5126. FHR5 have been also reported to inhibit C3 convertase though 
Figure 9. The Factor H (FH) and Factor H-related (FHR) proteins are 
aligned based on their homology. The percentage indicate the sequence 
similarity taken from Jozsi et al, (2015)9. 
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very high concentrations required to observe complement regulation by FHR5 
interrogate about its biological relevance. Inhibition of C3 convertase and terminal 
complement complex assembly, but not factor I cofactor activity, have been reported for 
FHR2127 while C5 convertase inhibition have been described for FHR1128. 
Native factor H-related (FHR) proteins can compete with FH for binding to C3b and 
other C3 activation fragments. In 2013 Goicoechea et al. showed that FHR1, FHR2 and 
FHR5 circulate in plasma as homo and hetero-oligomeric complexes, the formation of 
which is mediated by the conserved N-terminal domains129, 130. This dimerization 
significantly enhances avidity of FHRs for their ligands that, by competing with FH,  
prevents the normal complement  regulatory function of FH in a process termed "FH 
deregulation". 
The presence of several large regions of sequence similarity in the RCA cluster favors 
genomic abnormalities including genetic rearrangements, duplications and deletions131. 
Indeed, genomic rearrangements in CFHRs have been described both in DDD and 
C3GN94,130,132-135,136 (Table 2).  
In 2010 Gale et al. described an internal duplication of exons 2 and 3 of CFHR5, 
encoding the first two N-terminal domains, in Greek Cypriot patients with CFHR5 
nephropathy94. The same duplication, with a different DNA breakpoint, has been 
reported in a C3G British family without Cypriot ancestry134. A similar FHR5 protein, 
derived from the deletion involving exon 4 and 5 of CFHR2 that generates a hybrid 
protein between the first two SCRs of FHR2 (that have 91% and 85% of sequence 
homology with the first two SCRs of FHR5) and the full-length FHR5 was identified in 
a C3G-DDD familial case132. Malik et al. described in a C3GN family a heterozygous 
deletion involving exons 4-6 of CFHR3 and exon1 of CFHR1 producing a hybrid 
protein composed of the first two SCRs of FHR3 linked to full-length FHR1133. An 
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internal duplication of CFHR1 resulting in the duplication of FHR1 SCR1 to SCR4  was 
found in a Spanish family with C3G130. In a patient with familial C3GN, a hybrid 
protein containing the first two SCRs of FHR5 followed by all SCRs of FHR2 was 
found135. Recently, a large deletion involving CFHR1, CFHR2 and CFHR4  leading to a 
FHR1-R5 hybrid protein has been described  in a familial dominant form of C3G136. 
Most DDD/C3GN associated hybrid FHR proteins are characterized by duplication of 
the dimerization motifs, which result in the formation of large multimeric complexes 
leading to an increased affinity for surface bound C3b and enhanced competition with 
FH9,124,136-138. Interestingly, in patients carrying three of these hybrids, circulating C3 
levels were normal, indicating local alternative complement dysregulation within the 
glomeruli rather than in the circulation94,133,135.  
 
 
 
 
Table 2.  List of genomic rearrangements identified in C3GN and DDD. 
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1.5 Acquired drivers of C3G and IC-MPGN 
The commonest acquired factor associated with MPGN is C3 Nephritic factor (C3NeF), 
an auto-antibody directed against the AP C3 convertase (C3bBb). The binding of 
C3NeF to C3bBb stabilizes the complex and prolongs its half-life, preventing 
degradation by its normal inactivators such as FH, resulting in complement activation 
and chronic consumption of C3139. C3NeF presence is equally distributed in IC-MPGN 
and C3GN patients although the highest prevalence (around 80%) is in DDD patients95, 
103. C3 nephritic factors have been also observed in APL140 and in healthy 
individuals141. In around 3% of C3G patients,  a C4NeF has been identified. This is an 
auto-antibody that stabilizes the CP and LP convertase, C4bC2a, preventing the normal 
convertase decay mediated by CR1 and C4BP142, 143. C4NeF has been also associated 
with post-infectious glomerulonephritis, systemic lupus erythematosus and 
meningococcal infections144-146. Recently, Marinozzi et al, described auto-antibodies 
stabilizing the C5 convertase (C5 Nephritic Factors, C5NeFs) in around 50% of C3G 
patients. C5Nephritic Factors were predominantly identified in C3GN compared to 
DDD patients and often in concomitance with C3NeFs.  Both C3NeFs and C5NeFs 
correlated with low C3 levels while only C5NeFs correlated with high SC5b-9 levels147. 
Auto-antibodies against FH have been reported in MPGN and C3G. In the French 
cohort, 11% of C3G patients were positive for anti-FH autoantibodies100. These 
autoantibodies predominantly bind to the N-terminal domain148,149, preserving FH 
binding to cell surfaces and often are associated with the presence of C3NeF in 
children149 or with monoclonal gammopathy in adults100,150. 
In 2010, Strobel et al reported the presence of an autoantibody that bound FB in a DDD 
patient. FB antibody binds both the native FB and the Bb fragment that is part of C3 
convertase, making it more stable to FH-mediated decay and increasing C3 
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consumption. However, the anti-FB antibody reduces in vitro the C5 convertase 
activity, possibly by preventing the binding of additional C3b molecules to C3 
convertase. However, in vivo studies indicated that not all C5 convertases are 
inhibited96. Factor B auto-antibodies have been found in additional DDD patients151and 
also in association with auto-antibodies to C3b99. 
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1.6 Association of C3G/IC-MPGN with other diseases. 
1.6.1 Acquired partial lipodystrophy 
Acquired partial lipodystrophy (APL) is a rare condition characterized by progressive 
loss of fat in the upper part of the body and in the face. It commonly affects girls and 
usually begins during childhood. In 2004, Misra et al described low C3 levels and the 
presence of C3NeF in about 83% of patients with APL. About eight years after the APL 
onset, 22% of patients developed DDD91. Although the pathogenesis of fat loss and 
DDD is not clear, the AP dysregulation on kidney and adipose tissue appears to be the 
basis of the association between DDD and APL152. Adipocytes express Factor D and 
other complement proteins and the abnormal complement AP activity, caused by 
C3NeF,  may result in adipocyte destruction, leading to APL152. 
1.6.2  Ocular Drusen 
Non-renal manifestations of DDD include ocular drusen. Drusen are lipoproteinaceous 
deposits of complement-containing debris localized between retinal pigment epithelium 
and Bruch’s membrane137. The presence of ocular drusen in patients with DDD appears 
to be determined by structural and functional similarities between Bruch’s membrane, 
and glomerular basement membrane (Fig.10)93. 
Ocular drusen are the early-age hallmark of Age-related Macular Degeneration 
(AMD)153, the most common cause of acquired visual disability in the industrialized 
world. No correlation has been reported between disease severity in the kidney and in 
the retina1. However, unlike AMD, drusen in patients with DDD occur at a young 
age137, mainly in the second decade of life and initially has little impact on vision 
suggesting the need of ophthalmologic examination at the time of kidney diagnosis and 
a periodic fundoscopic examination1. 
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In 2009 Han et al,  reported  the presence of drusen in a patient with MPGN type I who 
may be actually classified as C3GN154. In 2012, Bomback et al, among a cohort of 
patients with C3G, described a C3GN patient with drusen deposition10.  
 
 
 
 
 
 
 
1.6.3  Secondary forms of C3G and IC-MPGN 
Immune-complex mediated MPGN are often secondary to chronic infections, 
autoimmune diseases and monoclonal gammopathy3. 
Among infections, hepatitis B and C are the most frequently described in association 
with MPGN although also bacterial (endocarditis, shunt nephritis, abscesses) and 
protozoal (malaria, schistosomiasis) infections have been reported155-158. 
Autoimmune diseases, as systemic lupus erythematosus, scleroderma, Sjögren’s 
syndrome and mixed cryoglobulinemia, are characterized by circulating immune 
Figure 10. Figure from Appel GB et al. (2005)1. Images representing the 
morphologic similarity observed in fenestrated capillaries of glomerulus 
(panel A) and retina (panel B). Podocytes are separated from capillary 
endothelial cells by GBM as well retinal pigment epithelial cells are 
separate from capillary endothelial cells by Bruch’s membrane. In DDD 
have been observed electron dense deposits in both membranes10. 
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complexes that activate the complement classical pathway favoring also leukocyte 
accumulation, cytokine release and subsequent glomerular damage. 
Monoclonal immunoglobulin deposition in mesangium and along the capillary walls, 
caused by monoclonal gammopathies but also by lymphomas, myelomas and leukemia 
can result in IC-MPGN and C3G97,159,160. 
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1.6.4  The spectrum of complement rare genetic variants among C3G, IC-MPGN and 
atypical HUS 
Rare genetic variants in complement genes (CFH, CFI, CFB, MCP, C3 and THBD) 
have been reported in about 50% to 60% of patients with atypical hemolytic uremic 
syndrome (aHUS)161 and in about 18% of patients with IC-MPGN and C3G103. 
Atypical HUS is a rare disease characterized by microangiopathic hemolytic anemia, 
thrombocytopenia and renal impairment161. The histology lesion is represented by 
thrombotic microangiopathy (TMA) and predominantly affects the renal 
microvasculature, at level of glomerular capillaries and preglomerular arteries. TMA 
also affects brain, heart, lung, gut, pancreas and liver. The main pattern of TMA is 
represented by thickening of vascular walls, with prominent endothelial damage 
(swelling and detachment) and accumulation of proteins and cell debris in 
subendothelium. The hypothesis that the activation of the complement alternative 
pathway may have a pathogenetic role in aHUS was based on the presence of intense 
glomerular and arteriolar C3 and C9 staining in the biopsy of aHUS patients and on 
reduced serum C3 levels with normal C4 levels in 30% to 40% of them162-165.  
The most frequent genetic abnormalities in aHUS (from 20% to 30%) are CFH variants. 
Factor H is a plasma protein that regulates the complement AP both in fluid phase and 
on cell surfaces. FH, through its N-terminal domains (SCR1-4) regulate AP activation 
by cofactor and decay accelerating activities whereas through C-terminal domains 
(SCR18-20) it recognizes C3b, heparin and glycosaminoglycans in host cell surfaces. 
The majority of aHUS patients carry heterozygous missense changes in the C-terminus 
of the protein, associated with normal FH levels. Functional studies of mutant FH 
showed impaired binding to endothelial cells, heparin and surface−bound C3b and 
consequently impaired surface cofactor activity, while FH cofactor activity in fluid 
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phase is not affected. These events culminate with renal endothelial detachment and 
swelling. 
IC-MPGN and C3G are glomerular diseases characterized by low C3 levels with normal 
C4 in about 70% of cases. Histology lesion is represented by mesangial 
hypercellularity, matrix expansion and thickening of peripheral capillary walls. These 
glomerular changes are caused by deposition of complement and /or immune complexes 
in the mesangium and along the capillary walls.  IC-MPGN glomeruli are characterized 
by C3 and dominant immunoglobulin staining while C3G is mainly characterized by C3 
staining.   
The most frequent variants affect C3 convertase genes (C3 and CFB) followed by CFH.  
Barricarte et al., showed that a two aminoacid deletion of C3 generated a C3 convertase 
resistant to decay by FH causing a continuous activation and consumption of C3101. IC-
MPGN/C3G associated CFH rare variants are mainly located in the N-terminus of the 
protein and are characterized by very low serum FH levels and/or complete block of FH 
cofactor and decay accelerating activity in fluid phase. The effect of these abnormalities 
is massive C3 deposition in the GBM.  
This CFH genotype-phenotype correlation has been confirmed by the model of Cfh-/- 
mice in which a massive C3 activation caused low C3 levels and low plasmatic 
activities with an histological pattern of C3G. Plasma C3 levels and complement 
activities were recovered after the introduction into Cfh-/- mice of a transgenic FH 
(FHΔ16-20) shifting the phenotype from C3G to aHUS119.  
An exception is represented by the CFH variant p.R1210C that is the most frequent in 
aHUS166 and has also been reported in a patient with C3G103. The p.R1210C variant 
generates complexes between FH and albumin impairing accessibility to all FH 
functional domains. This variant predisposes individuals to diverse pathologies but the 
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final phenotype is then determined by other genetic risk factors.167 Indeed, beside rare 
genetic variants, different common SNPs have been linked to either aHUS or IC-MPGN 
and C3G . The CFH-H3 haplotype increases the risk to develop aHUS 2 to 4 fold in 
comparison with control group.  A risk haplotype has been also identified in MCP 
(named MCPggaac) with a 2 fold increased risk of aHUS14, 168.   
On the other hand, the p.Y402H CFH SNP is over-represented in DDD patients 
compared with healthy controls while p.V62I have been reported as protective both in 
patients with DDD and C3GN116. The risk to develop DDD is associated with the 
presence of the CFH-H1 haplotype14. In 2012, one at risk-MCP haplotype (named 
MCPaaggt) have been identified in IC-MPGN and C3GN95. Finally, two C3 SNPs 
(p.R102G and p.P314L) have been reported in association with DDD116. 
The above reported SNPs are different from those identified in association with aHUS.  
Finally, genomic rearrangements in the RCA clusters have been described in C3G as 
well in aHUS. The most frequent rearrangements reported in aHUS patients result in the 
substitution of the last CFH exons (exon 23 or exon 22-23 or exon 21-23) with the last 
exons of CFHR1 (hybrid CFH1-22-CFHR16 gene and hybrid CFH1-21-CFHR15-6 gene) or 
with CFHR3 exons (hybrid CFH1-22-CFHR32-6 gene and hybrid CFH1-20-CFHR31-6 
gene)6,169-171. Additional CNVs have been reported in aHUS to generate reverse hybrid 
genes consisting of the first four or five exons of CFHR1 and the last two or one CFH 
exons (reverse hybrid CFHR11-5-CFH23 gene and  reverse hybrid CFHR11-4-CFH22-23 
gene)102,172. Overall, rearrangements related to aHUS result in gene products with a 
decreased complement regulation on host self-surfaces (endothelial surfaces included). 
As detailed reported in section 1.4 of this chapter, genomic rearrangements described in 
C3G did not involve FH and are mainly characterized by the duplication of dimerization 
domains of FHRs. Mutant protein studies with hybrid C3G proteins showed the 
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generation of large multimeric complexes  with an increased affinity for surface ligands 
and enhanced competition with FH. The hypothesis is that, differently from aHUS, FHR 
mutants in C3G compete with FH to bind a subset of cell surfaces but not endothelial 
surfaces. Of interest, the duplication of dimerization domains of FHR5 (CFHR51212) 
identified in CFHR5 nephropathy  led to a mutant protein that interacted with C3 on 
glomerular basement membrane more than wild-type FHR594. While in normal 
conditions, C3 activation on GBM is regulated by FH, in presence of mutant FHRs C3 
accumulate along GBM leading to C3 activation product deposition, typically observed 
in C3G9,136. 
Altogether these data indicate that the spectrum of kidney diseases determined by 
dysregulation of the AP is broad and spans from a thrombotic disorder associated with 
acute renal failure to chronic diseases leading to progressive renal failure.  
Differences in localization and functional consequences of rare variants in complement 
genes and in genomic rearrangements in the CFH-CFHR area, may drive a fluid-phase 
rather than cell-surface abnormal complement regulation resulting in either IC-
MPGN/C3G or aHUS, respectively. 
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1.7 Therapy 
There is no universally effective treatment for primary MPGN and C3G. Numerous 
therapeutic regimens have been tried, including the use of corticosteroids and other 
immunosuppressants, anticoagulants and thrombolytics and plasmapheresis. In a 
randomized, double-blinded clinical trial, eighty children with MPGN diagnosis, were 
treated with alternate-day prednisone (40mg/m2) or with placebo for 41 months. An 
improve outcome, in terms of decreased serum creatinine and renal survival rate, was 
seen in patients receiving prednisone in comparison to placebo. A retrospective study 
reported the effectiveness of corticosteroids plus mycophenolate mofetil (MMF) in C3 
glomerulonephritis173. Case report studies described treatment with plasma exchange 
(PEX)174, soluble CR1 (sCR1)175, Cp40176 and Rituximab177-180. 
Eculizumab (produced by Alexion Pharmaceuticals), is a humanized monoclonal 
antibody against C5 that prevents C5b-9 formation and C5a production. It is licenced 
for the treatment of anaemia in paroxysmal nocturnal haemoglobinuria and for the 
treatment of atypical HUS. It has been used in C3G. For example, eculizumab reduced 
circulating C5b9 and reduced proteinuria in some C3G patients10, 177. Eculizumab was 
also used in one patient with MPGN and nephrotic-range proteinuria, anemia, 
hypoalbuminemia, undetectable C3 and very high levels of SC5b-9. After the first dose 
kidney function normalized and by the sixth dose blood and urine tests normalised181.  
There is an ongoing clinical study of Eculizumab in ten primary MPGN patients with 
persistent heavy proteinuria, low C3 levels and high sC5b9. This will provide more data 
about the effectiveness of Eculizumab in well-characterized patients182. 
The recent report of KDIGO conference (“Kidney Disease: Improving Global 
Outcomes”90) recommended a tiered approach to treat patients with C3G. In patients 
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with abnormal blood pressure, angiotensin-converting enzyme (ACE) inhibitors or 
angiotensin receptor blockers (ARBs) were recommended. The disease is considered 
moderate when proteinuria is greater than 500mg/24h despite supportive therapy, or the 
biopsy has a moderate inflammation or there is a disease progression defined by recent 
serum creatinine increase. In this condition, treatment with prednisone or MMF is 
recommended.  Pulsed dosing of methylprednisolone and/or other anti-cellular immune 
suppressants were recommended when proteinuria is over 2000mg/24h despite 
immunosuppression and supportive therapy, renal biopsy shows severe inflammation 
and serum creatinine increases. Since the exact role of eculizumab in C3G is ill defined, 
KDIGO concluded that “Data are insufficient to recommend eculizumab as a first-line 
agent for the treatment of rapidly progressive disease”. 
Additional anticomplement drugs including small molecules that block FD (ACH-3856, 
ACH-4100, ACH-4471, Achillion Pharmaceuticals), or C5aR (CCX168, 
ChemoCentryx) and small interfering RNA (siRNA) agents that suppress the protein 
production as C5 production (ALN-CC5, Alnylam Pharmaceuticals) are in 
development183. 
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1.8  Summary 
Idiopathic MPGN is a rare glomerular disease characterized by increased mesangial 
cellularity and structural changes in glomerular capillary walls. MPGN primarily affects 
children and young adults who typically present with asymptomatic hematuria and 
proteinuria, hypertension, nephritic or nephrotic syndrome, chronic kidney disease or a 
rapid progressive glomerulonephritis. 
Although the pathogenesis of MPGN is not clear, hypocomplementemia is a common 
finding.  
In the last decade, the classification of MPGN has been revised.  At present, the 
diagnosis is based on IF data that distinguished IC-MPGN from C3G13. EM 
differentiates C3GN from DDD89. Genetic and acquired factors have been reported as 
drivers for the complement hyperactivation described in patients with IC-MPGN and 
C3G patients. Indeed, complement gene mutations (CFH, C3, CFI, CFB, MCP, THBD, 
CFHRs) have been reported in about 20% of patients while C3NeFs, an autoantibody 
that stabilizes the C3 convertase, is present in around 80% of DDD patients and in 45% 
of C3GN patients103.  Anti-Factor B and anti-Factor H autoantibodies have been also 
described149,151. Among genetic predisposing factors, copy number variations (CNVs) 
have been found both in C3GN and DDD9. 
At present there is no universal therapy strategy to treat patients with IC-MPGN and 
C3G although different approach, including corticosteroids and other 
immunosuppressants, anticoagulants and thrombolytics are used. Some patients have 
been reported to benefit from the treatment with  Eculizumab, a monoclonal antibody to 
C5 used in aHUS, but more data are necessary to confirm its effectiveness in these 
patients.   
Introduction 
 
 
37 
 
Further studies to identify genetic determinants in a cohort of well-characterized 
patients with IC-MPGN, C3GN and DDD will be instrumental to understand the 
mechanisms interfering with the control of the complement AP and will help to identify 
new therapeutic targets in these diseases. 
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2. COMPLEMENT ABNORMALITIES                                                     
IN AN ITALIAN COHORT OF PATIENTS WITH C3 
GLOMERULOPATHY AND IMMUNE COMPLEX-MEDIATED 
MPGN 
 
2.1 Introduction 
Membranoproliferative glomerulonephritis (MPGN) is an uncommon kidney disorder 
that mainly occurs in childhood but also in late adulthood. MPGN is characterized by 
glomerular injury including increased  mesangial cellularity, endocapillary proliferation 
and capillary-wall remodelling with generation of double contours13. Patients present 
with asymptomatic hematuria and proteinuria, nephritic or nephrotic syndrome, chronic 
kidney disease that often progress to end stage kidney disease (ESRD). 
MPGN classification has been revised in the last ten years. At present, MPGN is 
classified on the basis of glomerular deposition detected by immunofluorescence 
microscopy. Cases with a glomerular C3 staining and significant immunoglobulin 
deposition are defined immune-complex mediated MPGN (IC-MPGN) to distinguish 
them from C3 Glomerulopathy (C3G) cases with a dominant C3 staining with no or 
scanty immunoglobulins. IC-MPGN has been associated with the activation of the 
complement classic pathway caused by infections (viral and bacterial), autoimmune 
diseases (such as systemic lupus erythematosus or rheumatoid arthritis) or 
paraproteinemias caused by monoclonal gammopathy. On the other hand, C3 
glomerulopathy, further subclassified in Dense Deposit Disease (DDD) and C3 
glomerulonephritis (C3GN) in the basis of electron microscopy findings, has been 
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associated with complement alternative pathway caused by genetic and acquired factors. 
Indeed, rare functional variants in genes encoding the complement components or 
regulators of the AP (CFH, C3, MCP, CFI, CFB and THBD) and autoantibodies that 
stabilizes the C3 convertase and C5 convertase (C3NeF and C5NeF) or anti-FH and 
anti-FB autoantibodies have been described in patients with C3GN and DDD95, 103, 184. 
In addition, genomic abnormalities involving CFHR genes have been reported in DDD 
and C3GN patients and, in the majority of cases, generate hybrid FHR proteins that 
compete with FH to bind C3b causing an abnormal regulation of AP. 
Nevertheless, genetic and acquired abnormalities affecting the AP have been also 
reported in patients with IC-MPGN indicating that there are commonalities that cause 
AP dysregulation both in C3G and IC-MPGN. 
Recently, our group performed an unsupervised hierarchical cluster analysis on 173 well 
characterized patients from the Italian Registry of MPGN, to classify them in 
homogeneous groups. Using 34 variables regarding histological, biochemical, genetic 
and clinical features at onset, patients were divided in 4 clusters. Cluster 1 and 2 
included patients with C3 and C5 activation (high prevalence of LPVs and/or C3NeF, 
low serum C3 and high plasma SC5b-9). Cluster 2 was composed by patients with more 
intense deposition of IgG and C1q. In addition in cluster 2 there was an higher 
prevalence of patients receiving immunosuppressive therapies, probably due to the high 
prevalence of nephrotic syndrome at onset. In cluster 3, patients mainly had 
intramembranous highly electron dense deposits with a prevalent C3 activation (high 
prevalence of LPVs and/or C3NeF, low serum C3 but lower levels of SC5b-9) in 
comparison to those in cluster 1 and 2. Finally, cluster 4 included patients with solid-
phase complement activation (glomerular C3 deposits) but normal control of AP (low 
prevalence of LPVs and/or C3NeF, higher C3 levels and lower SC5b-9 levels in 
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comparison to the other clusters) in fluid phase, and with an higher risk to develop end 
stage renal disease (ESRD). Cluster 1 and 4 mainly included patients with C3GN and 
IC-MPGN. Cluster 2 was mainly composed by IC-MPGN patients while cluster 3 
regrouped patients with histological diagnosis of DDD. This statistical approach 
allowed to identify 4 different groups of patients suggesting the presence of four 
different pathogenetic mechanisms underlying IC-MPGN, DDD and C3GN. It also 
predicted the risk of poor renal survival and may be useful to identify the most adequate 
anticomplement therapy. In order to easily assign patients to the different clusters, we 
provided a three-step algorithm (that showed a 75% of concordance with the original 
cluster analysis) developed on the basis of histologic, biochemical and genetic features 
available at onset.   
This chapter was designed with the following objectives:  
1)  To evaluate the prevalence of genetic abnormalities (including rare functional 
variants and common variants) in known complement genes, the prevalence of C3NeF 
and the complement serum profile in a large cohort of patients with IC-MPGN/C3G that 
includes the 173 patients we reported in Iatropoulos et al2 plus 26 newly recruited  
patients.  
2) To apply in the enlarged cohort the three step–algorithm to classify patients into 
clusters. 
2.2 Patients 
Patients were recruited by the Italian Registry of MPGN, coordinated by the Clinical 
Research Center for Rare Diseases “Aldo e Cele Daccò” at Mario Negri Institute. 
Clinical information, demography and laboratory data from patients were collected by a 
case report form (Fig.11). Blood, plasma and serum were also collected for biochemical 
and genetic tests.  
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Biological samples from 48 healthy Italian donors were collected at Mario Negri 
Institute. 
The study was approved by Ethics Committee of The Azienda Sanitaria Locale of 
Bergamo (Italy). All participants received detailed information on the purpose and 
design of the study, according to the guidelines of the Declaration of Helsinki. 
2.3 Diagnosis 
All kidney biopsy reports were centrally reviewed by pathologists at the Mario Negri 
Institute. The diagnosis of MPGN was based on light microscopy findings. On the basis 
of the recent classification 89, 185, MPGN patients were further classified as follow: 
-  Immune-complex MPGN: cases with complement and immunoglobulin staining at 
immunofluorescence (IF); 
-  C3 Glomerulopathy: cases with "dominant C3 staining" at IF (defined in the Consesus 
Report as " C3c intensity≥ 2 orders of magnitude more than any other immune reactant 
on a scale of 0 to 3). 
On the basis of electron microscopy appearances, patients with C3 Glomerulopathy 
were further classified as DDD (in presence of very dense osmiophilic deposits) and 
C3GN. 
Patients with secondary MPGN, patients with a previous diagnosis of atypical 
hemolytic uremic syndrome (aHUS),  patients with MPGN diagnosis on allograft but 
without biopsy on native kidney and all patients with no IF or EM studies were 
excluded from this study.  
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Figure 11. The Italian Registry of Membranoproliferative glomerulonephritis  
(MPGN) used to recruit patients at Mario Negri Institute. 
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2.4 Methods 
2.4.1 Complement component assays 
Serum C3 and C4 concentrations were measured by kinetic nephelometry 166. Plasma 
levels of SC5b-9 levels were assessed using the MicroVue SC5b-9 Plus EIA 
commercial kit (SC5b-9 Plus, Quidel).The above evaluations were done at Mario Negri 
Institute.  
IgGs purified from plasma were used to test C3NeF activity at the Cordelier Research 
Center . The assay consisted in measuring the IgG ability to stabilize the convertase of 
the AP, C3bBb, as previously described186. 
 
2.4.2 DNA samples 
Genomic DNA (gDNA) was extracted from peripheral blood using the NucleonTM 
BACC2 Genomic DNA extraction kit (GE Healthcare, Little Chalfont, UK) and, more 
recently, the NucleoSpin Blood columns (Macherey-Nagel). DNA integrity was verified 
by 0.8% agarose gel electrophoresis. DNA quality was analyzed by NanoDrop 
Spectometer (ND-1000; Thermo Fisher). Before library preparation, DNA was 
quantified by Qubit (dsDNA HS Assay kit; Invitrogen). 
 
2.4.3 Complement Minipanel and Genetic data analysis 
Genetic analysis were performed in 198 patients by a next generation sequencing (NGS) 
diagnostic minipanel for simultaneous sequencing of 6 complement genes (complement 
factor H, CFH, NG_007259.1; complement factor I, CFI, NG_007569.1;  membrane 
cofactor protein, CD46/MCP, NG_007569.1; complement factor B, CFB, 
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NG_008191.1; complement C3, C3, NG_009557.1; and thrombomodulin, THBD, 
NG_012027.1). Amplicons were obtained by highly multiplex PCR using the Ion 
AmpliSeq™ Library Kit 2.0 (Life Technologies, LT). Ultra-high multiplex PCR 
primers have been custom designed using the online Ion AmpliSeq Designer tool (LT), 
creating 2 pools of primer-pairs for a total of 311 amplicons. Target were then subjected 
to clonal amplification on Ion PGM™ Template OT2 200 Kit and finally sequenced on 
Ion Torrent Personal Genome Machine Sequencer (PGM, LT).  
Sequence data were analyzed using TorrentSuite Software 3.6. Targets with a depth of 
amplicon coverage ≥20X reads were considered appropriately analyzed. ANNOVAR 
software was used to functionally annotate genetic variants.  
Genetic variants were considered as follows: 
-  Functional variants: missense variants, insertion/deletions in the coding regions and 
splicing variants affecting the first two nucleotides flanking the exons. 
- Rare variants: variants with an allelic frequency ≤ 0.01 in ESP or 1000 Genomes 
Project subpopulations. 
- Likely pathogenic variants (LPVs): variants with minor allele frequency (MAF) in the 
ExAC database <0.001 and with Combined Annotation Dependent Depletion 
(CADD)187 phred score ≥10. 
Rare variants and likely pathogenic variants were validated by Sanger sequencing on the 
3730 DNA Analyzer (LT). Targets with a depth of coverage ≤20x  were sequenced by 
Sanger sequencing, as previously described.166  
In the associations studies I used genotypes from  404 unphenotyped subjects of 
European origin from the 1000 Genomes Project (CEU, TSI, GBR and IBS 
subpopulations) and from 48 Italian healthy subjects. 
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2.4.4 Cluster analysis 
As reported in Iatropoulos et al., we created a three-step algorithm to assign patients to 
different clusters2. The algorithm (Fig.12) is based on four different features available at 
onset (presence of LPVs and or C3NeF, serum C3 levels, presence of intramembranous 
highly electron-dense deposits) and it was used to cluster all patients from our cohort.  
 
 
                                                              
            
 
     
Figure 12. Image,  taken from Iatropoulos et al. (2017)2, 
representing the three-step algorithm.  
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2.4.5  Statistics 
Clinical data in the three different groups of patients (IC-MPGN, DDD and C3GN) are 
reported in Table 3. To determine differences among the three histological groups, I 
used ANOVA test for continuous variables and the χ2 or Fisher Exact test for 
categorical variables.  
Candidate SNPs were selected from previous publications that associated CFH, CD46, 
CFB, C3 and THBD polymorphisms with MPGN95, 103, 115, 116, 119. In the association 
analysis was considered one patient for each family. Chi-square test was used to 
compare genotype and allelic frequencies between patients and controls. P-values <0.05 
were considered statistically significant. 
Survival analyses considered as cumulative fractions of patients free of events were 
estimated using Kaplan-Meier survival curves. Analyses were performed with the 
MedCalc software. 
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2.5  Results 
The cohort of patients investigated in this chapter include: 
- 173 patients described in the following published articles:   
~"Complement gene variants determine the risk of immunoglobulin-associated MPGN 
and C3 glomerulopathy and predict long-term renal outcome" (Iatropoulos P. et al; Mol 
Immunol. 2016 Mar103); 
~"Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 
Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN" 
(Iatropoulos et al; J Am Soc Nephrol. 2018 Jan2). 
-  26 unpublished patients. 
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2.5.1 Complement abnormalities in patients with IC-MPGN, DDD and C3GN. 
2.5.1.1 Patients and clinical parameters 
Kidney biopsy report review of 199 MPGN patients provided the diagnosis of IC-
MPGN in 48% (n=96), C3GN in 39% (n=77) and DDD in 13% (n=26) of them 
(Fig.13). 
Among the 199 patients, eight had familiarity for the disease. 
As reported in table 3, age of onset and gender distribution were similar among the 
different histology groups. 
Proteinuria and microhematuria were the main clinical features at onset in all patients. 
At onset, nephrotic syndrome was observed in 39%, 23% and 31% of patients with IC-
MPGN, DDD and C3GN, respectively, while renal impairment was statistically more 
frequent in patients with IC-MPGN (24%) and C3GN (22%) than in patients with DDD 
(4%. IC-MPGN versus DDD: p=0.022; C3GN versus DDD: p=0.038). 
  
Recruited 
patients  
n=379
-Secondary MPGN;
-IF or EM not 
available;
-Other diagnosis;
-No biopsy on 
native kidney;
n=180
Primary IC-MPGN/C3G       
n=199
IF: C3+, Ig+, C1q
IC-MPGN                         
n=96
IF: predominant C3+
C3 Glomerulopathy      
n= 103
Dense 
Deposit 
Disease                            
n=26
C3 
Glomerulonephritis 
n=77
Figure 13. Histological classification of patients recruited by the Italian Registry of 
MPGN. IC-MPGN: Immune complex-mediated MPGN; C3G: C3 glomerulopathy; 
DDD: dense deposit disease; C3GN: C3 glomerulonephritis. 
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Variable C3GN DDD IC-MPGN Overall p-value 
N 77 26 96  
Gender (% males) 58% 58% 54% 0.843 
Data at onset     
Age (y) - Mean (SD) 17.9 (±15.4) 15.1 (±11) 19.6 (±15) 0.360 
Microhematuria % 87   88   82   0.649 
Gross hematuria % 34   42   29   0.455 
Proteinuria % 88   88   90   0.951 
Nephrotic syndrome % 31   23   39   0.281 
Renal impairment % 22    4a,b   24   0.073 
Trigger event % 37   35   28   0.481 
Familiarity for nephropathy % 16   12   11   0.603 
Serum C3 (mg/dl)  50.7 (±42.4) 33 (±35.6)b 51.3 (±40.2) 0.108 
Serum C4  (mg/dl)  21.8 (±9.1) 24 (±9.6) 21 (±10.3) 0.366 
Plasma SC5b-9 (ng/ml)  1165 (±1274) 530 (±518)a,b 1079 (±1205) 0.061 
Low serum C3 and normal serum C4 % 72   85   70   0.285 
C3NeF positive % 39      79a,b   40   0.001 
LPV carriers % 24   15   15   0.284 
LPV carriers and/or C3NeF% 58       83a,b   49   0.012 
     
Data during follow-up     
Nephrotic syndrome %  47b   50   68   0.016 
High blood pressure % 35   23b   48   0.041 
Chronic kidney disease %  31b   27   46   0.068 
ESRD % 10   4   9   0.739 
Thrombotic microangiopathy % 5   0   3   0.652 
     
Histological features     
Time Onset to Biopsy (yr), median (IQR)  0.4 (0.1-2.3) 1.1 (0.2-3.8) 0.4 (0.1-1.8) 0.702 
Light microscopy     
Sclerotic glomeruli % 8 (±18) 2 (±6)b 9 (±14  ) 0.166 
Crescents % 3 (±11) 7 (±20) 6 (±16  ) 0.485 
Degree of mesangial proliferationd 1.6 (±1) 1.8 (±0.7) 1.9 (±0.9) 0.145 
Degree of endocapillary proliferationd 1 (±1.1) 0.9 (±1.1) 1.2 (±1) 0.291 
Degree of interstitial inflammationd 0.6 (±0.8)b 0.6 (±0.8) 0.8 (±0.8) 0.070 
Degree of interstitial fibrosisd 0.4 (±0.7) 0.2 (±0.4)b 0.5 (±0.8) 0.105 
Degree of arteriolar sclerosisd 0.3 (±0.8) 0 (±0.1)b 0.3 (±0.6) 0.163 
Immunofluorescence d     
C3 2.7 (±0.5) 2.8 (±0.3) 2.6 (±0.7) 0.045 
IgA 0.1 (±0.2) 0.1 (±0.3)   0.5 (±0.8)a,c <0.001 
IgG 0.2 (±0.4) 0.2 (±0.4)  1.6 (±1.1)a,c <0.001 
IgM 0.3 (±0.4)b    0.7 (±0.7)a,b  1.3 (±0.9) <0.001 
C1q 0.1 (±0.3) 0.1 (±0.3) 1.1 (±1)a,c <0.001 
Fibrinogen 0.3 (±0.7) 0.3 (±0.8) 0.3 (±0.7) 0.898 
Electron microscopy %     
Mesangial deposits  74b,c  46   58   0.019 
Subepithelial deposits  56b,c  8a   34  <0.001 
Subepithelial hump-like deposits 27 9 15 0.064 
Subendothelial deposits 73   12a,b   78   <0.001 
Intramembranous granular deposits 55   0a,b   48   <0.001 
Intramembranous highly electron-dense 
ribbon-like deposits 0   100
a,b  3   <0.001 
 
Complement abnormalities in C3G and IC-MPGN 
 
 
51 
 
 
 
 
 
 
 
 
2.5.1.2  Complement serum profile 
The majority of patients from the three histology  groups (IC-MPGN: 82%; DDD: 92%; 
C3GN:82% ) showed low C3 levels (<90mg/dl). The lowest mean C3 levels were 
observed in patients with DDD (DDD: 33 ± 35.6; IC-MPGN: 51.3 ± 40.2; C3GN: 50.7± 
42.4; p=0.108).  As shown in fig. 14, low C4 levels (<10mg/dl) were present in 14%, 
8%  and 7%  of patients with IC-MPGN, DDD and C3GN, respectively. The majority of 
patients from the three histology groups (IC-MPGN: 70%; DDD: 85%; C3GN:72%) 
showed low C3 levels and normal C4 (C3 < 90mg/dl and C4 >10mg/dl). High SC5b-9 
levels (>303 ng/ml) were present in the three groups although patients with IC-MPGN 
and C3GN had statistically higher SC5b-9 levels in comparison to patients with DDD 
(p=0.028 and p=0.018, respectively) (Table 3). 
 
 
0%
20%
40%
60%
80%
100%
IC-MPGN DDD C3GN
Low C3 levels % (<90 mg/dl)
Low C4 levels % (<10 mg/dl)
High plasma SC5b-9 % (>303 
ng/ml)
Low serum C3 levels and normal 
C4 (%)
Table 3.  Clinical features, complement assesment, genetic screening and histologic features 
in patients classified according to the C3G/IC-MPGN classification. 
Continuous variables are reported as mean (±SD) unless otherwise specified.  
Serum C3: reference 90-180 mg/dl; serum C4: reference 10-40 mg/dl; plasma SC5b-9: 
reference ≤303 ng/ml. 
a Significant different from C3GN. 
b Significant different from IC-MPGN 
c Significant different from DDD 
d Degree of mesangial proliferation, endocapillary proliferation, interstitial inflammation, 
interstitial fibrosis, and arteriolar sclerosis, as well as IF findings were graded using a scale 
of 0 to 3, including 0, trace (0.5+), 1+, 2+ and 3+. 
 
 
Figure 14. C3, C4, SC5b-9  levels in patients with IC-MPGN, DDD and C3GN. 
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The presence of C3NeF, an autoantibody that stabilizes the C3 convertase, was 
evaluated in all those patients whose plasma sample was available (n=167). Although it 
was found in all histology groups (IC-MPGN: 40% ; DDD: 79%; C3GN: 39% ), C3NeF 
was statistically more frequent in DDD patients in comparison to IC-MPGN and C3GN 
patients (p=0.0006 and p=0.0007, respectively). 
 
2.5.1.3 Genetic screening 
Among 198 patients analyzed by NGS, likely pathogenic variants (LPVs) were 
identified in 36 of them (18%) (Table 3; Table 4). As reported in Table 4, LPVs were  
spread in the three histology groups (IC-MPGN: 15%; DDD: 15% ; C3GN: 24% ; 
Fig.15). 
 
Among six complement genes included in the genetic screening, the C3 gene was the 
one with the highest prevalence  of  LPVs, followed by CFH (C3 = 42% and CFH = 
33% of all LPVs ). All C3 LPVs were heterozygous and were found in patients with IC-
MPGN and C3GN but not in patients with DDD. Their localization affected the C345C 
domain, important for the binding with Bb, the MG5 domain involved in the C3bBb-C3 
interaction, and domains of interaction with FH and FI (MG1, TED and CUBf)103, 188-190 
(Fig.16). 
 CFH likely pathogenic variants (n=12) were found in all histological groups and 5 of 
them were in homozygosity (four of five patients had parental consanguinity). The 
majority of LPVs in CFH affected N-terminal domains (SCR1-4) of the protein, which 
are involved in the regulation of the complement alternative pathway through cofactor 
and decay accelerating activities (Fig.16). 
Likely pathogenic variants in the gene coding CFB (n=3) were found only in patients 
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with IC-MPGN and affected domains important for the binding to C3191 (Fig.16). 
Heterozygous CFI LPVs were identified in two patients with C3GN and in one patient 
with DDD. The p.G119R,  variant in  FI, already found in aHUS, ARMD and MPGN, is 
located in the CD5 domain and was described to reduce C3b degradation95,192,193. The FI 
G57D affected the FIMAC domain, the main binding sites important for C4b and C3b 
degradation by FI194 (Fig.16).  
Only one CD46 LPV was found in a patient with IC-MPGN but its effect is unknown.  
Two heterozygous THBD LPVs were identified in two patients, one with DDD and one 
with C3GN. Both of them reside in the serine–threonine-rich region of thrombomodulin 
and were previously described in aHUS (Fig.16). Functional studies showed that both 
mutant THBD proteins had a reduced complement regulation through FI-mediated C3b 
inactivation22. 
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Figure 15. Complement likely pathogenic variant distribution in 
patients with IC-MPGN, DDD and C3GN. 
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Figure 16. Localization of likely pathogenic variants in CFH, CFI, CFB, THBD, MCP 
and C3 genes identified in patients with IC-MPGN (in red), DDD (in green) and C3GN 
(in blue). 
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Patient 
ID 
Histologic  
group Zygosity LPV 
ExAC 
Global 
Freq. 
ExAC   
Max 
Subpop.  
Freq. 
Pathogenic in 
functional 
studies 
CADD 
216 C3GN Het p.C3: R1042Q  9.9E-05 2.3E-04 No 16 
419 C3GN Hom p.FH: Y1008X 0 0 No 32 
521 IC Het p.C3: K1051M 1.6E-05 3.0E-05 Yes 23 
1073 IC Het p.FH: C494R 0 0 No 24 
1101 DDD Het p.FH: R1210C 1.7E-04 2.8E-04 Yes 12 
1132 C3GN Het p.C3: R1320Q 0 0 No 28 
1147 IC Het p.FB: H451R 0 0 No 25 
1157 C3GN Het p.C3: D1625H 0 0 No 12 
1264 IC Het p.FB: G161R 6.9E-05 3.0E-04 No 27 
1284 IC Hom p.FH: P88T 0 0 No 29 
1287 IC Hom p.FH: P88T 0 0 No 29 
1360 C3GN Het p.FI: c.1-4C>T 8.4E-06 1.5E-05 No 17 
1409 DDD Het p.FI: G57D 8.2E-06 6.1E-05 No 25 
1549 DDD Het p.FH: R2I 0 0 No 11 
1725 DDD Het p.THBD: P495S 5.8E-04 0.001 Yes 6 
1726 IC Hom p.FB: R679W 0 0 No 31 
1736 C3GN Het p.C3: R1303H 8.3E-06 1.5E-05 No 28 
1741 C3GN Het p.THBD: D486Y 0 0 Yes 12 
1828 C3GN Het p.C3:V619M 2.9E-04 0.001 No 22 
1890 IC Het p.C3: G637R 2.2E-04 3.8E-04 No 24 
1964 IC Het p.C3: R505C 8.3E-06 1.5E-05 No 25 
1983 C3GN Het p.C3: I761del 0 0 No 14 
1984 C3GN Het p.C3: I761del 0 0 No 14 
2009 C3GN Het p.C3: C1518R 0 0 No 26 
2011 IC Het p.C3: D1362N 4.9E-05 1.2E-04 No 11 
2018 IC Het p.CD46: K66N 5.3E-04 9.0E-04 No 13 
2032 C3GN Hom p.FH:R78G 0 0 No 16 
 2047* IC Het p.C3: S1063N 0 0 No 10 
2082 C3GN Het p.FH: R127C 0 0 No 33 
2158 C3GN Hom p.FH: R78G 0 0 Yes 16 
2192 C3GN Het p.FH:G133R 1.7E-05 3.0E-05 No 31 
2508 C3GN Het p.C3: D1456N 0 0 No 25 
SN249 C3GN Het p.FI: G119R 5.3E-04 9.5E-04 Yes 22 
2435 C3GN Het p.FH: R232X 1.7E-05 6.1E-05 Yes 36 
2350 IC Het p.C3: A257T 5.0E-05 9.1E-05 No 33 
2585 IC Het p.FH:G879R 0 0 No 28 
  
Table 4. List of likely pathogenic variants identified in the cohort. 
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2.5.1.4 Effect of complement genetic and acquired abnormalities on complement profile 
A statistically higher percentage of patients with genetic and/or acquired abnormalities 
was found in the DDD group vs. the other two histology groups (IC-MPGN: 49%; 
DDD: 83%; C3GN: 58% ; p overall=0.012. DDD versus IC-MPGN, p=0.006; DDD 
versus C3GN p=0.04) (Fig.17).  
 
 
To investigate whether the LPVs reported in table 4 or the presence of C3NeF, or both,  
were associated with a specific complement profile in each histology group, C3 and 
SC5b-9 levels measured at onset in patients with LPVs or C3NeFs or both were 
compared with those of patients without identified genetic or acquired complement 
abnormalities.  
Considering all patients together, low C3 levels appeared strongly associated with the 
presence of LPVs or C3NeF, both in single and in combination (p overall <0.001; Fig. 
18). Complement genetic and acquired abnormalities appeared to influence also plasma 
SC5b-9 levels (Fig.19) since patients with LPVs and/or C3NeF had higher SC5b-9 
levels than patients without genetic or acquired abnormalities. This difference is likely 
attributable to C3NeF since I found that SC5b-9 levels were significantly higher in 
0%
20%
40%
60%
80%
100%
Presence of 
C3NeF and/or LPV
No LPV nor C3NeF
IC-MPGN
DDD
C3GN
p = 0.01*
Figure 17. Representation of the presence of C3NeFand/or LPV in patients with 
IC-MPGN, DDD and C3GN. * Statistically different from C3GN and IC-MPGN 
(p=0.04 and p=0.006, respectively). 
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patients with only C3NeF in comparison to those in patients without complement 
abnormalities (Fig.19). 
 
 
 
 
 
As shown in Fig. 20, C3 levels of IC-MPGN patients with LPVs and /or C3NeF were 
statistically lower than those of IC-MPGN patients without C3NeF or LPVs (p<0.001). 
This hypocomplementemia is mainly caused by the acquired abnormality,  indeed  IC-
MPGN patients with only C3NeF (and no LPVs) showed lower C3 levels (median 
Figure 18. Box plot showing serum C3 levels in all recruited patients. 
* Significant different from the group with "No LPV nor C3NeF" (p= 2.2E-10);     
§ Significant different from the group with "No LPV nor C3NeF" (p= 0.035); 
# Significant different from the group with "No LPV and/or C3NeF" 
(p=0.0005). 
 
 
Figure 19. Box plot showing plasma SC5b-9 levels in all recruited patients. 
* Significant different from the group with "No LPV nor C3NeF" (p=5.8E-5).     
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(IQR) = 15(8-19)) in comparison to both those with only LPVs (median (IQR) = 56 (43-
70)) (Fig.20) and those with no LPVs nor C3NeF (median (IQR) = 77 (48-101). 
High SC5b-9 levels (>303 ng/ml) were observed in IC-MPGN patients with LPVs 
and/or C3NeF (median (IQR) = 1412 (345-2408)). IC-MPGN patient groups with only 
acquired abnormality or in combination with LPVs showed high SC5b-9 levels 
("C3NeF only" = 1643 (467-2474); “ LPV and C3NeF” = 1845 (1600-1874)) although 
only in the former group SC5b-9 levels were statistically higher than in patients without 
genetic and acquired complement abnormalities (median (IQR): 307 ng/ml (232-567) 
p<0.001) (Fig.21). 
 
 
 Figure 21. Box plot showing plasma SC5b-9 levels in in patients with IC-MPGN. 
* Significant different from the group with "No LPV nor C3NeF" (p=0.0001).     
 
 
Figure 20. Box plot showing plasma C3 levels in patients with IC-MPGN. 
* Significant different from the group with "No LPV nor C3NeF" (p=3.1E-7).  
§ Significant different from the group  with "No LPV nor C3NeF" (p= 0.008) 
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The majority (84%) of patients with C3 glomerulopathy (C3G) had lower than normal 
C3 levels. Of note, patients with only C3NeF showed C3 levels statistically lower in 
comparison to C3G patients without genetic and acquired abnormalities (median (IQR): 
"C3NeF  only" = 18 (9-44); "No LPV nor C3NeF" = 49 (28-101)) (Fig.22). 
C3G patients with genetic and/or acquired abnormalities had higher plasma SC5b-9 
levels in comparison to patients without abnormalities (Fig. 23). Among different 
subgroups, patients carrying only C3NeF showed SC5b-9 levels significantly higher 
than patients without abnormalities ("C3NeF only" = 665 (319-1894) ng/ml ; "No LPV 
nor C3NeF" = 273 (206-611) ng/m) (Fig.23).   
  
 
 
 
Figure 22. Box plot showing C3 levels in patients with C3 glomerulopathy (C3G). 
* Significant different from the group with "No LPV nor C3NeF" (p=0.027) 
 
Figure 23. Box plot showing SC5b-9 levels in patients with C3 Glomerulopathy 
(C3G). 
*Significant different from the group "No LPV nor C3NeF" (p=0.027). 
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To verify whether patients with DDD had a different complement profile from C3GN 
and whether it was influenced by the presence or absence of abnormalities, C3G 
patients were analyzed separately on the basis of electron microscopy data.  
Among DDD patients tested for C3NeF, C3, SC5b-9 and genetic complement 
abnormalities (n=24), only the C3NeF negative patient carrying a LPV showed normal 
C3 levels (C3 = 154 mg/dl). All remaining patients, had C3 levels lower than normal 
(90 mg/dl), independently from the presence or absence of genetic and/or acquired 
abnormalities (median (IQR): “only C3NeF" = 13 (9-26); “LPV and C3NeF” = 47 (33-
50); “No LPV nor C3NeF” = 41(34-46)) (Fig. 24).  
50% of DDD patients had higher than normal (>303 ng/ml) SC5b-9 levels. However, no 
significant difference was observed in SC5b-9 levels between DDD patients with or 
without genetic and/or acquired abnormalities (median (IQR): “LPV and/or C3NeF” = 
353 (226-583); “No LPV nor C3NeF” = 253 (234-345). Fig.25).  
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Figure 24. Box plots show that all DDD patients (including those without 
complement abnormalities) showed low C3 levels (<90mg/dl), with the exception 
of the patient carrying a LPV and negative for C3NeF.  
 
 
Figure 25.  Box plot showing SC5b-9 levels in patients with DDD patients (Patient 
with " LPV only " SC5b9 levels = 368 ng/ml. Median (IQR): " C3NeF only " = 430 
(226-833); “LPV and C3NeF” = 286 (211-304); “No LPV and/or C3NeF” = 
253(233-345)). 
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C3GN patients with acquired and/or genetic abnormalities (in single or in combination) 
showed C3 levels lower than C3GN patients without LPV or C3NeF (median (IQR): 
“LPV and/or C3NeF” = 22 (10-44), “No LPV nor C3NeF" = 55 (27-108)). No 
difference was observed in C3 levels between patients with only C3NeF and patients 
with only LPV or patients with LPV and C3NeF (median (IQR): “C3NeF only” = 24 (8-
46); “LPV only” = 21 (15-37); “LPV and C3NeF” = 12 (5-23)) ;  (Fig.26).  
Similarly to what observed in IC-MPGN patients, very high plasma SC5b-9 levels were 
observed only in C3GN patients with acquired and/or genetic abnormalities. Notably, 
patients with only C3NeF had SC5b-9 levels statistically higher than those observed in 
patients without abnormalities (median (IQR): “C3NeF only” = 999 (564-2380); “LPV 
only” = 888 (561-1530); “LPV and C3NeF” = 1909 (1073-2828) ; “No LPV nor 
C3NeF” = 286 (200-792)) (Fig 27). 
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In summary, patients with LPVs and/or C3NeF from all the three different histology 
groups showed low C3 levels (median (IQR):  IC-MPGN = 17 (10-45) mg/dl; DDD =17 
(9-49) mg/dl; C3GN = 24 (11-47) mg/dl; p overall = 0.888).  Among patients without 
genetic and acquired abnormalities, DDD patients showed a trend to have lower C3 
levels compared to  IC-MPGN and C3GN patients, ( median (IQR): IC-MPGN = 77 
(47-100) mg/dl; DDD = 41 (34-46) mg/dl; C3GN = 55 (27-107) mg/dl; p overall = 
0.324). 
Figure 27.  Box plot showing C3 levels in patients with C3GN.  
* Significant different from the group with "No LPV nor C3NeF" (p=0.014).   
  
 
 
 
 
               
          
           
     
 
Figure 26.  Box plot showing C3 levels in patients with C3GN.  
* Significant different from the group with "No LPV nor C3NeF" (p=0.003);    
§ Significant different from the group "No LPV nor C3NeF" (p=0.03). 
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High plasma SC5b-9 clustered among patients with genetic and/or acquired 
abnormalities. Among them, we observed that IC-MPGN and C3GN patients had  
SC5b-9 levels (IC-MPGN: median (IQR): 1412 (345-2408) ng/ml; C3GN median 
(IQR): 999 (463-2332) ng/ml) statistically higher than those found in patients with 
DDD (median (IQR): 352 (226-582) ng/ml; p overall = 0.007; IC-MPGN plus C3GN 
vs. DDD, p=0.002). 
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2.5.1.5  Renal survivals  
Eighteen patients (IC-MPGN=9; DDD=1; C3GN=8) developed end-stage renal disease 
(ESRD). In Kaplan-Meier plot in Fig. 28, survival curves overlapped indicating that the 
risk to develop ESRD is the same in IC-MPGN and C3G.  Similar results were also 
observed among IC-MPGN, DDD and C3GN (Fig.29).  
 
 
 
Figure 28. Kaplan-Meier representing the risk to develop 
ESRD in patients with IC-MPGN and C3G. 
Figure 29. Kaplan-Meier representing the risk to develop 
ESRD in patients with IC-MPGN, DDD and C3GN. 
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2.5.1.6  Effect of complement genetic and acquired abnormalities on clinical 
parameters. 
To investigate whether the outcome of patients with IC-MPGN, DDD and C3GN were 
influenced by the presence of LPVs and/or C3NeF, I performed survival analysis 
considering the nephrotic syndrome, the renal failure and end stage-renal disease during 
follow-up.  
Kaplan Meier analysis showed that the presence of C3NeF and/or LPVs decreased the 
risk to develop ESRD in IC-MPGN/C3G patients (p=0.052; Fig.30). Although no 
significant difference between patients with LPVs and/or C3NeF and those without 
abnormalities was observed in the three different histology groups considered 
separately, the presence of C3NeF and/or LPVs showed a trend to decrease the risk to 
develop renal failure in patients with IC-MPGN (p=0.09; Fig.31) or C3GN (p=0.09, 
Fig.33).  At variance, in DDD patients the presence of complement abnormalities 
showed a trend to increase the risk to develop nephrotic syndrome (p=0.09; Fig. 32). 
However, this finding may be questionable because of the low number of patients. 
 
Figure 30. Kaplan-Meier representing the risk to develop end-stage 
renal disease (ESRD)  in IC-MPGN/C3G patients with LPV or C3NeF 
compared to  IC-MPGN/C3G patients without abnormalities. 
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Figure 31. Kaplan-Meier representing the risk to develop nephrotic 
syndrome, renal failure and ESRD in IC-MPGN patients with LPV and 
or C3NeF versus IC-MPGN patient without complement abnormalities. 
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Figure 32. Kaplan-Meier representing the risk to develop nephrotic 
syndrome, renal failure and ESRD in DDD patients with LPV and or 
C3NeF versus IC-MPGN patient without complement abnormalities. 
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Figure 33.  Kaplan-Meier representing the risk to develop nephrotic 
syndrome, renal failure and ESRD in C3GN patients with LPV and or 
C3NeF versus IC-MPGN patient without complement abnormalities. 
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2.5.1.7 Susceptibility genetic variants 
Common single nucleotide polymorphisms (SNPs) in complement genes, previously 
associated with MPGN, were analyzed to determine whether they segregate  
preferentially with a specific histology group. As shown in table 5, I observed a trend of 
association  for the CD46 c.*783T allele in IC-MPGN patients (p=0.06) and  for THBD 
the A473 allele in DDD and C3GN patients (p=0.09 and  p=0.07 respectively). 
Considering a recessive model, CFH 936D was significantly associated with IC-MPGN 
(p=0.046) while CD46 c.-366G resulted in association with DDD (p=0.046; Table 7).  
 
 
 
  
Complement abnormalities in C3G and IC-MPGN 
 
 
71 
 
 
Histology 
Group
n A/A A/a a/a
p value    
vs ctrs
Allele frequency 
allele A 
Allele 
frequency 
allele a
p value    
vs ctrs
CFH c.-331C>T                    rs3753394 IC-MPGN 94 42 42 10 0.40 0.67 0.33 0.29
DDD 26 14 10 2 0.87 0.73 0.27 0.90
C3GN 74 31 34 9 0.21 0.65 0.35 0.14
Ctrs 452 223 198 31 0.71 0.29
CFH p.V62I                               rs800292 IC-MPGN 94 57 33 4 0.68 0.78 0.22 0.52
DDD 26 19 6 1 0.21 0.85 0.15 0.19
C3GN 74 46 25 3 0.58 0.79 0.21 0.43
Ctrs 452 252 180 20 0.76 0.24
CFH p.H402Y                              rs1061170 IC-MPGN 94 17 34 43 0.44 0.36 0.64 0.96
DDD 26 7 8 11 0.19 0.42 0.58 0.45
C3GN 74 13 32 29 0.76 0.39 0.61 0.52
Ctrs 452 66 194 192 0.36 0.64
CFH p.E936D                       rs1065489 IC-MPGN 94 63 23 8 0.05 0.79 0.21 0.51
DDD 26 18 8 0 0.64 0.85 0.15 0.72
C3GN 74 43 26 5 0.20 0.76 0.24 0.11
Ctrs 452 301 136 15 0.82 0.18
CD46 c.-652G>A                   rs2796267 IC-MPGN 91 11 38 42 0.68 0.78 0.22 0.45
DDD 22 4 6 12 0.42 0.32 0.68 0.66
C3GN 68 10 27 31 0.93 0.35 0.65 0.77
Ctrs 404 63 167 174 0.36 0.64
CD46 c.-366A>G                    rs2796268 IC-MPGN 94 11 42 41 0.71 0.34 0.66 0.45
DDD 26 5 5 16 0.03 0.29 0.71 0.28
C3GN 72 14 30 28 0.48 0.40 0.60 0.55
Ctrs 452 64 209 179 0.37 0.63
CD46 p.A309V                      rs35366573 IC-MPGN 79 77 2 0 0.83 0.99 0.01 0.82
DDD 22 22 0 0 0.80 1.00 0.00 0.96
C3GN 54 54 0 0 0.58 1.00 0.00 0.56
Ctrs 452 443 8 1 0.99 0.01
CD46 c*783T>C                           rs7144 IC-MPGN 94 44 43 7 0.12 0.70 0.30 0.06
DDD 26 15 6 5 0.08 0.69 0.31 0.38
C3GN 72 34 28 10 0.45 0.67 0.33 0.34
Ctrs 404 159 184 61 0.62 0.38
Genotype frequencies Allele frequencies
SNP
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Histology 
Group
n A/A A/a a/a
p value    
vs ctrs
Allele frequency 
allele A 
Allele 
frequency 
p value    
vs ctrs
CFB p.L9H                            rs4151667 IC-MPGN 93 87 6 0 0.74 0.97 0.03 0.63
DDD 26 25 1 0 0.72 0.98 0.02 0.63
C3GN 71 63 8 0 0.52 0.94 0.06 0.63
Ctrs 452 415 35 2 0.96 0.04
CFB p.K565E                        rs4151659 IC-MPGN 87 84 3 0 0.87 0.98 0.02 0.87
DDD 24 24 0 0 0.80 1.00 0.00 0.80
C3GN 59 58 1 0 0.85 0.99 0.01 0.85
Ctrs 452 438 14 0 0.98 0.02
CFB p.E566A                      rs45484591 IC-MPGN 88 84 4 0 0.63 0.98 0.02 0.63
DDD 24 23 1 0 0.80 0.98 0.02 0.80
C3GN 63 62 1 0 0.86 0.99 0.01 0.86
Ctrs 452 439 13 0 0.99 0.01
C3 p.R102G                              rs2230199 IC-MPGN 94 59 26 9 0.31 0.77 0.23 0.99
DDD 26 17 6 3 0.36 0.77 0.23 0.87
C3GN 73 47 24 2 0.46 0.81 0.19 0.34
Ctrs 452 271 153 28 0.77 0.23
C3 p.P314L                           rs1047286 IC-MPGN 94 62 27 5 0.79 0.80 0.20 0.70
DDD 26 18 6 2 0.56 0.81 0.19 0.86
C3GN 73 50 21 2 0.52 0.83 0.17 0.30
Ctrs 452 283 146 23 0.79 0.21
THBD p.A473V                               rs1042579 IC-MPGN 94 71 20 3 0.31 0.86 0.14 0.23
DDD 26 22 4 0 0.17 0.92 0.08 0.09
C3GN 74 57 17 0 0.13 0.89 0.11 0.07
Ctrs 452 306 131 15 0.82 0.18
Genotype frequencies Allele frequencies
SNP
Table 5. Association study between common polymorphisms and patients with IC-
MPGN, DDD and C3GN. 
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CFB 
p.R32Q/W   Genotypes 
Histology 
group n RR  RQ QQ RW WW QW 
p value vs 
ctrs 
IC-MPGN 95 59 17 0 16 2 1 0.57 
DDD 26 17 5 0 1 0 3 0.08 
C3GN 73 45 8 2 17 0 1 0.64 
ctrs 452 274 64 5 91 5 13   
         CFB 
p.R32Q/W Allelic frequencies 
  Histology 
group R 
p value 
vs ctrs Q 
p value 
vs ctrs W 
p value 
vs ctrs 
  IC-MPGN 0.79 0.67 0.09 0.94 0.11 0.64 
  DDD 0.77 0.98 0.15 0.27 0.08 0.41 
  C3GN 0.79 0.87 0.09 0.90 0.12 0.97 
  ctrs 0.78   0.10   0.13   
  
Table 6. Frequency of the CFB polymorphism p.R32Q/W in patients 
with IC-MPGN, DDD and C3GN compared to controls. 
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Risk 
Allele
Histology 
group n A/A A/a a/a
p value 
vs ctrs allele A allele a
p value    
vs ctrs
Risk 
allele Frequency
p value 
vs ctrs
Risk 
allele Frequency
p value 
vs ctrs
CFH p.E936D                       rs1065489 D IC-MPGN 94 63 23 8 0.0543 0.79 0.21 0.51 31 0.33 0.97 8 0.09 0.046
DDD 26 18 8 0 0.64 0.85 0.15 0.72 8 0.31 0.95 0 0.00 0.71
C3GN 74 43 26 5 0.2 0.76 0.24 0.11 31 0.42 0.20 5 0.07 0.27
Ctrs 452 301 136 15 0.82 0.18 151 0.33 15 0.03
CD46 c.-366A>G                    rs2796268 G IC-MPGN 94 11 42 41 0.71 0.34 0.66 0.45 83 0.88 0.64 41 0.44 0.54
DDD 26 5 5 16 0.026 0.29 0.71 0.28 21 0.81 0.67 16 0.62 0.046
C3GN 72 14 30 28 0.48 0.40 0.60 0.55 58 0.81 0.32 28 0.39 0.99
Ctrs 452 64 209 179 0.37 0.63 388 0.86 179 0.40
CD46 c*783T>C                           rs7144 T IC-MPGN 94 44 43 7 0.11 0.70 0.30 0.063 87 0.93 0.075 44 0.47 0.23
DDD 26 15 6 5 0.0784 0.69 0.31 0.38 21 0.81 0.78 15 0.58 0.10
C3GN 72 34 28 10 0.45 0.67 0.33 0.34 62 0.86 0.93 34 0.47 0.26
Ctrs 404 159 184 61 0.62 0.38 343 0.85 159 0.39
THBD p.A473V                               rs1042579 A IC-MPGN 94 71 20 3 0.31 0.86 0.14 0.22 91 0.97 0.80 71 0.76 0.17
DDD 26 22 4 0 0.17 0.92 0.08 0.09 26 1.00 0.71 22 0.85 0.11
C3GN 74 57 17 0 0.13 0.89 0.11 0.07 74 1.00 0.23 57 0.77 0.14
Ctrs 452 306 131 15 0.82 0.18 437 0.97 306 0.68
Genotype frequencies
Dominant model         
(homozygous  or 
heterozygous for risk allele)
Recessive model   
(homozygous for risk allele)Allele frequencies
snp
Table 7. Genotype and allele frequencies and models of inheritance of complement 
gene polymorphisms showing a trend of  association to IC-MPGN, DDD and C3GN 
in Table 6. 
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 2.5.2  Complement abnormalities and clinical outcome in patients with kidney 
injury classified by a three-step algorithm. 
2.5.2.1 Classification of recently recruited patients. 
173 patients from the IC-MPGN/C3G cohort described above were classified using an 
unsurpervised hierarchical cluster analysis. Data were reported in the paper with the 
title" Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 
Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN" published 
in the Journal of the American Society of Nephrology (Iatropoulos P et al,  Epub 2017 
Oct 132). 
Newly recruited patients (n=20; Table 8) whose clinical, histological and laboratory 
data were complete, were classified using the three-step algorithm (Table 9)2. 
Among 20 newly recruited patients, 4 IC-MPGN and 5 C3GN patients were assigned to 
cluster 1. These 9 patients showed low C3 (21.1 ± 10.6 mg/dl), high SC5b-9 
(1360±1068 mg/dl) levels and 88% and 78% had subendothelial and mesangial 
deposits, respectively. Five patients were assigned to cluster 2. They were characterized 
by low C3 (20.8±16.4 mg/dl), high SC5b-9 levels (1612±1274 ng/ml) and strong C1q, 
IgG and IgM staining (1.6±0.9, 1.2±0.8, 0.7±0.8, respectively). Interestingly, 2 out of 5 
(40%) showed low serum C4 levels suggesting a complement classical pathway 
activation. The single DDD patient was assigned to the cluster 3 and was characterized 
by low C3 (13 mg/dl) and normal SC5b-9. Finally, 3 patients with IC-MPGN and 2 
patients with C3GN, went to cluster 4. They showed normal C3 (121±32.4mg/dl)  and 
SC5b-9 (228±102 ng/ml)  levels, and 4 out of 5 had mesangial deposits. 
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Algor. 
Cluster 
Patient 
ID 
Histol. 
group Gender 
Age of 
onset 
(y) 
LPV C3NeF 
Serum 
C3 
(mg/dl) 
Serum 
C4 
(mg/dl) 
Plasma 
SC5-9 
(ng/ml) 
Glomer. 
C1q 
Intr. 
Dense 
deps 
1 2287 IC M 15.8 No NA 20 20 386 Trace No 
1 2328 C3GN F 7.8 No Yes 23 17 598 Neg No 
1 2347 C3GN F 32.2 No No 21 NA 1588 Neg No 
1 2435 C3GN M 23.5 Yes No 99 37 297 Neg No 
1 2516 IC F 6.9 No Yes 8 17 2109 Neg No 
1 2553 C3GN M 16.4 No Yes 5 23 3491 Neg No 
1 2557 IC M 4.8 No NA 33 11 605 Neg No 
1 2685 C3GN M 8.4 No NA 39 43 109 Neg No 
1 2752 IC M 6.8 No NA 22 22 1444 Neg No 
1 2782 C3GN F 14.4 No NA 19 5 1914 Trace No 
2 2186 IC F 14.3 No Yes 14 17 2583 2+ No 
2 2585 IC M 8.8 Yes NA 49 5 1209 3+ No 
2 2742 IC F 9.0 No NA 11 6 966 1+ No 
2 2748 IC F 6.4 No NA 21 17 75 1+ No 
2 2760 IC F 10.0 No NA 9 27 3227 1+ No 
3 2507 DDD M 12.2 No Yes 13 15 163 Neg Yes 
4 2352 IC M 15.3 No No 107 15 131 1+ No 
4 2439 IC F 33.3 No No 88 26 314 1+/2+ No 
4 2440 C3GN M 10.7 No NA 150 17 295 Neg No 
4 2453 IC M 5.2 No No 161 29 103 Neg No 
 
 
 
 
 
 
 
 
Histologic Diagnosis Cluster 1 Cluster 2 Cluster 3 Cluster 4 
IC-MPGN (n=12) 4 5 0 3 
DDD (n=1) 0 0 1 0 
C3GN (n=7) 5 0 0 2 
 
Table 9. Distribution of recently recruited IC-MPGN, DDD and C3GN patients 
into the four clusters. 
Table 8. Patients recently recruited by the Italian Registry of MPGN and cluster 
classified using a three-step algorithm.  
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2.5.2.2  Algorithm-based cluster classification on the updated Italian cohort of patients 
with complement-mediated kidney injury. 
Then, the new patients were re-analyzed together with previously described patients2. 
Clinical features, complement assessments, genetic screening and histologic features 
from all patients (n=193) of this cohort classified in the four algorithm-based clusters 
are reported in Table 11. In fig. 34 complement LPV distribution in the four clusters is 
reported. LPVs affecting C3 and CFB were more frequent in clusters 1 (17%) and 2 
(11%) vs. clusters 3 (0%) and 4 (2%) (Fig. 34).  
Gender distribution was similar in the four clusters while age of onset was significantly 
higher in patients from cluster 4 (25.5±19.3 y) in comparison to the other patients 
(cluster 1: 14.9±11.9 y; cluster 2: 17.1±12.3 y; cluster 3: 14.9±10.6 y; p overall <0.001). 
Proteinuria and microhematuria at onset were present in all patients while nephrotic 
syndrome at onset was more frequent in patient from cluster  2 (cluster 1: 34%; cluster 
2: 62%; cluster 3: 21%; cluster 4: 17%; p overall <0.001).   
Consistent with data reported in Iatropoulos et al., cluster 1 included 65 patients with 
histologic diagnosis of IC-MPGN (n=16) and C3GN (n=49) who presented with 
microhematuria (91%), proteinuria (91%) and nephrotic syndrome.  Gross hematuria at 
onset was similarly present in all clusters. These patients had low serum C3 (30.1±20.3 
mg/dl) and very high  SC5b-9 levels (1307 ±1243 ng/ml), high frequency of LPVs 
and/or C3NeF (75%). Electron microscopy data showed that mesangial and 
intramembranous granular deposits in these patients (73% and 61%, respectively) were 
more frequent than in patients from the other clusters. 
Cluster 2 included IC-MPGN patients (n=40) and few C3GN patients (n=5). Most 
patients had an onset accompanied by proteinuria in the nephrotic range (62%; p overall 
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<0.001; cluster 2: vs. cluster 1, p = 0.003; vs. cluster 3, p = 4.7E-04; vs. cluster 4 = 
3.1E-06) that increased during follow-up (87%; p<0.001). Microhematuria and gross 
hematuria were also present at onset (84% and 29 %, respectively). Similarly to patients 
in cluster 1, these patients showed high frequency of LPVs and/or C3NeF (76%), low 
serum C3 (21±18.4 mg/dl) and high SC5b-9 levels (1958±1367 ng/ml) although the 
latter were significantly higher in comparison to those in the other groups (cluster 2 
versus cluster 1: p = 0.014; cluster 2 versus cluster 3: p = 1.5E-06; cluster 2 versus 
cluster 4: p = 1.2 E-13). Interestingly, 24% of these patients showed low serum C4 
levels. Kidney biopsies from these patients were characterized by a strong IgM 
(1.2±0.9), IgG (1.5±1) and C1q (1.7±0.7) deposition at immunofluorescence. 
All patients with histologic diagnosis of DDD (n = 26) fell into cluster 3 together with 3 
patients with IC-MPGN diagnosis. Among them, few patients showed renal impairment 
at onset (3%; p = 0.013); microhematuria, (90%), gross hematuria (41%) and 
proteinuria characterized their onset although nephrotic syndrome was present in only 
21% of them.  These patients, like those included in cluster 1 and 2, had high frequency 
of LPVs and/or C3NeF (84%), low serum C3 levels (21±18.4 mg/dl) with plasma 
SC5b-9 significantly higher (510±503 ng/ml) than those observed in patients in cluster 4 
(p = 0.007). However in cluster 3 plasma SC5b-9 levels were significantly lower than 
those found in patients from cluster 1 (p = 0.002) and cluster 2 (p = 1.5 E-06). Similarly 
to patients in cluster 1, they had low IgA, IgG, IgM and C1q deposition but they differ 
from patients from the other groups for the strong predominance of intramembranous 
highly electron dense deposits  with low subepithelial and subendothelial deposits. 
Finally, cluster 4 was composed by 33 IC-MPGN and 21 C3GN patients. 
Microhematuria (75%), gross hematuria (31%), proteinuria (81%) (in the nephrotic 
range only in 17% of patients) were present at onset although renal impairment was 
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more frequent than in other groups (31%; p = 0.013).  This cluster group distinguished 
from the others for the low prevalence of LPVs and/or C3NeF, normal serum C3 
(98.1±29.7mg/dl) and plasma SC5b-9 (300±151 ng/ml) and later age of onset (25.5 
±19.3 y). This cluster had statistically higher prevalence of sclerotic glomeruli (16% 
±21%; p<0.001), interstitial fibrosis (0.7±0.9; p = 0.001) and arteriolar sclerosis (0.6±1; 
p<0.001) in comparison to other cluster groups.  
  
 
Histologic Diagnosis Cluster 1 Cluster 2 Cluster 3 Cluster 4 
IC-MPGN (n=92) 16 40  3 33 
DDD (n=26) 0 0 26 0 
C3GN (n=75) 49 5 0 21 
Table 10. Distribution of IC-MPGN, DDD and C3GN patients from our cohort 
(n=193) into the four clusters. 
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Variable 1 2 3 4 
Overall 
p-
value 
N 65 45 29 54 . 
Gender (% males) 57% 44% 59% 63% 0.308 
Data at onset      
Age (y) - Mean (SD) 14.9 (±11.9) 17.1 (±12.3) 14.9 (±10.6) 25.5 (±19.3)a,b,c <0.001 
Microhematuria  91%d 84% 90% 75% 0.140 
Gross hematuria 33% 29% 41% 31% 0.724 
Proteinuria 91%  98%d 86% 81% 0.054 
Nephrotic syndrome  34%d      62%a,c,d 21% 17% <0.001 
Renal impairment 15% 24% 3%b    31%a,c 0.013 
Trigger event 34% 25% 35% 36% 0.681 
Familiarity for nephropathy 14% 11% 10% 15% 0.928 
Serum C3 (mg/dl)  30.1 (±20.3) 21 (±18.4)a,c 34.8 (±35.2) 98.1 (±29.7)a,b,c <0.001 
Serum C4  (mg/dl)  21.4 (±9.8) 19.8 (±12.3) 23.9 (±9.2) 21.7 (±7.3) 0.376 
Plasma SC5b-9 (ng/ml)  1307 (±1243)b 1958 (±1367) 510 (±503)a,b 300 (±151)a,b,c <0.001 
Low serum C3        100%b 100% 93.1%   44.4% a,b,c <0.001 
Low serum C4                 6%          24%a,d                                                    7%                                        6% 0.007
C3NeF positive  54%c 61% 80%   6% a,b,c <0.001 
LPV  carriers 29% 24% 14% 4% a,b 0.003 
LPV carriers and/or C3NeF 75% 76% 84%   10% a,b,c <0.001 
      
Data during follow-up      
Nephrotic syndrome 49%        87% a, c,d 48% 46% <0.001 
High blood pressure 28% 44% 24%    56% a,c 0.005 
Chronic kidney disease     26% b,d 44%   24% d 50% 0.016 
ESRD 5% 7% 3% 15% 0.187 
Thrombotic microangiopathy 2% 0% 0%     11% a,b 0.010 
Histological features      
Time Onset to Biopsy (yr), median (IQR) 0.4(0.1-1.4) 0.3 (0.1-2.1) 1.1 (0.3-3.5) 0.3 (0.1-2.6) 0.859 
Light microscopy      
Sclerotic glomeruli 3% (±7%) 5% (±11%) 2% (±6%) 16% (±21%)a,b,c <0.001 
Crescents 5% (±16%) 2% (±8%) 6% (±18%) 5% (±16%) 0.683 
Degree of mesangial proliferatione 1.9 (±0.9) 1.8 (±1.1) 1.9 (±0.8) 1.5 (±1) 0.273 
Degree of endocapillary proliferatione 1.3 (±1.1) 1.5 (±1) c 1 (±1.1) 0.6 (±0.8) a,b,c <0.001 
Degree of interstitial inflammatione 0.4 (±0.6) b,d 0.8 (±0.7) 0.7 (±0.8) 1 (±0.9) 0.001 
Degree of interstitial fibrosise 0.3 (±0.6) 0.5 (±0.7) 0.2 (±0.4) 0.7 (±0.9)a,c 0.001 
Degree of arteriolar sclerosise 0.1 (±0.4) 0.2 (±0.5) 0.1 (±0.2) 0.6 (±1)a,b,c <0.001 
Immunofluorescence e      
C3 2.7 (±0.5) 2.8 (±0.5) 2.8 (±0.3)    2.5 (±0.7)b,c 0.016 
IgA 0.1 (±0.4)b,d 0.4 (±0.6)c 0.1 (±0.3) 0.3 (±0.7) 0.015 
IgG 0.4 (±0.9)b,d 1.5 (±1) 0.4 (±0.7)b,d 1.1 (±1.2) <0.001 
IgM 0.6 (±0.8) 1.2 (±0.9)a,c,d 0.6 (±0.6) 0.8 (±1) 0.002 
C1q 0 (±0.1)c,d 1.7 (±0.7)a,c,d 0.2 (±0.5)d 0.6 (±0.9) <0.001 
Fibrinogen 0.4 (±0.9) 0.5 (±0.8) 0.3 (±0.7)     0.1 (±0.3) a,b 0.033 
Electron microscopy      
Mesangial deposits    73% c,d 68% 48% 53% 0.051 
Subepithelial deposits 48%         48%       10% a,b,d 42% 0.004 
Subepithelial hump-like deposits 23%         15% 12% 23% 0.480 
Subendothelial deposits 78%          85%       10%a,b,d 69% <0.001 
Intramembranous granular deposits 61%d     53%      0% a,b,d 41% <0.001 
Intramembranous highly electron-dense 
ribbon-like deposits               0% 0%        100%
 a,b,d 0% <0.001 
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Table 11.  Clinical features, complement assessment, genetic 
screening and histologic features in patients classified according to  
cluster groups calculated on the basis of three-step algorithm. 
Continuous variables are reported as mean (±SD) unless otherwise 
specified. 
Serum C3: reference 90-180 mg/dl; serum C4: reference 10-40 mg/dl; 
plasma SC5b-9: reference ≤303 ng/ml. 
a Significant different from cluster 1. 
b Significant different from cluster 2. 
c Significant different from cluster 3. 
d Significant different from cluster 4. 
e Degree of mesangial proliferation, endocapillary proliferation, 
interstitial inflammation, interstitial fibrosis, and arteriolar sclerosis, 
as well as IF findings were graded using a scale of 0 to 3, including 0, 
trace (0.5+), 1+, 2+ and 3+. 
Figure 34. Complement likely pathogenic distribution in the four 
clusters. 
* Significant different from cluster 4 (p= 2.8 E-04);  
° Significant different from cluster 4 (p= 0.002). 
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2.5.2.3  Renal survival 
Fifteen patients developed end stage renal disease (cluster 1: n=3; cluster 2: n=3; cluster 
3: n=1; cluster 4: n=8; p=0.187). Kaplan-Meier analysis showed that patients in cluster 
4 had an higher risk to develop ESRD in comparison to the other patients (p=0.0134; 
cluster 1-3 vs cluster 4, Fig.35-36). 
 
 
 
 
Figure 35. Kaplan-Meier representing the risk to develop ESRD in different 
groups of patients classified by the three-step algorithm. 
Figure 36. Kaplan-Meier representing the risk to develop ESRD in cluster 1-3 
versus cluster 4.  
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2.5.2.4  Susceptibility genetic variants 
Single nucleotide polymorphisms analyzed in the three histology groups (IC-MPGN, 
DDD and C3GN; section 2.5.1.6) were also studied in the four algorithm clusters (Table 
12).  The CFH, p.936D  allele was over represented in cluster 2 (allele frequencies: 
cluster 2 = 0.31; ctrs = 0.18; p = 0.008), while the THBD p.A473 was in association 
with cluster 1 (allele frequencies: cluster 1 = 0.92; ctrs = 0.82; p = 0.008) and showed a 
trend of association with cluster 2 (allele frequency: 0.91; p=0.098). These results fitted 
with a recessive inheritance model (Table 14). 
Genotype frequency analyses showed a trend of association for the CFH, c.-331T in 
cluster 2 (recessive model: p=0.06 vs. ctrs) and for CD46 c.-366A in cluster 3 (recessive 
model: p=0.068 vs. ctrs, Table 14) . 
 
  
Cluster 
group n A/A A/a a/a
p 
value 
vs ctrs
Allele 
frequency 
allele A 
Allele 
frequency 
allele a
p value    
vs ctrs
CFH c.-331C>T                    rs3753394 Cluster 1 63 31 26 6 0.73 0.70 0.30 0.83
Cluster 2 44 17 20 7 0.07 0.61 0.39 0.07
Cluster 3 29 17 10 2 0.60 0.76 0.24 0.54
Cluster 4 53 20 27 6 0.21 0.63 0.37 0.11
Ctrs 452 223 198 31 0.71 0.29
CFH p.V62I                               rs800292 Cluster 1 63 41 20 2 0.37 0.81 0.19 0.23
Cluster 2 44 24 16 4 0.38 0.73 0.27 0.63
Cluster 3 29 19 9 1 0.59 0.81 0.19 0.44
Cluster 4 53 34 18 1 0.42 0.81 0.19 0.26
Ctrs 452 252 180 20 0.76 0.24
Genotype frequencies Allele frequencies
SNP
Table 12. Association study between common polymorphisms and patients included in 
different clusters. It continues in next pages. 
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Cluster 
group n A/A A/a a/a
p 
value 
vs ctrs
Allele 
frequency 
allele A 
Allele 
frequency 
allele a
p value    
vs ctrs
CFH p.H402Y                              rs1061170 Cluster 1 63 10 29 24 0.80 0.39 0.61 0.60
Cluster 2 44 6 13 25 0.16 0.28 0.72 0.19
Cluster 3 29 9 9 11 0.056 0.47 0.53 0.14
Cluster 4 53 10 23 20 0.66 0.41 0.59 0.42
Ctrs 452 66 194 192 0.36 0.64
CFH p.E936D                       rs1065489 Cluster 1 63 40 21 2 0.87 0.80 0.20 0.78
Cluster 2 44 23 15 6 0.003 0.69 0.31 0.008
Cluster 3 29 21 8 0 0.56 0.86 0.14 0.48
Cluster 4 53 36 13 4 0.25 0.80 0.20 0.82
Ctrs 452 301 136 15 0.82 0.18
CD46 c.-652G>A                   rs2796267 Cluster 1 58 9 25 24 0.96 0.37 0.63 0.95
Cluster 2 43 7 13 23 0.34 0.31 0.69 0.44
Cluster 3 25 4 9 12 0.86 0.34 0.66 0.86
Cluster 4 51 4 23 24 0.34 0.30 0.70 0.29
Ctrs 404 63 167 174 0.36 0.64
CD46 c.-366A>G                    rs2796268 Cluster 1 62 12 27 23 0.56 0.41 0.59 0.47
Cluster 2 44 5 18 21 0.57 0.32 0.68 0.37
Cluster 3 29 5 7 17 0.06 0.29 0.71 0.28
Cluster 4 53 6 22 25 0.55 0.32 0.68 0.34
Ctrs 452 64 209 179 0.37 0.63
Genotype frequencies Allele frequencies
SNP
Table 12. Association study between common polymorphisms and patients included 
in different clusters. It continues in next pages. 
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Cluster 
group n A/A A/a a/a
p 
value 
vs ctrs
Allele 
frequency 
allele A 
Allele 
frequency 
allele a
p value    
vs ctrs
CD46 p.A309V                      rs35366573 Cluster 1 48 48 0 0 0.61 1 0.00 0.62
Cluster 2 39 37 2 0 0.35 0.97 0.03 0.56
Cluster 3 24 24 0 0 0.78 1.00 0.00 1.00
Cluster 4 40 40 0 0 0.67 1.00 0.00 0.72
Ctrs 452 443 8 1 0.99 0.01
CD46 c*783T>C                           rs7144 Cluster 1 62 28 25 9 0.67 0.65 0.35 0.56
Cluster 2 44 22 18 4 0.32 0.70 0.30 0.16
Cluster 3 29 16 8 5 0.16 0.69 0.31 0.37
Cluster 4 53 26 23 4 0.22 0.71 0.29 0.10
Ctrs 404 159 184 61 0.62 0.38
CFB p.L9H                            rs4151667 Cluster 1 60 54 6 0 0.73 0.95 0.05 0.91
Cluster 2 44 39 5 0 0.64 0.94 0.06 0.75
Cluster 3 29 28 1 0 0.65 0.98 0.02 0.54
Cluster 4 52 49 3 0 0.78 0.97 0.03 0.67
Ctrs 452 415 35 2 0.96 0.04
CFB p.K565E                        rs4151659 Cluster 1 52 51 1 0 0.97 0.99 0.01 0.97
Cluster 2 42 40 2 0 0.90 0.98 0.02 0.90
Cluster 3 26 26 0 0 0.75 1.00 0.00 0.76
Cluster 4 46 45 1 0 0.92 0.99 0.01 0.92
Ctrs 452 438 14 0 0.98 0.02
Genotype frequencies Allele frequencies
SNP
Table 12. Association study between common polymorphisms and patients included in 
different clusters. It continues in next page. 
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Cluster 
group n A/A A/a a/a
p 
value 
vs ctrs
Allele 
frequency 
allele A 
Allele 
frequency 
allele a
p value    
vs ctrs
CFB p.E566A                      rs45484591 Cluster 1 55 54 1 0 0.99 0.99 0.01 0.99
Cluster 2 42 41 1 0 0.76 0.99 0.01 0.77
Cluster 3 26 25 1 0 0.75 0.98 0.02 0.76
Cluster 4 47 44 3 0 0.39 0.97 0.03 0.39
Ctrs 452 439 13 0 0.99 0.01
C3 p.R102G                              rs2230199 Cluster 1 62 40 20 2 0.59 0.81 0.19 0.41
Cluster 2 44 30 10 4 0.29 0.80 0.20 0.66
Cluster 3 29 20 6 3 0.28 0.79 0.21 0.79
Cluster 4 53 30 19 4 0.87 0.75 0.25 0.67
Ctrs 452 271 153 28 0.77 0.23
C3 p.P314L                           rs1047286 Cluster 1 62 42 18 2 0.67 0.82 0.18 0.43
Cluster 2 44 29 13 2 0.91 0.81 0.19 0.78
Cluster 3 29 21 6 2 0.42 0.83 0.17 0.58
Cluster 4 53 35 16 2 0.85 0.81 0.19 0.66
Ctrs 452 283 146 23 0.79 0.21
THBD p.A473V                               rs1042579 Cluster 1 63 53 10 0 0.02 0.92 0.079 0.008
Cluster 2 44 36 7 1 0.15 0.90 0.10 0.098
Cluster 3 29 24 5 0 0.20 0.91 0.09 0.11
Cluster 4 53 34 17 2 0.87 0.80 0.20 0.71
Ctrs 452 306 131 15 0.82 0.18
Genotype frequencies Allele frequencies
SNP
Table 11 Table 12. Association study between common polymorphisms and patients included in 
different clusters.  
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CFB p.R32Q/W   Genotypes 
Histology group n RR  RQ QQ RW WW QW p value vs ctrs 
Cluster 1 62 41 5 1 15 0 0 0.44 
Cluster 2 44 28 8 0 6 1 1 0.80 
Cluster 3 29 18 6 0 2 0 3 0.13 
Cluster 4 53 30 10 1 10 1 1 0.91 
Ctrs 452 274 64 5 91 5 13   
         CFB p.R32Q/W Allelic frequencies 
  
Histology group R p value vs ctrs Q 
p value 
vs ctrs W 
p value 
vs ctrs 
  Cluster 1 0.82 0.31 0.06 0.20 0.12 0.99 
  Cluster 2 0.80 0.80 0.10 1.00 0.10 0.63 
  Cluster 3 0.76 0.86 0.16 0.22 0.09 0.49 
  Cluster 4 0.75 0.68 0.12 0.49 0.12 0.96 
  Ctrs 0.78   0.10   0.13   
   
 
 
Table 13. Frequency of the CFB polymorphism p.R32Q/W in different 
clusters. 
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Risk 
allele
Cluster 
group n A/A A/a a/a
p value 
vs ctrs Risk allele Frequency
p value 
vs ctrs Risk allele Frequency
p value 
vs ctrs
CFH c.-331C>T                    rs3753394 T Cluster 1 63 31 26 6 0.73 32 0.51 0.91 6 0.10 0.61
Cluster 2 44 17 20 7 0.07 27 0.61 0.23 7 0.16 0.06
Cluster 3 29 17 10 2 0.60 12 0.41 0.44 2 0.07 0.71
Cluster 4 53 20 27 6 0.21 33 0.62 0.15 6 0.11 0.37
Ctrs 452 223 198 31 229 0.51 31 0.07
CFH p.E936D                       rs1065489 D Cluster 1 63 40 21 2 0.87 23 0.37 0.73 2 0.03 0.75
Cluster 2 44 23 15 6 0.0031 21 0.48 0.08 6 0.14 0.004
Cluster 3 29 21 8 0 0.56 8 0.28 0.66 0 0.00 0.66
Cluster 4 53 36 13 4 0.25 17 0.32 0.97 4 0.08 0.25
Ctrs 452 301 136 15 151 0.33 15 0.03
CD46 c.-366A>G                    rs2796268 G Cluster 1 62 12 27 23 0.56 50 0.81 0.37 23 0.37 0.81
Cluster 2 44 5 18 21 0.57 39 0.89 0.78 21 0.48 0.37
Cluster 3 29 5 7 17 0.06 24 0.83 0.85 17 0.59 0.068
Cluster 4 53 6 22 25 0.55 47 0.89 0.72 25 0.47 0.36
Ctrs 452 64 209 179 388 0.86 179 0.40
THBD p.A473V                               rs1042579 A Cluster 1 63 53 10 0 0.0213 63 1.00 0.29 53 0.84 0.01
Cluster 2 44 36 7 1 0.15 43 0.98 0.94 36 0.82 0.08
Cluster 3 29 24 5 0 0.20 29 1.00 0.66 24 0.83 0.14
Cluster 4 53 34 17 2 0.87 51 0.96 0.82 34 0.64 0.71
Ctrs 452 306 131 15 437 0.97 306 0.68
snp
Genotype frequencies
Dominant model                          
(homozygous or heterozygous for 
risk allele)
Recessive model                     
(homozygous for risk allele)
Table 14. Genotype and allele frequencies and models of inheritance of complement 
gene polymorphisms showing a trend of association to different clusters in Table 13. 
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2.5.3  Discussion 
In this study, 199 patients recruited by the Italian Registry of MPGN, were 
histologically classified in IC-MPGN, DDD and C3GN according to the current 
classification89, 185.  
Since hypocomplementemia (represented by low C3 levels) was present in all histology 
groups, genetic and biochemical analyses were performed to investigate the presence of 
likely pathogenic variants in complement genes and C3NeF, an autoantibody that 
stabilizes the C3 convertase. These results were then correlated with different 
ultrastructural lesions, complement profile and clinical outcome to understand the 
mechanism underlying IC-MPGN, DDD and C3GN and to contribute to identify new 
molecular targets for complement inhibitory therapies. 
Onset of patients with IC-MPGN, that occurred at a mean age of 19.6 years, was mainly 
characterized by microhematuria and proteinuria that in 39% of cases was in the 
nephrotic range. Electron microscopy revealed predominant subendothelial deposits but 
also mesangial and intramembranous granular deposits whilst immunofluorescence 
showed a strong C3, IgG, IgM and C1q deposition. The presence of C3NeF was 
associated with low C3 levels and high SC5b-9 levels, while patients with LPVs 
showed high SC5b-9 levels and near normal C3 levels. These data suggest that in IC-
MPGN patients C3NeF affected both C3 and C5 convertase activation while genetic 
abnormalities mainly influenced the terminal pathway of complement. LPVs identified 
in IC-MPGN patients were mainly localized in CFH and C3 genes. Notably, a few IC-
MPGN patients carried LPVs in CFB gene, while no CFB LPVs were identified in the 
other histology groups. A CFB mutation was already described in a familial case of 
C3GN, indicating that such abnormalities may not be restricted to IC-MPGN113. 
Although functional effects of CFB LPVs associated with IC-MPGN and C3GN are still 
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unknown, it is important to consider that FB, together with C3, generate the C3 
convertase (C3bBb) and C5 convertase (C3bBbC3b) of the complement alternative 
pathway. I hypothesize that C3 and CFB LPVs identified in these patients, may generate 
C3 and C5 convertases more resistant to inactivation by complement regulators causing 
complement activation until the terminal pathway. 
Furthermore, association analysis showed that the presence of the CFH 936D 
polymorphism increased the risk to develop IC-MPGN.  
These data suggest that, although the strong glomerular presence of immune-complexes 
indicates that IC-MPGN is initiated by activation of the classical complement pathway, 
genetic risk factors predisposes to a switch from classical pathway driven disease to a 
chronic alternative pathway-driven process.  
Patients with C3GN showed a clinical onset (characterized by microhematuria, 
proteinuria, nephrotic syndrome, renal impairment and mean age of onset of 17.9 years) 
similar to IC-MPGN patients. Electron microscopy was characterized by mesangial, 
subepithelial and subendothelial deposits with predominant C3 deposition at IF. Low 
C3 levels and high SC5b-9 levels were associated with both LPVs and C3NeF although 
patients with only C3NeF had higher plasma SC5b-9 levels in comparison to patients 
with only LPVs. Compared to IC-MPGN and DDD patients, C3GN patients showed a 
higher frequency of LPVs, involving CFH, CFI, C3 and THBD genes. The most 
abundant LPVs, involved the C3 gene followed by the CFH gene, like in IC-MPGN. 
However, at variance with IC-MPGN patients in whom the CFH LPVs were broadly 
distributed, CFH LPVs in C3GN mainly affected the N-terminal domains that are 
responsible for the regulatory activity of FH.  
Notably, about 46% of patients with IC-MPGN or C3GN did not carry either LPVs 
and/or C3NeF and showed normal complement profile in the face of strong C3 
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glomerular deposition, suggesting that in these patients other complement abnormalities 
not affecting circulating C3 and SC5b-9 levels may be present.  
Patients with DDD had a slightly earlier onset in comparison to patients in the other two 
histology groups (mean age of onset: 15.1 years), characterized by the microhematuria, 
proteinuria but also by a more frequent gross hematuria. Differently from the other 
patient groups, DDD patients rarely showed renal impairment at onset. The frequency of 
genetic and/or acquired abnormalities was statistically higher than in the other patient 
groups mainly due to the significantly higher prevalence of C3NeF (79%). DDD 
patients had lower C3 levels than IC-MPGN patients while SC5b-9 levels were lower in 
DDD than in the other histology groups. Interestingly, DDD patients without genetic or 
acquired abnormalities showed low C3 levels but normal SC5b-9 levels suggesting the 
presence of an unknown factor underlying hypocomplementemia. In DDD patients, 
LPVs were localized in the CFH, CFI and THBD genes. Among them, the FH 
p.R1210C, carried by a DDD patient,  is the most frequent LPV in aHUS and has been 
described to complex with albumin impairing accessibility to all FH functional 
domains166, 167. The DDD-associated LPV in THBD, as well as the one identified in 
C3GN, were already described in aHUS and functional studies demonstrated that 
mutant THBD proteins affected the complement regulation through CFI-mediated C3b 
inactivation22. Thrombomodulin is a cell membrane protein but it also exists in a soluble 
plasma form that increases in diseases characterized by vascular damage and regulates 
complement and inflammation. Reported studies showed that high plasma 
thrombomodulin levels may be vasculoprotective195, 196. An increased expression of 
thrombomodulin in glomerular endothelial cells was described in 
membranoproliferative glomerulonephritis and lupus glomerulonephritis and may 
represent a protective response following the glomerular complement activation 
occurring in MPGN120, 121.  
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Altogether these data suggest that the presence of C3NeF is the main cause of low C3 
levels in all histology groups. In DDD patients C3NeF seems to mainly affect the C3 
convertase than the terminal pathway whilst in IC-MPGN and C3GN it showed greater 
effects on terminal pathway than on C3 convertase. These findings are in accordance 
with published data. Zhang et al197 compared the complement profile between patients 
with DDD and C3GN, showing that C3 convertase dysregulation was higher in patients 
with DDD while C5 convertase dysregulation was predominant in C3GN. 
 C3NeFs represent a heterogeneous group of autoantibodies198, 199 with different effects 
on complement activation. Regarding the functional assays used to detect C3NeFs, 
different subtypes of these autoantibodies could be identified according to their capacity 
to selectively stabilize the C3 or the C5 convertases, or whether their stabilizing activity 
occurs in the absence or in the presence of properdin, the only known positive regulator 
of the AP complement system200-202. Recently, the Fremaux-Bacchi’s group described 
the presence of circulating autoantibodies that stabilize C5 convertase (C5 Nephritic 
Factors, C5NeFs). C5NeFs correlated with consumption of C3 and with SC5b-9 levels 
and were more frequent in patients with C3GN than in patients with DDD184. The 
presence of C5NeF in C3GN and in IC-MPGN could explain the very high SC5b-9 
levels in patients of these two histologic groups from our cohort. In addition, patients 
with IC-MPGN without C3NeF, may have high SC5b-9 levels because LPVs in two 
components of convertases result in hyperactivation of the AP C3 and C5 convertases. 
 
Complement genetic abnormalities were identified in only 18% of IC-MPGN and C3G 
patients. However, the frequency of LPVs identified in our cohort may be 
underestimated. Indeed, we considered as likely pathogenetic variants those rare 
variants (MAF <0.001) with a pathogenecity score >10 calculated by an in silico 
predictive algorithm (CADD). Recently, Merinero et al203 showed that 73% of CFH 
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LPVs, predicted in silico to be benign or of uncertain significance were functionally  
pathogenic. These data indicate that in silico prediction may fail to assign a correct 
pathogenicity and that we may have lost rare genetic variants considered benign by 
CADD. Thus, functional studies on genetic variants are strongly required to better study  
their causal relationship with the pathology.   
 
The finding of genetic complement abnormalities in IC-MPGN is not in accordance 
with the current classification that considers C3 glomerulopathy caused by a abnormal 
complement alternative pathway activation and IC-MPGN mediated by classic pathway 
because of the immune-complex deposition in the biopsy. 
To address the above discrepancy, we recently proposed a new approach  based on  
unsupervised hierarchical cluster analysis using histologic, biochemical, genetic and 
clinical data. The analysis  separated patients in four homogeneous groups characterized 
by specific pathophysiologic mechanisms2. We also provided a simple three-step 
algorithm (that had a 75% of concordance with the original cluster analysis) to assign 
patients to different groups.  
In the updated cohort described in this chapter (n=193), patients with complete clinical, 
histological and laboratory data were classified using the three-step algorithm.2 As 
already published, patients were included in four groups called clusters. Cluster 1, 2 and 
3 were characterized by low C3 and high SCb-9 levels and high frequency of LPVs and 
or C3NeF . Cluster 4 had normal complement profile and low frequency of complement 
abnormalities and later age of onset. 
Cluster 1 and 2 differentiated from cluster 3 for the very high levels of plasma SC5b-9. 
Indeed, in these clusters are included IC-MPGN and C3GN patients who, as discussed 
above, carried LPVs in the two convertase components (C3 and FB) and may have 
C5NeFs that stabilize the C5 convertase. The frequency of nephrotic syndrome at onset 
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was significantly higher in cluster 2 than in the other clusters. In addition, cluster 2 was 
represented by patients with low C4 levels and a significantly higher glomerular 
deposition of IgG, IgM and C1q in comparison to other patients suggesting an important 
role of classical pathway of complement in initiating the disease.  
Cluster 3, composed by all DDD patients and few patients with IC-MPGN, was 
characterized by low C3 levels and only slightly elevated  SC5b-9 levels, suggesting a 
prevalent C3 convertase dysregulation in fluid-phase. SC5b-9 levels in cluster 3 were 
significantly lower than in clusters 1 and 2, indicating the presence of different 
pathogenetic mechanisms leading to complement dysregulation. This hypothesis is  
confirmed by the difference in LPV localization that in cluster 3 mainly involved genes 
encoding complement regulator proteins (CFH, CFI and THBD), while no LPV 
localized on C3 and CFB genes, at variance with clusters 1 and 2 .  
Finally, identification of cluster 4 including patients with IC-MPGN or C3GN and with 
a normal complement profile, rare C3NeF and LPVs in the face of intense C3 
glomerular staining, indicates the existence of still unknown genetic or acquired factors 
determining  local glomerular complement deposition in  subgroups of IC-MPGN and 
C3GN patients.  
This may result in accumulation of complement effector molecules causing slow 
chronic progression of injury that explain a late onset and  an higher risk to develop end 
stage renal disease that characterize this cluster.  
Altogether these findings confirmed our published data on cluster analysis identifying 
distinct pathogenetic patterns underlying IC-MPGN, DDD and C3GN2 . In summary, 
the histology, clinical, genetic and biochemical data in a large cohort of patients with 
kidney injury showed complement alternative pathway abnormalities both in C3 
glomerulopathy and in IC-MPGN.  Among the three histology groups,  the DDD  group 
showed a clinical and complement profile different from IC-MPGN and C3GN and 
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C3NeF or LPVs till now identified do not seem to be the only risk factors responsible 
for hypocomplementemia. Cluster analysis allowed the identification of distinct 
pathogenetic patterns separating patients with an intense C5 convertase activity from 
patients with a predominant C3 convertase activity (including DDD patients). Of 
interest, it also identified a group of patients without known complement abnormalities 
despite intense glomerular complement deposition. 
These results may contribute to better discover target therapies and indicate that the 
identification of new biochemical and genetic factors is required to refine the 
classification of these glomerular diseases. 
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3. COMPLEMENT AND COAGULATION GENETIC SCREENING 
IN PATIENTS WITH DENSE DEPOSIT DISEASE 
 
3.1 Introduction 
Dense Deposit Disease (DDD) is a glomerular lesion with a prevalence of 2 to 3 
individuals per million population and traditionally is diagnosed either in childhood or 
adulthood137,204,205. 
Due to  the presence of intense glomerular C3 staining with scanty or no 
immunoglobulin at immunofluorescence, DDD is considered a C3 glomerulopathy 
(C3G). DDD is characterized at electron microscopy by electron-dense,  sausage-shape 
deposits in the central layer (lamina densa) of GBM and often in the mesangium and 
Bowman's capsule137. The dense deposits characteristic of DDD are composed both by 
components of the AP of complement (C3b and its breakdown products iC3b, C3dg, 
C3c) and also by component of the terminal pathway206. 
The clinical onset of DDD is mainly characterized by microhematuria,  proteinuria 
(with or without nephrotic syndrome) and hypertension137. Among non renal 
manifestations of DDD, acquired partial lipodystrophy (APL) and ocular lesions similar 
to drusen have been reported91-93. 
Although the pathogenesis of DDD has not been fully clarified, hyperactivation of the 
complement alternative pathway (AP) is found in more than 80% of patients, as 
documented by low C3 levels with normal C4 levels in serum. The reported causes of 
the AP dysregulation include both acquired and genetic factors. Indeed, the C3 nephritic 
factor (C3NeF), an autoantibody that stabilizes the C3 convertase, is present in around 
80% of  DDD patients95,103 (Chapter 2, section 2.5.1.) and anti-factor B and anti-factor 
H autoantibodies have been also reported in a few cases96,97,100. Mutations and rare 
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functional variants in genes coding the AP complement regulators  Factor H (CFH)  and 
Factor I (CFI) and more rarely, gain of function mutations in the gene coding the 
component of the AP C3 convertase, complement C3 (C3) have been reported 95,101,103 
(Chapter 2, section 2.5.1.3). 
Genomic rearrangements in the complement factor H-related genes, that include a 
CFHR2-CFHR5 hybrid gene and an internal duplication in CFHR1, have also been 
described in a few patients with DDD130,132.  
However, the genetic determinants of DDD are still unknown for the majority (>80%) 
of patients. The high rate of incomplete penetrance indicates that likely pathogenic 
variants (LPVs) and genomic rearrangements predispose individuals to diverse 
pathologies and that additional genetic risk factors are necessary to cause the disease 
and determine the final phenotype. 
Indeed, besides LPVs and genomic rearrangements, there are also common variants in 
the CFH, C3 and CD46 genes that increase the risk of DDD95,116. A trend of association 
of a common THBD allele (A473) was also observed in DDD patients from the Italian 
cohort103(see section 2.5.1.7).  
Thanks to a collaboration with the University of Iowa, I spent 6 months at the 
laboratory of Dr Richard Smith where I used a wide NGS panel (called CasCADE) to 
search rare variants in complement and coagulation genes in patients with DDD.  Eighty 
five genes were sequenced in 17 patients with DDD. All variants were filtered by 
quality parameters, frequency and functional effects. Final variants were classified by a 
pathogenicity score. 
The majority of variants involved complement regulator genes. Besides abnormalities in 
the CFH-CFHR gene family, I also found likely deleterious variants in complement 
genes not previously associated with DDD, although always in combination with other 
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deleterious complement variants. Few variants were found in genes of classical and 
coagulation pathways. 
Results from this study suggest the existence of new genetic risk factors that require 
further investigation to confirm their involvement in the pathogenesis of DDD. 
 
This chapter was designed with the following objective:  
1) To search new likely deleterious variants in candidate complement and 
coagulation genes in patients with Dense Deposit Disease. 
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3.2 Patients 
Patients are included in the Italian cohort described in Chapter 2. 
 
3.3 Methods 
3.3.1  DNA samples 
DNA samples were extracted and quantified as reported as reported in section 2.4.2 
 
3.3.2  CasCADE panel 
Target genomic enrichment was performed on DDD samples using a wide panel called 
CasCADE (called CasCADE: Capture and Sequencing of Complement- Associated 
Disease Exons), developed at the University of Iowa. CasCADE is a RNA-bait panel 
that, based on Agilent SureSelect Target Enrichment System, targets coding regions of 
85 complement and coagulation genes. Following the manufacturer’s protocol, 2 μg 
genomic DNA was sheared to 100-300 bp fragments by Covaris sonification system. 
DNA fragments followed end-repair, 3' end adenylation, adapter ligation and pre-
hybridization PCR steps. Prepped adaptor-ligated DNA libraries were combined with 
the biotinylated RNA-baits via a 24-hours hybridization at 65°C. 
Then in the bead capture step, streptavidin-coated beads were used to selectively 
capture the biotinylated RNA-bait-DNA complexes. During the following post-
hybridization PCR, targeted regions were enriched and each library barcoded with a 
unique index.  Final libraries quality and concentration were verified by Agilent High 
Sensitivity DNA Kit on a Bioanalyzer 2100 (Agilent Technologies). After pooling, 
libraries were sequenced on a HiSeq 2000 (Illumina) at the DNA Core Facility of the 
University of Iowa’s Institute of Human Genetics or on an in-house MiSeq (Illumina). 
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Sequence data analysis was performed using a bioinformatic pipeline on Galaxy, a web-
based platform. All genetic variants were annotated by ANNOVAR software.  
All annotated variants with QD <5, Depht <10 and phred-scaled quality score <30 were 
excluded.  Among variants with a minor allele frequency (MAF) in 1000 genome, 
ESP6500 and Exac (European Non Finnish population) databases less than 0.001, I 
focused on nonsynonymous, frame shift, splicing e nonsense variants.  A pathogenicity 
Score (PS) was calculated by combining prediction results deriving from PhyloP, Sift, 
Polyphen2_HDiv, Polyphen2_HVar, LRT, Mutation Taster and Gerp++ computational 
prediction methods. Variants with a PS ≥4 were considered "likely deleterious".  
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3.4 Results 
Targeted genomic enrichment and next generation sequencing (TGE+NGS) were used 
to analyze 17 patients with DDD. The CasCADE panel covered 1071 exons of  85 
complement and coagulation genes (Fig. 37).  
 
 
 
 
Among  9096 variants identified, 8231 passed the quality control step. Variants (n= 
716) with a minor allele frequency (MAF) in 1000 genome, ESP6500 and Exac 
(European Non Finnish population) databases less than 0.001 were retained and filtered 
by functional effect as described in methods. Filtering steps provided 25 heterozygous 
rare functional variants (including missense and nonsense variants) in 12 patients (Table 
15). Eight patients (47%) carried two or more rare variants while four patients showed a 
single rare variant, two of them in CFH and CFI and already identified by the NGS 
minipanel (see section 2.5.1.3). In five patients no rare variants were detected in 
Figure 37. Complement and coagulation genes included in the CasCADE panel. 
Image taken from Fengxiao et al. (2014)4. 
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complement and coagulation genes. Among rare variants, 17 were predicted likely 
deleterious by the presence of a premature stop codon or by a pathogenicity score (PS) 
≥4 (Table 15).  
The most frequent abnormalities (60%) involved complement regulator genes, followed 
by complement receptor (12%) and coagulation genes (12%) (Fig.38).  Not surprisingly, 
6 variants (24%) were found in the genes of the CFH family (CFH, CFHR2, CFHR4 
and CFHR5) suggesting their important role in the DDD phenotype. 
 
 
  
 
 
 
 
 
 
 
 
Figure 38. Distribution of variants identified in patients with DDD. 
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Sample ID Gene Nucleotide AA Change Exac European (Non Finnish) MAF  PS  dbSNP 
633 MASP2 c.A1616G  p.N539S 1,50E-05  1/7 rs776770754 
633 PTX3 c.A574G  p.I192V 1,05E-04 7/7 rs762560584 
1101 CFH c.C3628T  p.R1210C 2,85E-04 1/6 rs121913059 
1124 C4BPA c.G676A  p.V226I 1,50E-04 5/7 rs117760512 
1124 ITGAM c.G2486A  p.R829Q 1,05E-04 5/7 rs201299141 
1149 CR1 c.A4594G  p.S1532G 2,85E-04 4/6 rs189863730 
1149 KLKB1 c.G1694A  p.G565D 6,00E-05 7/7 rs150832692 
1149 C5AR1 c.C185T  p.T62M 1,49E-05 4/7 rs200003809 
1218 C6 c.G143A  p.R48K 3,75E-04 6/7 rs145422926 
1218 SERPINA1 c.G1093T  p.D365Y NA 5/7 NA 
1218 ITGAM c.C1226T  p.A409V NA 2/6 NA 
1332 F11 c.A731G  p.Q244R 5,10E-04 2/7 rs5969 
1332 MBTPS1 c.A2873G  p.D958G NA 4/7 NA 
1409 CFI c.G170A  p.G57D 0 6/7 rs776080713 
1549 CFH c.G5T  p.R2I 4,54E-05 3/6 rs142266551 
1549 VTN c.A831C p.K277N 3,01E-05 1/7 rs201356175 
1678 C1QB c.C562T  p.R188W 4,50E-05 5/7 rs772220643 
1678 CFHR2 c.C631T  p.Q211X 8,55E-05 - rs41299605 
1678 CFHR2 c.C760T p.R254X 9,23E-04 - rs41313888 
1678 CPN1 c.C73T  p.H25Y 0 5/7 rs373785594 
1742 FGL2 c.T16G p.W6G NA 3/7 NA 
1773 CFHR4 c.G847A  p.E283K 0 1/6 rs780015139 
1773 CFHR5 c.C865G  p.H289D 0 4/6 rs777469135 
1773 C3AR1 c.C1346T  p.S449F 7,34E-04 7/7 rs147364129 
1837 COLEC11 c.G92A  p.R31H 1,05E-04 6/7 rs139694918 
 
 
The likely deleterious SERPIN1 (PS=5/7) variant, found in the patient #1218 in 
combination with two additional variants, is reported in Human Gene Mutation 
Database (HGMD) in association with  antitrypsin alpha-1-deficiency disease. A rare 
variant in F11 gene (PS=2/7) was found in the patient #1332, in combination with a 
likely deleterious variant in MBTPS1 (encoding the Membrane-bound transcription 
factor site-1 protease. MAF: NA and PS = 4/7). The F11 variant is common in the 
African population and has been previously reported in combined heterozigosity with 
additional F11 variants in patients with  Factor XI deficiency disease207.  
Missense variants were found in the genes of C3aR1 and C5aR1, encoding receptors of 
the pro-inflammatory anaphylatoxins C3a and C5a, respectively. Although an insertion 
Table 15. List of variants obtained after filtering steps. 
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in C3aR1 was also reported in aHUS4,  the effect of these abnormalities in complement-
mediated diseases requires further investigation. The patient with the C5aR1 rare variant 
(#1149), also carries two additional missense variants in CR1 and KLKB1 genes, 
respectively.  CR1 gene encodes a complement receptor, highly expressed on podocytes, 
that acts as surface complement regulator.  Plasma kallikrein (encoded by KLKB1 gene) 
has been reported to be able to cleave the C3 and also Factor B contributing to 
complement activation208.  
Rare functional variants in the ITGAM gene were found in two DDD patients. This gene 
encodes an integrin,  physiologically expressed on endothelial glomerular cells and 
peritubular capillaries of Bowman’s capsule. It acts as a surface receptor protein 
implicated in monocytes, macrophage, and granulocyte interactions209. It has been 
suggested that genetic variants in ITGAM may determine an increased expression of a 
defective molecule, causing a loss of clearance of glomerular deposits, with 
inflammatory process development210. Genetic variants in ITGAM were reported in 
Systemic Lupus Erythematosus209. In one of the two DDD patients with ITGAM 
variants, I also found a likely deleterious rare variant in C4BPA gene (PS=5/7). Human 
C4b-binding protein (C4BP) is the main fluid phase regulator of classical pathway211 
but it has also been reported  to  regulate the complement alternative pathway acting as 
a co-factor of factor I in the proteolytic inactivation of C3b26 . However until now rare 
genetic variants in C4BP were not reported in association with DDD. 
Relatives of #633 and #1678 patients were available for genetic screening. 
Patient #633, an 11-year-old girl, presented with hematuria and nephrotic syndrome177. 
She had low C3 levels (7 mg/dl; normal range: 90-180 mg/dl), normal C4 and high 
SC5b-9 levels (1364 mg/dl; normal range < 303 mg/dl). She received a bioptic 
diagnosis of DDD. After 5 years of ineffective treatment with glucocorticoids, patient 
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was referred to our center and she was treated with ramipril and losartan but nephrotic 
syndrome persisted. 
Since laboratory studies showed the presence of C3NeF, patient was infused with 
rituximab without any reduction of proteinuria. Her serum creatinine increased.  
Low C5 (30%; normal range, 70 to 130)  and high SC5b-9 levels (>1000 ng/ml; normal 
range < 303 ng/ml)  and C5b-9 glomerular deposition suggested an activation of the 
terminal complement pathway. On the basis of these findings, the patient was treated 
with Eculizumab. After 48 weeks of treatment, serum creatinine decreased, proteinuria 
decreased below the nephrotic range and SC5b-9 normalized177. 
Genetic screening of CFH, CFI and MCP disclosed the homozygous CFH V62 and 
H402 common variants, previously reported to affect FH functions on AP regulation117, 
118,212.   
Next generation sequencing using the CasCADE panel, revealed the presence of a rare 
variant in the MASP2 gene (p.N539S; PS=1/7), encoding a protease involved in the 
lectin pathway activation, and a likely deleterious rare variant in PTX3 (p.I192V; 
PS=7/7). Both variants were inherited from the unaffected mother who carried the 
homozygous CFH V62 but the H402 in heterozygosity, while the patient was 
homozygous for the latter variant (Fig.39). In 2008, Deban et al,213 showed that long 
pentraxin (PTX3) interacts with Factor H, modulating the activation of the AP and 
suppressing  injury-induced inflammation.  
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The patient #1678, a Caucasian female (Fig.40), presented at the age of 26 years with 
proteinuria (2g/day) and low C3 levels (C3=45 mg/dl; normal range: 90-180 mg/dl). 
Kidney biopsy showed DDD. She received 3 kidney grafts. The first and second grafts 
were lost due to disease recurrence. While on dialysis before the third transplant she had 
slight C3 reduction (72.5 mg/dl), normal C4 (23mg/dl; normal range: 10-40 mg/dl) and 
SC5b9 (269 ng/ml; normal range: normal levels ≤ 303 ng/ml). C3NeF and anti-factor H 
(FH) autoantibodies were absent. Genetic screening using NGS diagnostic panel set up 
in our laboratory including 6 genes (CFH, C3, MCP, CFI, CFB and THBD) did not 
show any LPV. Targeted Sequencing using CasCADE identified two heterozygous stop 
codons in the CFHR2 gene (p.Q211X and p.R254X), a likely deleterious variant in 
C1QB (PS=5/7), one of the genes that encodes for component C1q, and another 
Figure 39. Pedigree #381. The proband (#633) inherited both rare variants from 
her mother (#1126). The only genetic difference between the proband and her 
mother is represented by the homozygous CFH SNP p.Y402H.  
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abnormality in the CPN1 gene (PS= 5/7), encoding the catalytic subunit of 
carboxypeptidase N which is involved  in the degradation of the anaphylatoxins C3a 
and C5a214. The unaffected patient’s sons, #2589 and #2171, inherited C1QB and CPN1 
variants, respectively,  but not the two CFHR2 nonsense variants (Fig.40). 
In 2013 Eberhardt et al, showed that two molecules of FHR2 form homodimers through 
their N-term domains (SCR1 and SCR2) while the FHR2 C-term domains (SCR3-
SCR4) can bind C3b although with a lower affinity than Factor H127. In addition, SCR3 
and SCR4 domains of FHR2 showed to have an inhibitory activity on C3 convertase 
while SCR1 and SCR2 inhibited the terminal complement pathway. They also reported 
that C3b and C3 convertases bound by FHR2 homodimers, were still accessible to 
complement regulation by FH (and FI in the case of C3 convertase). These data 
suggested that the combined FH and FHR2 binding to C3 convertase may ensure a fast 
and efficient control of complement hyperactivation. The p.R211X variant is located in 
the first portion of SCR4 and causes a premature protein truncation thus affecting 
cystein residues located in this domain (p.C241, C257, C267) and, consequently, 
protein folding.  
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Figure 40. The proband carries two nonsense variants in CFHR2 and two 
likely deleterious variants in C1QB and CPN1. Her sons did not inherit 
nonsense variants in CFHR2.  
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3.5  Discussion 
A wide NGS panel (CasCADE) including 85 genes involved in complement and 
coagulation pathways, was used to study 17 DDD patients. 
All variants were filtered by quality parameters, minor allele frequency and functional 
effects. The resulting variants (n=25) were analyzed by multiple predictor softwares to 
assign them a pathogenicity score (PS).  Seventeen variants were considered likely 
deleterious because of a PS≥4 or nonsense variants. 
Rare genetic variants in complement and coagulations genes were found in 70 %  of 
patients (n=12) and all were heterozygous.  
Sixty percent of variants (n=15) were found in complement regulator genes, including 
the already reported CFH variants (patient ID #1101 and #1549; see section 2.5.1.3) and 
those in CFHR2 (patient ID #1678), CFHR4 and CFHR5 (both are present in patient 
#1773) genes.  
Factor H-related proteins belong to the FH family composed by glycoproteins 
characterized by short consensus repeat (SCR) domains. FHR1, FHR2 and FHR5 are 
present in the plasma exclusively as dimers. Although their function is not completely 
clear, their involvement in the complement pathway has been reported. 
FHR2 protein is a complement regulator that, through its C terminal domains (SCR3 
and SCR4) binds C3b and inhibits the C3 convertase activity127. The FHR2 nonsense 
variant (p.Q211X in SCR4) that I found in the patient #1678 by CasCADE and in 
another DDD patient by direct sequencing (see Chapter 4), creates a premature stop 
codon that leads to a early truncated protein. The resulting protein lacks 57 aminoacids, 
including three of the four cysteine residues involved in two disulfide bonds that are 
crucial for the proper folding of SCRs. On these basis, I hypothesize that the p.Q211X 
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variant may substantially alter the folding of the FHR2 protein resulting either in 
impaired protein secretion or complement regulatory activity.  
FHR4 protein is reported to bind C3b and to form an active C3 convertase (FHR4-
C3bBb) that is less sensitive to the decay mediated by Factor H compared to the normal 
C3Bb convertase. However, variant found in patient #1773 (PS=1/6), is located in the 
SCR5 domain, not involved in the C3b binding and its effect remains unknown.  
FHR5 has been reported to co-localize with complexes derived from complement 
activation in human kidney diseases215 and to bind the complement fragment C3b216.  
FHR5 has been reported to have a cofactor activity for factor I-mediated C3b cleavage 
and to inhibit the C3 convertase activity in fluid phase. However, non physiological 
concentrations were required for these activities126. In addition, McRae et al reported 
that FHR5 binds C-reactive protein (CRP; belonging to the pentraxin family) and they 
hypothesized that CRP can recruit FHR5 to sites of tissue damage resulting in local 
complement inhibition126. However the authors did not clarify the possible mechanisms 
by which CRP-FHR5 complexes could regulate complement.  
More recent literature rather supports a complement activating function for FHR5. In 
2010, Gale et al, described a mutation in CFHR5 in Cypriot patients with 
glomerulonephritis, leading to the duplication of dimerization domains (SCR1 and 
SCR2) . Functional studies on mutant FHR51212  protein showed the generation of large 
multimeric complexes that strongly compete with FH to bind C3b, reducing cell surface 
protection from complement attack94,129.  
Furthermore, in 2015, Csincsi et al, showed that physiological concentrations of FHR5 
compete with FH to bind pentraxins CRP and PTX3 (long pentraxin), causing an 
enhanced complement activation217.  
Since the interaction site of FHR5 with PTX3 (as well as those with CRP) have been 
localized  in SCR3-7 of the protein217,  I hypothesize that the p.H289D variant in SCR5 
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of FHR5 identified in the patient #1773, may act as a gain of function variant and 
increase the capability of  FHR5 to compete with FH for CRP and PTX3 binding.  
Due the complexity of FHR activities on the complement system, functional studies are 
needed to verify the effect of the above CFHR genetic variants on complement 
activation and disease pathogenesis. 
A likely deleterious missense variant in PTX3 gene, which causes the p.I192V 
amino acid change in the C terminal domain of the protein, was found in patient #633, 
combined with the common FH variant p.Y402H (located in SCR7 of the protein), 
previously associated with DDD.  PTX3 is an acute phase protein involved in 
inflammation, innate immunity and female fertility218. It also participates in 
complement classical pathway activation through its interaction with C1q219-221. It has 
been reported that glomerular cells produce PTX3222. In addition, Deban et al213 showed 
that the C-terminal pentraxin domain of PTX3 interacts with FH and can act as a 
nonactivating surface that anchors FH. They hypothesized that PTX3-bound FH at the 
site of tissue injury and inflammation regulates the activation of the complement AP, 
preventing the excessive inflammatory response following tissue injury. Since the 
p.I192V is located in the C terminal of PTX3, it is tempting to speculate that this variant 
may affect the interaction between PTX3 and FH.  In addition, the FH H402 variant that 
is carried in homozygosity by patient #633, is known to reduce FH capability to bind 
glycosaminoglicans on cell surfaces and extracellular matrix117. I hypothesize that in 
this DDD patient, the PTX3 abnormality combined with the homozygous FH H402 
variant concur to reduce the capability of FH to localize at glomerular level and exert 
complement regulation.  
Besides abnormalities in known disease-associated complement genes and in PTX3, 
sequencing by CasCADE disclosed likely deleterious variants in complement genes not 
previously associated with C3G, like ITGAM, C4BPA, C5aR1, C5aR2 and other genes. 
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These variants were all found in heterozygosity, and were always combined with one or 
two additional likely deleterious complement variants, thus it is difficult to establish 
their relative role in the pathogenesis of the disease.  
I found only a rare variant (patient #1678) in genes of the classical pathway (p.R188W 
in C1QB), which is in accordance with normal serum C4 levels and the absence of 
immunoglobulins in the biopsy of patients with DDD.  
Finally, only three variants were found in coagulation genes. This finding is consistent 
with clinical and histology data from patients with DDD from our cohort (see chapter 2) 
who did not show hematologic signs of thrombotic microangiopathy and their biopsies 
were negative for fibrinogen.  
Altogether these data confirm an involvement of CFH-CFHR gene abnormalities in the 
predisposition to DDD and suggest the existence of variants in new complement genes 
that may represent potential risk factors. Genetic studies in other DDD cohorts and 
functional studies are required to clarify the role of the identified variants in disease 
pathogenesis.  
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4. ABNORMALITIES IN FH-FHR FAMILY 
 
4.1 Introduction 
 
The FH/FHR family is composed by a group of highly related proteins: factor H (FH),  
factor H-like (FHL-1), both deriving from different alternative splicing of CFH, and 
five complement factor H-related proteins (FHR1, FHR2, FHR3, FHR4 and FHR5). 
Factor H is abundant in the plasma and represents the main regulator of the complement 
alternative pathway, both in fluid and on cellular surfaces. Since FHRs are 
evolutionarily and structurally related to FH, it was expected that FHRs have similar 
complement inhibiting activities. Contrariwise, the FHR appear to promote the 
complement activation. However, the biological role of FHR proteins is not completely 
clear129.  
As described in Chapter 1, FHR proteins, each one composed by short consensus 
repeats (SCRs) of about 60 amino acids, have high sequence identity in their two N-
terminal domains. In FHR1, FHR2 and FHR5 this identity constitutes a dimerization 
domain leading to generation of homodimers or heterodimers. This dimerization 
increases the FHR avidity for complement surface ligands and enables these proteins to 
efficiently compete with FH for ligand binding129,130. The N-terminal domains of FHR3 
and FHR4 (SCR1-3 of both) share high sequence similarity with FH SCR6 to SCR8 and 
FH SCR6-8-9, respectively, region involved in the binding to heparin, C-reactive 
protein and microbial surface ligands. Finally, the twoC-terminal SCR domains of 
FHRs, are homologous to each other and also share an high sequence homology with 
the C-terminal SCR domains (SCR19-20) of FH (36-100%)124. These similarities 
indicate that FHR proteins may bind similar surface ligands as FH. At variance, FHRs 
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do not show homology with complement regulatory domains of FH (SCR1-4), 
suggesting the absence of direct complement regulatory activity.  
The chromosomal segment (1q32) including the six CFH, CFHR1-5 genes is 
characterized by several large genomic repeat regions with high sequence similarity that 
predispose to genomic rearrangements, including deletions and duplications. The most 
frequent is the deletion of about 84kb resulting in the deficiency of  CFHR3 and CFHR1 
(ΔCFHR3-CFHR1), which is found in normal population in heterozygosity with a 
frequency ranging from 2% to 51 %, depending on ethnicity, and is considered a 
polymorphism223. The homozygous ΔCFHR3-CFHR1 has been associated with a lower 
risk of age-related macular degeneration (AMD)224 and IgA Nephropathy225 and a 
higher risk of aHUS226 and Systemic lupus erythematosus (SLE) 227. A less common 
polymorphism is the deletion of CFHR1 and CFHR4 (ΔCFHR1-CFHR4), also reported 
in aHUS patients226.  
Genomic rearrangements in CFHRs have been reported in patients with C3 
glomerulopathy94,130,132-135,136  (see Section 1.4.2). The majority of them result in 
duplication of the dimerization domains of FHRs leading to the generation of 
complexes that show a high avidity for surface ligands, thus reducing the FH capability 
to regulate complement activation.  
The aims of this chapter are: 
- to study CFHR copy number variations in an Italian cohort of patients with DDD, 
C3GN and also with IC-MPGN; 
- to evaluate circulating levels and genetic and molecular patterns of FH/FHR proteins 
in a cohort of patients with DDD. 
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4.2 Methods 
4.2.1 Patients 
Patients with primary forms of IC-MPGN or C3G were recruited by the Italian Registry 
of MPGN and histologically classified as reported in Chapter 2. Patient #2026, with a 
secondary form of DDD (monoclonal gammopathy) was also included in the study of 
circulating levels and molecular pattern of FH/FHR proteins. 
Biological samples from 54 healthy individuals were collected at Mario Negri Institute. 
The study was approved by Ethics Committee of The Azienda Sanitaria Locale of 
Bergamo (Italy). All participants received detailed information on the purpose and 
design of the study, according to the guidelines of the Declaration of Helsinki. 
 
4.2.2 Complement Minipanel and Genetic data analysis 
CFH-CFHR genes were sequenced in 17 DDD patients using a wide NGS panel 
including 85 genes of complement and coagulation pathways (CasCADE; results 
reported in Chapter 3). To analyze 9 additional DDD patients, I used a new diagnostic 
NGS panel, recently developed in our laboratory, for the simultaneous sequencing of 15 
complement genes (including six genes already included in the NGS minipanel 
described in chapter 2, and CFHR1 to 5, C5, DGKE, ADAMTS13, MMACHC genes). 
Library preparation, sequencing and data analysis were performed as reported in 
Chapter 2. 
CFHR2 exons not fully covered by CasCADE and by the new NGS complement panel 
were analyzed by direct sequencing using primers reported in Table 16. 
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Exon  Left Primer (5’→3’) Right Primer (5’→3’) 
Exon 1 GTAGAGATGGGGTTTCACCAG TGCAACTTAGAGGATGGAGAT 
Exon 2 TGCTAGTCTTACACTCTGC CTCCTCTGGTCACTGCT 
Exon 3 AGTGCAGGGATTACCAGC CTTAGACACAATTGGAACTGAG 
Exon 4 GAATCATTTCATTCAGCAC AGCAGAATGCTTGTTTGT 
Exon 5 CATCCATTAAACATAGTACCTCAT GGTTGTTACTTAGATTTGGTGAAGA 
 
 
4.2.3 Anti-FH Autoantibodies Assessment 
The presence of autoantibodies anti-FH was evaluated by an Enzyme-Linked 
ImmunoSorbent Assay (ELISA). The original method is described by Dragon-Durey et 
al.228 but here a modified method was used. Nunc MaxiSorp ELISA plates (Nunc, 
Roskilde, Denmark) were coated with 0.1 μg of purified human FH (Calbiochem, 
Meudon, France) overnight at 4°C, washed with PBS, 0.2M NaCl and 0.1% Tween20, 
and blocked with PBS, 0.1% Tween20 and 0.3% milk for 1h at room temperature (RT). 
Diluted (1:100) patient plasma/serum samples were added and incubated for 40 minutes 
at RT, washed and incubated for 1 hour with goat anti-human IgG labelled with 
horseradish peroxidase (Sigma-Aldrich). After washing tetramethylbenzidine (TMB, 
Bethyl) substrate was used to reveal enzymatic activity. Two positive controls with 
2000 and 1000 AU/ml titers at 1:100 dilution, kindly gifted by Dr. Dragon-Durey, were 
used as references. A standard curve was obtained by serial dilutions of reference 
positive plasma. All samples were tested in duplicate. The sample concentrations were 
determined by extrapolation of sigmoidal curve.  
 
Table 16. Sequence primers used to analyze CFHR2 gene. 
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4.2.4 FH quantification 
A homemade sandwich ELISA was developed in order to measure plasma or serum FH. 
Nunc MaxiSorp ELISA plates (Nunc, Roskilde, Denmark) were coated with 100 μL of 
diluted sheep polyclonal anti-factor H antibody (dilution 1:6333; Abcam) and were 
incubated overnight at 4°C. The day after the plate was washed with PBS and 0.05% 
Tween20, and was blocked with PBS and 1% BSA for 1 hour at RT. After washing, 
100μL of each diluted test and control samples and standard curve were added. 
Plasma/serum samples from patients and controls were diluted 1:10000 in PBS-BSA 
1%. A standard curve was obtained by serial dilutions of purified human FH 
(Calbiochem, Meudon, France). The plate was incubated for 2 hours at RT and then was 
washed with PBS and 0.05% Tween20. 100 μL of the mouse monoclonal anti human 
FH antibody (diluted 1:10000 in PBS-BSA 1%;  LSBio), which specifically detects FH 
and FHL-1, was added to each well. After 2 hours of incubation at RT, wells were 
washed and 100 μL of diluted goat anti-mouse IgG HRP conjugated (dilution 
1:2000;Thermo Fischer Scientific) were added (1 hour of incubation at RT). After 
washing, tetramethylbenzidine (TMB, Bethyl) was used as substrate to reveal enzymatic 
activity. Enzymatic reaction was terminated using 100 μL of sulphuric acid and the 
absorbance was read at 450 nm. All samples were tested in duplicate. The sample 
concentrations were determined by extrapolation of sigmoidal curve.  
 
4.2.5  Copy Number Variations (CNVs) 
Multiplex-ligation dependent probe amplification (SALSA MLPA; kit P236-A3) was 
used to search for rearrangements/deletions/duplications in the CFH, CFHR3, CFHR1, 
CFHR2, CFHR5 genes.  A subgroup of patients (n=25) were also analyzed for CFHR4 
CNVs. 
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CFHR4 copy number was measured by the use of a multiplex polymerase chain reaction 
(mPCR) that amplified the intron 1, the exon 2 of CFHR4 and intron 3 of CFHR1, as 
reported by Moore et al226. This approach was also used to analyze 224 healthy controls.    
To analyze the uncovered regions of CFHR4 and CFHR5, I designed new homemade 
probes (Table 17) that I set up using SALSA MLPA kit P300-B1.  
 
The procedure of MLPA is the following:  
After DNA denaturation, a mixture of MLPA probes was added to each sample, 
following the manufacturer’s instructions. Each probe, consisting of two 
oligonucleotides that hybridize to immediately adjacent target sequences in order to be 
ligated into a single probe, has a unique amplicon length, ranging from 64 to 454 
nucleotides. During the subsequent PCR reaction, all ligated probes were amplified 
simultaneously using the same PCR fluorescent prime pair. Fragment separation was 
done on the 48-capillary 3730 DNA Analyzer (Life Technologies), yielding a specific 
electropherogram. The height of each probe peak was subjected to an intrasample 
normalisation (comparison of each probe peak with peaks from reference probes) and 
intersample normalisation (comparison of previously normalized probe peaks with 
normalized probe from reference samples.)  
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Gene Exon/Intron Left Primer (5’→3’) Right Primer (5’→3’) 
CFHR4 Intron1 
TACAACCATTTACAAGGCAA
AGGAAGAGGCCTCAGAAGA
ATGCAG 
CCCTGTTGACAGCCACATCTCA
AAGTATTAGCCTCCAGAA 
CFHR4 Intron5 AACAGGAATGTTCAGAGACCTCAATTTGTTAATG 
GACACAATGAGTCTTCAAGAAT
GATATCCATTTATTG 
CFHR4 Exon10 TTCGCATCTGGGGTATTCCACTATGCCTTCCCT 
ACACACTGCTTGAAATGATAGA
ACTGATGTATTCGCATTATAT 
CFHR5 Exon5 
CACCTCCTCAACTCTCCAAT
GGTGAAGTTAAG 
GAGATAAGAAAAGAGGAATAT
GGACACAATGAAGTAGTGG 
CFHR5 Exon6* 
GGATACATACCTGAACTCGA
GTACGGTTATGTTCAGCCGT
CTGTC 
CCTCCCTATCAACATGGAGTTT
CAGTCGAGGTGAATTGC 
CFHR5 Exon7 CGTTACAGATGTTCAGACATCTTCAGATACAG 
GCACTCAGTCTGTATAAACGGG
AAATGGA 
CFHR5 Exon8* 
GGGAACAATTCTGCCCACCG
CCACCTCAGATACCTAATG 
CTCAGAATATGACAACCACAGT
GAATTATCAGGATGG 
CFHR5 Exon9* 
CCCATTATCAGTATATCCTC
CAGGGTCAACAGTGACGTA
CCGTTGC 
CAGTCCTTCTATAAACTCCAGG
GCTCTGTAACTGTAACATGC 
CFHR5 Exon10 
GGATGCTGTTGAATTCCAGT
GTAAATTCC 
CACATAAAGCGATGATATCATC
ACCACC 
 
 
 
 
4.2.6  Breakpoint Analyses 
To identify the breakpoint region in a patient showing abnormal CNV in CFHR3-
CFHR4 genes, a long polymerase chain reaction was performed using a forward primer 
located in the intron 3 of CFHR3 (5’GGAGAGTCTCCTAGATCTGCAC3’)  and a 
reverse primer designed in the exon 10 of CFHR4 
(5’CAGTTAAAAGGAAAAAGTGACAT3’).  PCR was carried out in 25 ul of reaction 
volume using 125 ng of genomic DNA and  the Accuprime Taq DNA Polymerase 
(Thermo Fisher Scientific; 35 cycles of amplification : 94°C for 30 seconds, 59°C for 30 
seconds, 68°C for 10 minutes) according to the manufacture’s protocol.  The breakpoint 
region was identified by bidirectional sequencing of the long-range PCR product, using 
primers reported in Table 18 and BigDye® Terminator v3.1 Cycle Sequencing Kit 
Table 17. Homemade MLPA probes hybridization sequences for CFHR4 and 
CFHR5. * Sequence probes taken from Challis R. et al (2015)6. 
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(Thermo Fisher Scientific) following the manufacturer’s instructions. The BigDye 
XTerminator® Purification Kit (Thermo Fisher Scientific) was used to purify DNA 
sequencing reactions removing non-incorporated BigDye® terminators and salts. 
Sequencing analyses were carried out on the 48-capillary 3730 DNA Analyzer (Life 
Technologies). 
The localization of the Alu-like repeat region was verified by PCR using 50 ng of 
genomic DNA, a forward primer within intron 5 of CFHR3 
(5’GAAGTATTTAGAGTTCAAAC-3’) and a reverse primer within the Alu-like 
region (5’CTGCAGTCCGCAGTCCGGCCTG3’) and Ampli Taq Gold DNA 
polymerase (Thermo Fisher Scientific; 35 cycles of amplification: 95°C for 45 seconds, 
55°C for 30 seconds, 72°C for 35 seconds) according to the manufacture’s protocol.  
Purified PCR products were sequenced and analyzed as reported above. 
 
Gene Exon/Intron Primer sequences  (5’→3’) 
CFHR3 Intron 3 GGAGAGTCTCCTAGATCTGCAC 
CFHR3 Exon 4 GAAATTGAAAATGGATTCATTTCC 
CFHR3 Intron4 GCATGAGAGTATCAGCAAAATA 
CFHR3 Intron 4 AGCTGCTTGTATTGCATTCCG 
CFHR3 Intron 4 TTGAAAATGCAGATGTCTTCC 
CFHR3 Intron 5 AGGCCGAGGCAGGCAGACCAT 
CFHR3 Intron 5 CAAACTATTAAACCCTACTTGAAC 
CFHR3 Intron 5 AGTCTTAAATTTGATTGACTGA 
CFHR3 Intron 5 GAAGTATTTAGAGTTCAAAC 
CFHR4 Intron 9 AGTCTCAAATTTGATTGAATGG 
CFHR4 Intron 9 TAGGTATTAAGCCTAATT 
CFHR4 Intron 9 CATACACCTCAATATCTGTCAA 
CFHR4 Exon 10 ATGTCACTTTTTCCTTTTAACTG 
 
 
 
Table 18. Sequence primers used to identify the 
breakpoint of the CFHR31-5-CFHR410. 
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4.2.7 Western-Blot 
The molecular pattern of FH-FHRs was studied by Western Blot using serum/plasma 
(diluted 1:40 for FHRs and 1:80 for FH). Proteins were separated by 10-12% SDS-
PAGE (Mini-Protean TGX Precast Gels, BioRad), under non reducing conditions, and 
transferred by electroblotting to a PVDF membrane (Trans-Blot® Turbo™ Midi PVDF 
Transfer; Bio-Rad). The membranes were blocked in 4% skim milk and developed 
using FH/FHR antibodies (reported in Table 19) followed by horseradish peroxidase 
(HRP) conjugated secondary antibodies (Table 19) and ECL chemiluminescence 
detection system (Amersham).  
 
 
 
    
    
    
 
4.2.8  FHR quantitative Western Blot analysis 
Quantitative variations in FHR molecular pattern were confirmed by a quantitative WB 
analysis of FHRs bands using FH band as reference standard. Each membrane was cut 
Target protein Primary                        antibody 
Dilution Secondary antibody 
N-Term FHR1* αFHR1 mAb (JHD) 1:1000 HRP goat anti-mouse IgG (dil 1:5000; Thermo Fisher, Ref 62-6520) 
C-Term FHR2* αFHR2 mAb (A72) 1:1000 HRP goat anti-mouse IgG (dil 1:5000; Thermo Fisher, Ref 62-6520) 
FHR2° αFHR2 mAb(6F7) 1:300 HRP goat anti-mouse IgG (dil 1:5000; Thermo Fisher, Ref 62-6520) 
FHR1-2-5° FHR1-2-5 mAb (2C6) 1:1000 HRP goat anti-mouse IgG (dil 1:5000; Thermo Fisher, Ref 62-6520) 
FHR3* αFHR3 pAs 1:2000 HRP Goat Anti-Rabbit IgG (dil 1:30000; Vector Laboratories) 
FHR4* αFHR4 pAs 1:3000 HRP Goat Anti-Rabbit IgG (dil 1:30000; Vector Laboratories) 
FH αFH mAb (OX-23;                    
LS-C58560;LSBio) 
1:3000 HRP goat anti-mouse IgG (dil 1:5000; Thermo Fisher, Ref 62-6520) 
 
Table 19. List of antibodies used in Western Blot experiments. 
*kindly given from Prof. Zipfel; 
 °kindly given from Prof. DeCordoba. 
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in two parts; the upper part was incubated with the anti-FH Ab that detects a FH band at 
155 kDa; the lower part was incubated either with an anti-FHR3 Ab (that detects bands 
at 35-56 kDa) or an anti-FHR4A revealing a 86 kDa band. Each protein band intensity 
was calculated by densitometry using ImageJ (NIH). For patients we calculated the 
FHR3/FH and/or the FHR4/FH band intensity Ratios and compared them with the 
median FHR3/FH or FHR4/FH Ratios in a set of 5 plasma control samples (with normal 
CNVs and normal FH levels) analyzed in the same experiment, taken as 100%.  
 
4.2.9  AP convertase formation and C3 convertase decay. 
Microtiter wells were coated with purified C3b (5μg/ml; Complement Technology) in 
PBS by overnight incubation at 4°C, blocked with 1% bovine serum albumin (BSA), 
0.1% Tween20 in PBS for 1h at 37°C, and washed with a wash buffer (8.1 mM 
Na2HPO4, 1.8mM NaH2PO4, 0.1% Tween 20, 25mM NaCl) supplemented with 5mM 
MgCl2. C3 [C3bBb(Mg2+)] and C5 [C3bBbC3b(Mg2+)] convertase complexes were 
assembled by incubating C3b-coated wells at 37°C for 30 minutes with 20% normal 
human serum (NHS; a pool obtained from 15 healthy volunteers) or serum from a 
patient with DDD and the CFHR31-5-CFHR410 hybrid or serum from her unaffected 
sons, diluted in PBS containing 5mM MgCl2. After washes, the remaining C3 and C5 
convertase complexes were detached from wells by incubation with 10 mM EDTA and 
1% SDS for 1h at room temperature and analyzed by WB under reducing conditions 
(baseline). Convertase complexes were detected by Bb band (60kDa) with a goat anti-
FB antibody (Quidel; dilution 1:10000; incubation over night at 4°C), followed by 
HRP-conjugated anti-goat antibody (Vector Laboratories; dilution 1:10000; 1h at room 
temperature) and ECL chemiluminescence detection system (Amersham). In additional 
wells, formed C3 and C5 convertase complexes were then allowed to dissociate for a 
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further 60 min at 25°C in the absence (spontaneous decay) or in the presence of FH 
(FH-mediated decay; 60 µg/ml; Calbiochem, Meudon, France). After washing, 
convertase complexes were detached and analyzed as described above.  
 
4.2.10  Statistics 
Analyses to calculate odds ratios (OR) and 95% CI were performed with the MedCalc 
software. 
The control population used to calculate OR was represented by the 54 healthy Italian 
subjects recruited by the Italian Registry of MPGN and published data on healthy Italian 
population223 (n=103 total healthy controls).  
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4.3     Results 
4.3.1 Copy number variations (CNVs) 
4.3.1.1 Common CNVs 
Among 185 patients (IC-MPGN=86; DDD=26; C3GN=73) analyzed by MLPA (kit 
P236-A3), copy number variations (CNVs) of CFHR genes were found in 32% of them.  
As shown in Fig. 41, the common heterozygous deletion of CFHR3-CFHR1 (Het 
CFHR3-CFHR1∆; frequency in Italian healthy population: 33%223) was found in all 
histology groups whilst the same deletion in homozygosity (Hom CFHR3-CFHR1∆; 
frequency in Italian healthy population: 6%223) was found in patients with IC-MPGN 
(n=3) and in DDD (n=3) but not in patients with C3GN. No significant difference in the 
prevalence of the deletion was found between patients and controls (Table 20).  
In one C3GN patient the heterozygous CFHR3-CFHR1∆ was found in combination 
with the known deletion of CFHR1-CFHR4 (frequency in UK healthy population: 
1.8%226).  
 
 
  
Figure 41. Histogram representing CNVs in the three 
histology groups. 
Abnormalities in FH-FHR family 
 
 
127 
 
  
 
 
∆Het CFHR3-CFHR1 
 
 
OR 
 
 
95% Cl 
 
 
p value 
IC-MPGN n=86 27 0.93 0.50 - 1.71 0.81 
DDD n=26 5 0.48 0.17 - 1.40 0.18 
C3GN n=73 18 0.66 0.34 - 1.30 0.23 
Ctrs n=103 34 
   
       ∆Hom CFHR3-CFHR1 OR 95% Cl p value 
IC-MPGN n=86 3 0.89 0.19 - 4.11 0.89 
DDD n=26 3 3.23 0.68 - 15.43 0.14 
C3GN n=73 0 0.15 0.008 - 2.84 0.21 
Ctrs n=103 4 
   
       Other CFHR CNVs OR 95% Cl p value 
IC-MPGN n=86 1 1.20 0.074 - 19.5 0.90 
DDD n=26 2 8.50 0.74 - 97.66 0.09 
C3GN n=73 1 1.41 0.09 - 23.02 0.81 
Ctrs n=103 1 
    
 
 
 
 
 
 
 
 
 
 
Table 20. OR to carry common and uncommon copy number abnormalities in patients 
with IC-MPGN, DDD and C3GN vs. controls. 
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4.3.1.2 Uncommon CNVs in IC-MPGN and DDD 
In one IC-MPGN patient (#1726; also carrying the homozygous CFB LPV p.R649W, 
section 2.5.1.3) and in one DDD patient (#1549; also carrying the heterozygous CFH 
LPV, p.R2I, section 2.5.1.3), MLPA analysis showed one copy of CFHR3 while the 
other CFHRs showed normal copies. By a further analysis using homemade probes 
covering CFHR4 and CFHR5, I found three copies of CFHR4 in both patients (Fig.42). 
In detail, homemade probes on CFHR4 located in the intron 1, the intron 5 and the exon 
10 of CFHR4 allowing to conclude that the duplication involved the entire CFHR4 
gene. 
 
 
 
 
In Fig.43 is reported the pedigree (Family code #950) of the IC-MPGN patient (#1726) 
carrying the CFB variant and the CFHR4 duplication. Copy number variations studies 
in healthy subjects of the family indicated that the IC-MPGN patient carries 0 copy of  
Figure 42. Results of MLPA showing in the DDD patient #1549 and in IC-MPGN 
patient #1726,  the presence of one copy of CFHR3, two normal copies of CFHR1 and 
three copies of CFHR4 in both patients. 
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CFHR3, a copy of  CFHR1 and two copies of CFHR4 on the same allele (CFHR4-R1-
R4-R2-R5 allele).  I speculate that this allele may derive from a double rearrangement 
implying CFHR1-CFHR4 duplication and CFHR3-CFHR1 deletion. 
This allele is also present in other family members (Fig.43, III-5 and V-2) who also 
carry the CFB lpv p.R679W in heterozygosity.  
I hypothesize that the DDD patient (#1549) with one copy of CFHR3 and three copies 
of CFHR4, whose family members were not available, may have the same CFHR4-R1-
R4-R2-R5 allele. 
Besides the patients #1549 and #2026, I did not find additional patients with a MLPA 
pattern that might suggest the presence of the CFHR1-CFHR4 duplication. Two 
hundred twenty four healthy subjects were analyzed by mPCR (that amplifies the intron 
1 and exon 2 of CFHR4 and intron 3 of CFHR1 genes), and nobody resulted with more 
than 2 copies of CFHR4.  
However, the presence of CFHR4-R1-R4-R2-R5 allele may be hidden in individuals 
who, by MLPA analysis, showed one copy of both CFHR3 and CFHR1 and normal 
CFHR4 (compatible with the heterozygous CFHR3-CFHR1∆). Indeed, this MLPA 
pattern may also theoretically apply to individuals who carry the CFHR4-R1-R4-R2-R5 
allele and the CFHR1-CFHR4Δ rare deletion  (Fig.44) on the other allele , although the 
effect in term of gene copy number will appear be the same as in subjects with  the 
heterozygous CFHR3-CFHR1∆. 
Identification of the CFHR1-CFHR4dupl breakpoint and further studies to easily 
recognize the CFHR1-CFHR4dupl and to estimate its frequency in healthy population 
and in patients are required. 
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V-2 V-1 
IV-3 IV-2 
Figure 43. CNVs in the members of the family #950. The proband  (IV-2; #1726) who 
also carries a homozygous CFB LPV (p.R679W), has the same MLPA pattern of her 
father (III-5) characterized by 1 copy of CFHR3, 2 copies of CFHR1 and 3 copies of 
CFHR4. The patient’ son (V-2) carries the heterozygous CFHR4 duplication and also 
the homozygous deletion of CFHR3 and the heterozygous deletion of CFHR1. 
Altogether these data suggest that the duplication involves both CFHR1 and CFHR4 
and that a double rearrangement implying the CFHR1-CFHR4 duplication and the 
CFHR3-CFHR1∆ may be occurred. 
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Figure 44. Schematic representation of the hypothesized condition with a CFHR4-
R1-R4-R2-R5 allele (allele a) and the allele with CFHR1-CFHR4∆ (allele b). The 
MLPA pattern is the same observed in individuals with the heterozygous CFHR3-
CFHR1∆. 
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4.3.1.3 CFHR abnormalities in a DDD patient 
In one DDD patient (#1678) I found an uncommon deletion involving CFHR3 and 
CFHR1. 
Clinical history of the patient #1678 has been reported in section 3.4. Briefly, she 
received 3 kidney grafts. While on dialysis, before the third transplant, she had slight C3 
reduction (72.5 mg/dl; normal range: 90-180 mg/dl) and normal C4 and SC5-b9 levels. 
C3NeF and anti-factor H (FH) autoantibodies were absent.  
MLPA analysis was consistent with the absence of the CFHR1 genes. There was also 
evidence of only one copy of the CFHR3 gene. Notably, this single CFHR3 gene lacked 
exon 6 (Fig.45). MLPA analysis of the unaffected patient’s son (III-2; Fig.46) were 
consistent with one copy of CFHR1, one normal copy of CFHR3 and one CFHR3 gene 
missing exon 6 (Fig.45). 
 
 
 
 
Figure 45.  Results of MLPA showing the genomic deletion including 
CFHR3-exon 6 and the intron 3, intron 5 and exon 6 of CFHR1, found in 
patient #1678 (in red) and in her healthy son (in blue). 
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Genetic screening using the NGS diagnostic panel including 6 genes (CFH, C3, MCP, 
CFI, CFB and THBD) did not show any LPV. As previously reported (section 3.4), 
Targeted Sequencing using the wide CasCADE panel identified two heterozygous stop 
codons in the CFHR2 gene (p.Q211X, Exac European MAF: 8,55E-05; p.R254X, Exac 
European MAF: 9,23E-04). The two CFHR2 variants were not present in the unaffected 
patient’s son (III-2; Fig. 46) suggesting that the two stop codons in the CFHR2 gene 
were not on the allele carrying the exon 6-deleted CFHR3 gene.  
 
 
 
 
 
To establish whether the exon 6 deletion in the CFHR3 gene, also included the CFHR4 
gene, I performed a quantitative mPCR using primers located within intron 1 and exon 2 
of CFHR4 gene and intron 3 of the CFHR1 gene226. Results showed that both patient 
(II-1) and the unaffected son (III-2) have only one copy of intron 1 and exon 2 of 
Figure 46 . Pedigree of family #913 with genetic abnormalities. The proband (II-1; 
#1678) is indicated by the arrow. 
H = Hybrid gene CFHR3-CFHR4;  ∆ = Deletion CFHR3-CFHR1;  X = CFHR2 
p.Q211X; CFHR2 p.R254X. 
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CFHR4, indicating that the deletion also involves exon 1 and 2 of the CFHR4 gene (Fig. 
47).  
Sequencing reads obtained by NGS with the CasCADE  panel in the DNA from the 
patient (II-1; #1678) were aligned and quantified on the Integrative Genomics Viewer 
(IGV). There were no reads within exon 6 of the CFHR3 gene and within the CFHR1 
gene. In comparison to controls carrying two copies of CFHR3 and CFHR4 genes, reads 
in the patient (II-1; #1678) were 50% of normal from exon 1 to exon 8 of CFHR4 and 
normal (100 %) in exon 9 and exon 10 of the CFHR4 gene. 
Data obtained by MLPA, NGS and quantitative mPCR suggested that the patient (II-1; 
#1678) and her unaffected son (III-2; DNA code #2171), have an allele that contains a 
deletion of exon 6 of the CFHR3 gene, deletion of the whole CFHR1 gene and deletion 
of exons 1 to 8 of the CFHR4 gene. This data would predict the presence of a hybrid 
gene consisting of CFHR3 exons 1-5 and CFHR4 exons 9/10 (Fig.48).  
 
 
 
Figure 47.  Results of the quantitative multiplex PCR. 
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Since the sequence of exon 5 of the CFHR3 gene and the sequence of exon 9 of the  
 
Since the sequence of exon 5 of the CFHR3 and the sequence of exon 9 of CFHR4 gene 
differ by only a single nucleotide (Fig.49a), I had to exclude that reads containing the 
sequence of exon 5 of the CFHR3 gene had been mistakenly aligned to exon 9 of the 
CFHR4 gene or viceversa. Sanger sequencing of exon 5 of the CFHR3 gene in the 
patient identified three homozygous variants: c.721C>T; c.786A>T; c.796+22T>A. 
Among them, the variant c.721C>T (p.P241S) converts exon 5 of the CFHR3 gene into 
exon 9 of the CFHR4 gene (Fig.49a). However I excluded amplification of exon 9 of 
the CFHR4 gene since primers used to amplify exon 5 of the CFHR3 gene were specific 
for this exon since no amplification was obtained using DNA from individuals lacking 
CFHR3 (samples homozygous for the ∆CFHR3-CFHR1 alleles, Fig.49b). 
 
 
 
 
 
 
Figure 49. Panel a:  DNA sequence alignment between exon5-CFHR3  and exon 9-
CFHR4 that shows the high homology between the two exons. In red is indicated the 
only nucleotide that is different in the two sequences.  Panel b: Agarose gel image 
that shows no amplification for DNA with the homozygous ∆CFHR3-CFHR1 
confirming the primer specificity . 
 
 Figure 48.  Graphic representation summarizing data obtained by MLPA, NGS and 
quantitative mPCR. 
 
a b 
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Combined data from the above approaches revealed in the proband (II-1) the following: 
1) CFHR1: zero copies; 2) CFHR3: one copy which lacks exon 6; 3) CFHR4: one 
normal copy and one copy lacking exons 1 to 8 or 9 (Fig.50). These results indicate the 
formation of a CFHR3-CFHR4 hybrid gene that consisted of exon 1 to 5 of CFHR3 and 
most likely exon 9 or 10 of CFHR4.  
 
 
 
 
To define the extent of the deletion and the breakpoint, genomic DNA was amplified 
using a forward primer specific for the intron 3 of the CFHR3 gene together with a 
reverse primer located at the end of intron 9 of the CFHR4 gene (Fig.51a). Sanger 
sequencing showed a deletion extending from exon 6 of the CFHR3 gene to exon 9 of 
the CFHR4 gene. The breakpoint region was located between chr1:196,760,556 in 
intron 5 of CFHR3 and chr1: 196,886,396 in intron 9 of CFHR4 . Unexpectedly, within 
the breakpoint area I also found an insertion of 305 bp  (Fig. 51b). This sequence is not 
Figure 50.  Graphic representation of the 2 alleles in the DDD patient. On one allele the 
patient carries the deletion of  CFHR3-CFHR1 (ΔCFHR3-CFHR1) and the two CFHR2 
nonsense variants. On the other allele she carries the CFHR3-CFHR4 hybrid gene. 
Abnormalities in FH-FHR family 
 
 
137 
 
present in the reference sequence of either intron 5 of CFHR3 or intron 9 of CFHR4. 
However it is common in the genome. In particular, this sequence has a 100% of 
homology with two BAC clones (CH17-370K15 and CH17-86J21 on chromosome 1) 
and about 98-99 % of homology with several sequences scattered within the genome. 
 
 
 
Analysis of the sequence of CH17-370K15, indicated that it included the sequence of 
CFH, CFHR3 and CFHR1 with only minimal differences from the reference sequence. 
The BAC clone sequence of intron 5 of the CFHR3 gene showed minimal mismatches 
with the CFHR3 gene reference sequence. The BAC sequence matched the first part of 
the CFHR3 intron 5 sequence of CFHR31-5-CFHR410hybrid gene. This included the 
insertion of 305 bp, which is not present in the CFHR3 reference sequence. After the 
305bp insertion, the sequence of the CH17-370K15- BAC clone continues with the last 
part of intron 5 of CFHR3 gene and with exon 6 of CFHR3 (Fig.52a). In contrast, after 
the 305bp insertion, the sequence of the CFHR31-5-CFHR410hybrid gene continues with 
the intron 9 of the CFHR4 gene. 
The sequence of the 305 bp insertion looks similar (but with several mismatches) to the 
ones of two Alu repeats located in the first part of intron 5 of CFHR3 and of intron 9 of 
CFHR4 and in other introns of  CFHR genes (Fig.52b). My hypothesis is that the 305 
Figure 51. (a) Representation indicating the deleted exons in the CFHR31-5-
CFHR410hybrid gene. The arrows indicate primers used to amplify the CFHR31-5-
CFHR410 hybrid gene. (b) The CFHR31-5-CFHR410 hybrid gene with the breakpoint 
region including  the insertion of a 305bp sequence. 
 
Abnormalities in FH-FHR family 
 
 
138 
 
bp insertion may be present in intron 5 of normal controls and might predispose to 
rearrangments, similarly to previously reported effect of Alu repeats in other diseases229. 
By sequencing with specific primers,  I detected the 305 bp insertion in 2 healthy 
controls who have normal copies of the genes across the CFHR region. Therefore, the 
Alu-like insertion is not restricted to individuals with the CFHR31-5-CFHR410 hybrid 
gene. The same PCR done in a subject homozygous for the ΔCFHR3-CFHR1 did not 
give any product confirming that the Alu-like insertion is located in intron 5 of CFHR3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genetic studies in the other unaffected son of #1678 (Fig.46, III-1; DNA code #2589) 
subsequently recruited, revealed the presence of the CFHR31-5-CFHR410 hybrid gene 
a 
b 
Figure 52. Representation of CH17-370K15- BAC clone (panel a) and its sequence 
alignment with Alu sequences located in intron5 of CFHR3 and intron 9 of CFHR4 
(panel b). 
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but no missense variant in CFHR2.   
Among 290 patients with aHUS analyzed for CNVs by MLPA we identified four with 
the CFHR31-5-CFHR410 hybrid gene; three of them carries other complement 
abnormalities (Table 21) . The hybrid and breakpoint were confirmed by PCR and 
Sequencing.  
 
In all the four aHUS patients and the control with the CFHR31-5-CFHR410 hybrid gene 
we found the presence of the 305bp insertion. 
We genotyped all the carriers of the CFHR31-5-CFHR410 hybrid gene for a number of 
SNPs in CFH, CFHR1 and CFHR3  to establish the haplotype associated with the 
hybrid. 
As shown in Table 21, in all carriers the CFHR31-5-CFHR410 hybrid gene was 
associated with the H3 haplotype. 
 
 
 
 
Patient ID CNVs Haplotype
CFH
c1-331C>T
rs3753394
CFH
c.184G>A
Val62Ile
rs800292
CFH
c.1204T>C
Tyr402His
rs1061170
CFH
c.2016A>G
Gln672Gln
rs3753396
CFH
c.2237-543G>A
rs1410996
CFH
c.2808G>T
Glu936Asp
rs1065489
CFHR3
c1-90A>C
rs385390
CFHR3
c.1-53C>A
rs446868
CFHR3
c.721C>T
Pro241Ser
rs13867543
3
CFHR1
c.906G>T
Arg302Arg
rs4230
CFHR1
c.942A>T
Arg314Arg
rs414628
  305bp Insertion Notes
DDD patient (II-1)
hybrid CFHR3 1-5 -CFHR4 10 +    
ΔCFHR3-CFHR1
H4b T G T A A G del del del del del no
CFHR2 : p.Q211X + 
p.R254X
 H3 T G T G G T C A T del del yes
Healthy DDD 
patient'son (III-2)
hybrid CFHR3 1-5 -CFHR4 10 H2 C A T A A G A C C T T no
H3 T G T G G T C A T del del yes
UP003                           
(healthy subject)
hybrid CFHR3 1-5 -CFHR4 10 H3 T G T G G T C A T del del yes
H3 T G T G G T C A T T T no
aHUS patient_1 hybrid CFHR3 1-5 -CFHR4 10  H3 T G T G G T C A T del del yes C3 : p.D1115H
H7 T G T A G G A C C G A no
aHUS patient_2 hybrid CFHR3 1-5 -CFHR4 10  H3 T G T G G T C A T del del yes
H1 C G C A G G A C C G A no
aHUS patient_3
hybrid CFHR3-CFHR4+    
ΔCFHR3-CFHR1
H3 T G T G G T C A T del del yes FH autoantibodies
H4a C G T A A G del del del del del no
aHUS patient_4 hybrid CFHR3 1-5 -CFHR4 10  H3 T G T G G T C A T del del yes
C3 : p.I167F + 
p.L1434M
H1 C G C A G G A C C G A no
Table 21. List of subjects carrying the CFHR31-5-CFHR410 hybrid gene and the 
corresponding haplotype in the region of CFH-CFHR3. Some of them also carry 
additional complement abnormalities (see Notes). 
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We also analyzed 224 healthy controls and found one carrier of the CFHR31-5-CFHR410 
hybrid gene. This was rather unexpected since in the published description of the rare 
CFHR1-CFHR4 deletion (detected in 9/503 controls), the CFHR3 gene was intact in all 
subjects that carried this deletion, which would exclude the presence of carriers of the 
CFHR31-5-CFHR410 hybrid gene in this large control cohort226.  
4.3.2  The FHR31-4-FHR49 hybrid protein 
4.3.2.1  Protein studies on a DDD patient with multiple FHR abnormalities. 
To understand the effect of CFHR31-5-CFHR410 hybrid gene and the nonsense CFHR2 
likely deleterious variants at protein level, we performed Western blot (WB) 
experiments  by using a panel of antibodies against FHR proteins with the serum of the 
patient (Fig.46; II-1; #1678), her unaffected son (III-2; Fig.46) carrying the CFHR31-5-
CFHR410 hybrid gene but not the two nonsense CFHR2 variants, an healthy subject with 
two copies of CFHR3-CFHR1 (CTR038) and a DDD patient (#1135) with the 
homozygous CFHR3-CFHR1 deletion.  
WB experiments by using a monoclonal anti-human Factor H-Related 1 (FHR1) 
antibody, in non reducing conditions, confirmed that the DDDCFHR31-5-CFHR410  patient has 
a total deficiency of FHR1 (Fig.53). 
 
 
 
Figure 53. Western blot analysis of FHR1 confirmed the total FHR1 deficiency in the 
DDDCFHR31-5-CFHR410 patient. In the DDD patient’son the FHR1 bands appeared 
slightly weaker than in the healthy subject with normal CNVs. DDDΔCFHR3-CFHR1 
patient carries the homozygous ΔCFHR3-CFHR1 and represents the negative control. 
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Since the DDDCFHR31-5-CFHR410  patient carries two stop codons (p.Q211X and p.R254X) 
in one copy of CFHR2 gene, we expected to find a different FHR2 pattern on WB in 
comparison to the healthy control. However, using a monoclonal anti-human C-terminal 
FHR2 antibody (A72), the WB membrane showed similar FHR2 bands and intensity 
between the patient and the control (Fig.54a). WB using a different monoclonal FHR2 
antibody (6F7; Fig.54b) and an anti-human FHR1-FHR2-FHR5 antibody (2C6; 
Fig.54c), displayed FHR2 bands that appeared slightly weaker in the DDDCFHR31-5-
CFHR410  patient than in the healthy subject.  
 
 
 
 
WB by using a polyclonal anti-human FHR3 antibody (Fig.55) showed 3 bands in the 
DDDCFHR31-5-CFHR410 patient, corresponding to the different glycosylated variants of 
FHR3. These bands were absent in the negative control homozygous for the CFHR3-
CFHR1 deletion and notably were more intense in the DDDCFHR31-5-CFHR410 patient than 
in the healthy subject. Since the DDDCFHR31-5-CFHR410 patient carries the deletion of 
CFHR3-CFHR1 on one allele and the CFHR31-5-CFHR410 hybrid gene on the other 
allele, the only CFHR3 copy is the one involved in the hybrid gene. Thus the finding of 
specific FHR3 bands on WB indicates that the FHR31-4-FHR49 hybrid protein, which is 
Figure 54. Western blot analysis of FHR2 using anti-human C-
terminal FHR2 antibody (panel a), monoclonal FHR2 antibody 
(6F7;panel b) and an anti-human FHR1-FHR2-FHR5 antibody 
(2C6; panel c). 
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predicted to have a molecular weight and migration pattern almost identical to FHR3, is 
well secreted in the serum of the DDDCFHR31-5-CFHR410 patient. 
 
 
 
 
 
WB by using the polyclonal anti-human FHR4 antibody (Fig.56) showed a FHR4A 
band of similar molecular weight and intensity in the DDDCFHR31-5-CFHR410 patient as 
compared to the healthy subject. Instead, in the unaffected patient' son the FHR4A band 
is weaker compared to the other samples, even though he has the same CFHR4 copy 
number as the DDDCFHR31-5-CFHR410 mother. 
 
 
 
 
 
Figure 55. Western blot analysis of FHR3 showing that FHR31-4-FHR49 
hybrid protein is secreted in the serum of the DDDCFHR31-5-CFHR410 patient. 
Figure 56. Western blot analysis of FHR4. 
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4.3.2.2  Effect of DDDCFHR31-5-CFHR410 patient serum on C3 and C5 convertase formation 
and C3 convertase  decay. 
 
To understand whether the FHR31-4-FHR49  hybrid protein alone (present in the plasma 
of the DDDCFHR31-5-CFHR410 patient as well as in her unaffected sons) or its combination 
with the FHR2 abnormalities (present only in the DDDCFHR31-5-CFHR410 patient) could 
affect the formation and decay of the alternative pathway C3 and C5 convertase 
complexes, C3b- coated wells were incubated with NHS or DDDCFHR31-5-CFHR410 patient 
serum or serum from her unaffected sons. C3 [C3bBb(Mg2+)] and C5 
[C3bBbC3b(Mg2+)] convertase complexes, remaining on the wells after decay with 
buffer alone or added with FH (60 µg/ml), were analyzed by WB and the Bb was 
detected. As reported in Fig.57, Bb bands corresponding to the spontaneous decay were 
slightly more intense in the wells added with serum from DDDCFHR31-5-CFHR410 patient 
(Fig.57a, lane 5; Fig.57b, lane 5) and from her healthy sons (III-1: Fig.57a, lane 8; III-2: 
Fig.57b, lane 8) in comparison wells incubated with  NHS (Fig.57a, lane 2; Fig.57b, 
lane2). A weak C3/C5 convertase stabilization was also detected in the condition of FH-
mediated decay in the well with serum from the DDDCFHR31-5-CFHR410 patient (Fig.57a, 
lane 6; Fig.57b, lane 6) and from her sons (III-1: Fig.57a, lane 9; III-2: Fig.57b, lane 9) 
compared to NHS (Fig.57a, lane 3; Fig.57b, lane 3). 
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Figure 57. Microtiter wells coated with C3b, were incubated with NHS 
or DDDCFHR31-5-CFHR410 patient serum or serum from her unaffected sons 
(III-1, panel a; III-2, panel b). Spontaneous (decay +buffer; panel a: 
lanes 2, 5, 8) and FH-mediated decay (Decay+FH 60ug/ml; lanes 3, 6, 
9) were tested. C3/C5 convertase formation was detected as Bb band 
(60 kDa). 
a 
b 
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4.3.2.3 Future studies 
- Mass spectrometry studies have been planned to verify the exact FHR31-4-FHR49  
hybrid  protein sequence in the DDD patient.  
- To confirm the convertase stabilizing properties of the serum from carriers of the 
FHR31-4-FHR49 hybrid protein and establish whether the convertase stabilization 
described above includes C3 convertase or C5 convertase or both, the assay with 20% 
of serum on C3b-coated wells, will be repeated to analyze: 1) C3 convertase formation 
and decay by detection of C3b β-chain (75 kDa) and Bb (60 kDa) bands on WB at 
baseline and after different times of spontaneous and FH-mediated decay; 2) C5 
convertase activity by detection of C5b α'-chain (104 kDa) band on WB; 3) the terminal 
complement C5b-9 complex formation by detection of C6 (105 kDa) and C9 (66 kDa) 
bands on WB; 4) Binding of FHRs proteins to C3b by detection of corresponding bands 
on WB. 
- Serum samples from the DDD patient with the CFHR31-5-CFHR410 hybrid on one 
allele and the CFHR3-CFHR1 deletion on the other allele will be used for FHR31-4-
FHR49 hybrid protein purification and functional studies since this patient lacks normal 
FHR3 and is predicted to carry only the hybrid copy of FHR31-4-FHR49. 
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4.3.3  Likely pathogenic variants across CFH-CFHR gene cluster in DDD patients. 
In 17 DDD patients we sequenced CFHR genes using a wide NGS panel including 85 
genes of complement and coagulation pathways (CasCADE; results reported in Chapter 
3).  In addition, we used a new diagnostic NGS panel for the simultaneous sequencing 
of 15 complement genes, recently developed in our laboratory, to analyze 9 additional 
DDD patients. Sequencing data showed the presence of two likely pathogenetic variants 
in CFHR4 (p.E283K) and CFHR5 (p.H289D) in the patient #1773 (See section 3.4). A 
rare variant in CFHR5, tolerated by prediction softwares and with PHRED CADD score  
of 0.001 (p.I222T; ExAC MAF All: 4.9*10-5; Polyphen/Sift: benign/Tolerated), has 
been found in the patient #2162. Less rare variants, but with a deleterious software 
prediction, are the heterozygous variants identified in the patient #1742 (CFHR2: 
p.Y264C; ExAC MAF All: 0.014; Polyphen/Sift: probably damaging/deleterious; 
PHRED CADD score: 23.2) and in the patient #2507 (CFHR4: p.Q142L; ExAC MAF 
All: 0.002; Polyphen/Sift: probably damaging/tolerated; PHRED CADD score: 10.19 ).    
Since CFHR2 is not fully covered by the CasCADE and the new NGS complement 
panel, I also performed direct sequencing of the CFHR2 gene in 25 patients with DDD 
and found another patient (#1286) with the same p.Q211X and p.R254X nonsense 
variants as the index patient #1678 previously described (Section 3.4 and 4.3.1.3). The 
newly identified patient carries the CFHR3/CFHR1 deletion in homozygosity and, at 
variance with the index case, does not carry the CFHR3/R4 hybrid gene. Plasma/serum 
samples from this patient were not available to analyze FHR pattern on WB. 
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4.3.4 Circulating levels and molecular pattern of FH/FHR proteins in a cohort of 
DDD patients. 
Factor H levels were measured in 22 DDD patients (whose plasma or serum was 
available).  Only one patient (DNA code #1149; negative for CFH likely pathogenic 
variants) showed a slightly decreased level of FH (160 mg/L; normal range: 173-507 
mg/L).  All remaining patients showed normal FH levels ranging from 179 mg/L to 357 
mg/L.  
ELISA to detect circulating anti-FH autoantibodies in 23 DDD patients showed a high 
title (451 AU/ml) in a patient (DNA code#1837) who carries the homozygous CFHR3-
CFHR1 deletion. This patient was also positive for C3NeF. 
The molecular pattern of circulating FH/FHR proteins in our cohort of DDD patients 
was studied by WB experiments.  
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FHR1 
FHR1 circulates in plasma in two glycosylated forms: FHR1α at 37kDa and FHR1β at 
43 kDa. Results of WB analysis in 24 DDD patients (each identified by the specific 
DNA code) are reported in Fig. 58. 
 
  
 
 
 
WB results confirmed the total absence of FHR1 in all patients with the homozygous 
deletion of CFHR1 (Fig.58; #1837, panel a, lane 4;  #1135, panel a, lane 11; #1416, 
panel b, lane 7). Bands weaker than in the wt CTR 038 (with 2 copies of CFHR1), were 
evident in those patients with the heterozygous deletion of CFHR1 but notably also in 
samples from patients with DNA codes #1218 (Fig.58, panel a, lane 7) and #2162 
(Fig.58, panel a, lane 10) who have normal CFHR1 copies. In samples from patients 
Figure 58. Western blot analysis of FHR1 and table resuming CFHR1 copy number. 
 
a 
c 
b 
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with DNA codes #1101 and #2020 (with 2 copies of CFHR1) FHR1 bands were 
stronger than in the control and in the other DDD patients with normal CFHR1 copies. 
An abnormal band with an apparent molecular weight around 45kDa was evident in the 
patient #1742 (Fig.59, lane 7). The band was not present in healthy controls (Fig.59). 
                                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Same 
membrane at 
different 
exposures 
Figure 59.  The same membrane exposed for two different times to underline the 
abnormal band detected in patient #1742. All samples indicated with “DNA code 
CTR” are healthy controls with normal CNVs. 
 
Abnormalities in FH-FHR family 
 
 
150 
 
FHR2 
FHR2 has two glycosylated forms, FHR2 (at 24KDa) and FHR2α (at 28KDa). Results 
of WB analysis in 24 DDD patients are reported in Fig.60. Although the intensity of the 
two FHR2 bands on WB was very variable among plasma's patients, we did not observe 
any abnormal band. 
 
 
 
 
  
Figure 60. Western blot analysis of FHR2 and table resuming CFHR2 copy 
number. 
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FHR3 
In plasma, multiple variants of FHR3 (ranging from 35 to 56 kDa) are detected (Fig.61-
62). The polyclonal antibody we used to detect FHR3 (AbαFHR3) in 25 DDD patients 
also recognizes FHR4A (at 86 kDa), FH (at 155 kDa) and a band at low molecular 
mass, previously associated to FHR4B (about 40kDa)230.  
 
 
 
 
 
Same 
membrane at 
different 
exposures 
Figure 61. Western blot analysis of FHR3. 
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Figure 62. Western blot analysis of FHR3. 
 
a 
b 
 c 
FH-HSA complexes 
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DNA code  CNV CFHR3  Note  
CTR 038  2   
2198  1  ∆CFHR3-CFHR1 het  
1135  0  ∆CFHR3-CFHR1 hom  
1725  2   
1549  1  CFH : p.R2I + dupl CFHR4  
1218  2   
1101 *  2  CFH : p.R1210C  
923*  2  CFHR4 snp in homozygosity: p.G306E (rs10494745)  
633*  2   
   
1124  2   
1416  1  ∆CFHR3-CFHR1 het + ∆CFHR1-CFHR4 het  
2026  2   
2215  2   
2297  2  ∆CFHR1-CFHR4 het  
2301  2   
2388  2   
2507  1  ∆CFHR3-CFHR1 het + CFHR4: p.Q142L  
2109  2   
   
1773  2  CFHR4: p.E283K +  CFHR5: p.H289D  
2020  2   
1742  1  ∆CFHR3-CFHR1 het  +  CFHR2: p.Y264C  
1409  2   
1149  2   
1115  1  ∆CFHR3-CFHR1 het  
1837  0  ∆CFHR3-CFHR1 hom  
   
2162  2  CFHR5: p.I222T  
 
 
Table 22.  Table resuming CFHR3 copy number. 
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WB confirmed the total FHR3 deficiency for patients with DNA code #1135 (Fig.61, 
lane 2; Fig.62, panel a, lane 1) and #1837 (Fig.62, panel b, lane11) who have zero copy 
of CFHR3 (Table 22).  
Patient with DNA code #1773 (Fig. 62, panel b, lane 5) with 2 copies of CFHR3 
showed weaker FHR3 bands than the wt control (CTR 038), while for patients #633 
(Fig.61, lane 8; Fig.62, panel b, lane 4) and #1101 (Fig.61, lane 6; Fig.62, panel b, lane 
2 and panel c, lane 5) stronger than normal FHR3 bands were evident.  
In patient #1101, I observed an extra FH band at higher molecular weight, with an 
apparent molecular weight of 210 kDa, in the WB lane, and  FHR3 bands more intense 
than the control. This patient, who has a healthy identical unaffected twin (DNA code 
#1234), was analyzed by our in house NGS complement minipanel,  by CasCADE and 
by MLPA for CNVs: both the patient and the identical twin carry a heterozygous 
pathogenetic variant in CFH (p.R1210C), previously reported in aHUS patients and 
shown in functional studies to affect protein function231. The FH 1210C variant forms 
high-molecular-weight complexes with human serum albumin (HSA)232, which explains 
the extra FH band at higher molecular weight observed in patient #1101 and of his 
identical twin #1234 (Fig. 62, panel c, lanes 4 and 5, see arrow). 
At variance with patient #1101, his unaffected twin #1234 showed FHR3 bands of 
normal intensity (Fig.62 panel c, lane 4). To exclude that the high intensity observed for 
FHR3 bands in patient #1101 was related to the severe renal impairment (serum 
creatinine : 1.77 mg/dl ) that the patient had developed at the time of blood sampling, 
we analyzed additional samples collected on previous dates, including the one of July 
2009, when the patient had normal renal function (serum creatinine levels lower than 
1.1 mg/dl). All samples from patient #1101 showed stronger than normal FHR3 bands 
(Fig. 63), indicating that the high levels of FHR3 were not associated to kidney failure. 
Consistently, plasma from a patient with glomerulopathy with fibronectin deposits 
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(GFND) and renal impairment (creatinine levels of 2.52 mg/dl) showed normal intensity 
of FHR3 bands on WB (#720, Fig. 63,  lane 8). 
 
 
 
 
 
We observed interesting WB abnormalities in other patients. As reported in Fig.61 (lane 
7) and Fig. 62 (panel b and c, lane 3), patient #923 showed normal FHR3 bands but a 
weaker than normal band corresponding to the MW of FHR4A. He carries normal 
copies for CFHR4 but CFHR sequencing revealed that he has a homozygous Single 
Nucleotide Polymorphism in CFHR4 (SNP; rs10494745; p.G306E; 
MAF_All_Frequency from ExAC: 0.08), inherited from his heterozygous parents. The 
variant is predicted to be damaging by some computational prediction softwares (Sift: 
deleterious; polyphen2: possibly damaging; Mutation Taster: polymorphism; Gerp++: 
highly conserved; CADD: 22.7). Among 27 patients sequenced on CFHR4, we found 
that #923 is the only one carrying this SNP in homozygosity. WB analysis showed 
Figure 63. Plasma of #1101 from different data collections were analyzed on 
Western Blot in comparison to that from his identical healthy twin (#1234) and from 
a GFND patient with creatinine levels of 2.52 mg/dl (#720) and from healthy 
controls. 
Abnormalities in FH-FHR family 
 
 
156 
 
normal FHR4A band in the parents (Fig.62, panel c; #1866: father of 923; #1867: 
mother of 923) and confirmed a reduction of FHR4A in the patient, which was specific 
for FHR4A since it was not associated to a global reduction of FHRs.  
Abnormal bands at high molecular weight (above 100 kDa) appeared on WB of patients 
with DNA codes #1742 (Fig.62, panel b, lane 7), #2026 (Fig.62, panel a, lane 4; Fig.64, 
lane 6) and #2301 (Fig.62, panel a, lane 7; Fig. 64, lane 7). Although some healthy 
controls showed bands above 100 KDa of similar apparent molecular weight (MW) to 
that identified in #2301 and #1742, the molecular patterns of patient #2026 was very 
peculiar (Fig.64). 
Finally, in patient #2026 the band appearing at around 40KDa was very intense as 
compared with the ones in other patients and the controls (Fig.64, lane 6). 
 
 
 
 
 
 
 
Figure 64. Western blot analysis of 
FHR3 showing the weaker FHR4A band 
in patient #923 in comparison to healthy 
controls and the peculiar molecular 
pattern in patient #2026. 
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FHR4 
FHR4 has been described to circulate in plasma in two spliced variants, FHR4A 
(86kDa) and FHR4B (42kDa).  
Results of WB analysis in 24 DDD patients are shown in Fig.65 and Fig.66. 
 
 
 
 
 
  
DNA 
  
CNV CFHR4  Note  
CTR 
  
2  
 1149  2  
 
1742  2  ∆CFHR3-CFHR1 het  +  CFHR2: 
  1409  2  
 
2020  2  
 
2109  2  
 
2507 ° 2  ∆CFHR3-CFHR1 het + CFHR4: 
  1837  2  ∆CFHR3-CFHR1 hom  
° sample appeared like gel ; it could be underloaded  
1416  1  ∆CFHR3-CFHR1 het + ∆CFHR1-CFHR4 
  1124  2  
 
2026  2  
 
2215  2  
 
2388  2  
 
2297  1  ∆CFHR1-CFHR4 het  
2301  2  
 
1135  2  ∆CFHR3-CFHR1 hom  
Figure 65. Western blot analysis of FHR4 and table resuming CFHR4 copy 
number. 
 
 
 
a 
b 
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WB analysis using a polyclonal antibody αFHR4 (AbαFHR4) confirmed in patient #923 
the FHR4A partial deficiency observed with the AbαFHR3 antibody, and the normal 
FHR4 molecular pattern in his parents (Fig.66, panel b, lanes 6,7,8). 
Although multiple abnormal bands at high molecular mass were visible in the majority 
of patients, the molecular pattern of #1742 (Fig.65, upper panel, lane 3) , #2020 (Fig. 
65, upper panel, lane 5) and #1549 (Fig 66, panel a, lane 4) were peculiar and not 
comparable to those identified in the other DDD patients and in healthy controls 
(Fig.65, 66, 67). Genetic studies on patient #1549 showed a heterozygous likely 
Figure 66. Western blot analysis of FHR4 and table resuming CFHR4 copy number. 
*samples loaded in different western blot experiments. #1866 and #1867 are the 
parents of patient #923.  
 
a 
b 
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pathogenetic variant in CFH (p.R2I; see chapter 2.5.1.3) and a duplication of CFHR4 
that needs further investigation (see chapter 4.3.1.2). 
 
 
 
 
Jozsi et al. in 2005230 reported two transcript products of CFHR4: FHR4A with a 
mobility of 86 kDa on WB and FHR4B with a mobility of about 42kDa. As shown in 
figure 66, in the aHUS patient #H177, carrying the homozygous CFHR1-CFHR4 
deletion, the band at around 40kDa was detected on the WB with the AbαFHR4 
antibody, excluding that this band corresponds to FHR4B. These results suggest that the 
AbαFHR4 antibody recognizes another protein at low molecular weight that is not 
FHR4B and is likely the same recognized also by the AbαFHR3 antibody. This band 
was very strong in the patient #1101 (Fig. 66, panel a, lane 6; panel b, lane 4) and #2026 
(Fig.64, lane 6). 
 
 
  
Figure 67. Western blot analysis of FHR4 in healthy subjects and table resuming 
CFHR4 copy number. 
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FHR5 
In the FHR family, FHR5 is the longest protein with nine short consensus repeats 
(SCRs) and is present in plasma as a glycosylated protein of 62kDa. Results of WB 
analysis in 24 DDD patients are shown in Fig.68. 
 
 
 
 
 Figure 68. Western blot analysis of FHR5 and table resuming CFHR5 copy number. 
*samples loaded in different western blot experiments. 
 
a 
b 
c 
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The intensity of bands of FHR5 was very variable among plasma's patients. In detail, 
patients #1218, #633, #2162, #2297 and #1773 showed a weaker than normal FHR5 
band. The most clear-cut abnormality was the strongest FHR5 band in the WB of 
patient #1101 (Fig.68 panel a, lane 9). 
 
 
FH 
Factor H (FH) is a plasma glycoprotein with a molecular weight of 155kDa. In Fig.69 
are reported results of WB analysis in 25 DDD patients. 
  
 
 
 
 
 
b 
c d 
Figure 69. Western blot analysis of FH. 
 
 
FH-HSA complexes 
a 
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WB with a specific anti-FH antibody did not reveal any abnormal band with the 
exception of patient #1101 that showed two bands corresponding to the wild-type and 
mutant proteins (p.R1210C) (Fig.69, panel d, lane 2; Table 23). This data, already 
observed in WB with the anti-FHR3 antibody, was confirmed using plasma samples of 
#1101 from different data collection (Fig.70) 
 
 
 
 
 
A strong band around 40kDa already observed in #1101 and #2026 using AbαFHR3              
(Fig.62), was evident in the same patients also using the antibody that recognizes FH 
and the FH-like (FHL1) (Fig.69 , panels c and d) and represented the product of the 
alternative transcript derived from the CFH gene. 
These data indicate that the band with a mobility around 40kDa appearing on WB using 
AbαFH, AbαFHR3 and AbαFHR4 corresponded to FHL1 and not to FHR4B, as 
reported in literature230. 
Figure 70. Plasmas from #1101 taken on different data were analyzed in comparison 
to plasma from his identical healthy twin (#1234) and  from a GFND patient with 
creatinine levels of 2.52 mg/dl (#720). 
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4.3.4.1  Quantitative WB analysis. 
Among 25 DDD patients analyzed, 8 showed either FHR quantitative abnormalities or 
FHR abnormal bands (Table 24). To confirm quantitative variations (patients #633, 
#1101, #1218 and #1773; for #923 plasma/serum samples were no more available) we 
performed a quantitative WB analysis of FHRs bands using FH band as reference 
standard. Results showed 27% and 97% reduction of FHR4A/FH ratio in patients #1218 
and #1773, respectively (Fig.71). FHR3/FH reduction was 80% in patient #1218 and 
99% in patient #1773. In patients #633 and #1101 we observed 260% and 370% 
FHR3/FH intensity ratios in respect to control medians, respectively (Fig.72). 
 
 
 
 
 
Table 23. Tables resuming CFH copy number and FH circulating levels. 
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Patient Interpretation of WB results Genetic results 
#633 High FHR3 levels No LPVs; normal copy number. 
  #923* Decreased FHR4A levels No LPVs; normal copy number. 
#1101 All FHR proteins and FHL1 are 
overexpressed; presence of  FH wild-type and 
p.1210C mutant in plasma 
LPV: CFHp.R1210C; normal copy number. 
#1218 Global reduction of FHRs No LPVs; normal copy number. 
  
#1549* 
Multiple abnormal bands above 100KDa 
detectable by AbαFHR4 
- LPV: CFHp.R2I. 
- Duplication of CFHR4. 
 
 #1742 
Abnormal band around 40kDa detected by 
AbαFHR1; Multiple abnormal bands above 
100kDa detectable by AbαFHR3 and 
AbαFHR4  
- Variant: CFHR2: p.Y264C; 
- ∆CFHR3-CFHR1 het. 
 
 #1773 Global reduction of FHRs 
 
- LPVs: CFHR4:p.E283K;  CFHR5: p.H289D; 
- normal copy number. 
  
#2026* 
Multiple abnormal bands above 100kDa 
detectable by AbαFHR3; Peculiar intense 
expression of FHL1 
No LPVs; normal copy number. 
Table 24. DDD samples with an abnormal molecular pattern identified by WB. 
*Samples included in the pilot study of SMRT (see next section) 
Figure 71. Western  blot to quantify FHR4 variations.  The membrane 
was cut in two parts: the upper part was incubated with the anti-FH Ab to  
detects the FH (155 kDa) while the lower part was incubated with an 
anti-FHR4A to reveal the FHR4 (86 kDa). In patient #1101 is evident the 
band corresponding to FH 1210C, already described in section 4.6. 
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4.3.5 Prospective Studies 
To identify genetic basis of the above reported abnormalities, we chose the emerging 
technique of Single Molecule Real Time sequencing (SMRT) sequencing. This new 
technique uses long-read sequencing and can be coupled with target enrichment capture 
methods to study genomic regions of interest to discover variants, gene isoforms and 
structural variations233. On this basis, we decided to use this strategy to study the 
complex genomic region of chromosome 1 spanning CFH and the 5 CFHR genes. To 
test the quality and depth of PacBio sequencing, we designed a pilot study selecting 5 
samples to be sequenced on Sequel system, the most powerful platform for SMRT 
sequencing (output 4-7 Gb per run). The 5 selected samples include 3 patients (#923, 
#1549 and #2026, Table 24) with an abnormal molecular pattern on WB, a healthy 
subject with no CNVs in CFH/CFHRs (CTR038; negative control in the pilot study) 
and a DDD patient with the hybrid gene CFHR31-5-CFHR410 (#1678; positive control). 
We designed probes targeting CFH-CFHRs on the human genome reference hg19 using 
the online Nimble Design Software. 2 μg of genomic DNA, fragmented at 7-8 Kb and 
Figure 72. Western  blot to quantify FHR3 variations. The membrane was exposed 
twice to clearly reveal the FH (at first exposure) and FHR3 (at the second exposure). 
Abnormalities in FH-FHR family 
 
 
166 
 
processed following standard manufacturer's procedures, will be sequenced using the 
Sequel system (output 4-7 Gb).  
SMRT Library preparation and Sequencing are ongoing at a Certified Service Provider 
(Norwegian Sequencing Centre, Oslo University).  
We expect that the pilot study will document that SMRT with PacBio sequencing is 
capable to correctly detect the CFHR31-5-CFHR410 hybrid and the corresponding 
breakpoint in the positive control, and will be successful in disclosing the genomic 
abnormalities in test DDD patients  #923, #1549 and #2026. The pilot study will also 
allow determining the maximum number of patients that can be successfully sequenced 
in each run. 
Results of the pilot study will be the basis to sequence by SMRT with PacBio the other 
DDD patients with the abnormal molecular pattern reported in Table 24, namely 
patients #633, #1101, #1218, #1742 and #1773. 
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4.3.6 Discussion 
In this study I analyzed CFH-CFHR copy number variations in an Italian cohort of 
patients with IC-MPGN, DDD and C3GN diagnosis. I found that the frequency of 
CFHR3-CFHR1 deletion (CFHR3-CFHR1∆) was similar in IC-MPGN, DDD and 
C3GN and was not different from that observed in Italian healthy controls.  
However, I found two new rearrangements in the CFH-CFHR genomic region both in 
patients with DDD and IC-MPGN. Both rearrangements involve the CFHR4 gene.  
The first one is an uncommon duplication of the CFHR4 gene that was identified in a 
DDD patient (#1549) and in an IC-MPGN patient (#1726), carrying a CFH and a CFB 
likely pathogenic variants (LPVs), respectively. Copy number analysis in the family 
members of the IC-MPGN patient supported the presence of the CFHR4 duplicated 
gene in the allele carrying zero copy of CFHR3, and a copy of CFHR1 suggesting that a 
double rearrangement involving CFHR1-CFHR4 duplication and CFHR3-CFHR1 
deletion may be occurred. 
Although the CFHR1-CFHR4 duplication (CFHR1-CFHR4dupl) was not previously 
described in literature, data regarding the duplication of CFHR1 in patients with aHUS 
and in healthy controls were reported226, 234 suggesting that further studies involving 
also CFHR4 (not commonly analyzed) and the breakpoint localization of CFHR1-
CFHR4dupl are required to establish its frequency in aHUS and in healthy controls. The 
patient #1726 also carries a homozygous LPV in CFB (p.R679W). Although I 
hypothesize that the abnormal FB generates strong AP C3 convertases hardly 
inactivated by complement regulators, functional studies are necessary to understand the 
effect of the CFB LPV and CFHR1-CFHR4dupl and whether these abnormalities may 
synergize in inducing to AP complement hyperactivation. 
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The other rearrangement was represented by the CFHR31-5-CFHR410 hybrid gene, 
identified in a DDD patient (#1678), with slightly reduced C3 levels. The same hybrid 
gene was found in her healthy sons and also in four patients with aHUS, three of them 
with other complement abnormalities.  
An insertion of 305 bp located in intron 5 of CFHR3 was found in linkage with the 
CFHR31-5-CFHR410 hybrid gene. However, the insertion (here called Alu-like region 
because of its sequence similarity with Alu repeat sequences located in CFHR3 and 
CFHR4) was also found in some individuals without the CFHR31-5-CFHR410 hybrid 
gene suggesting that the insertion fixed in a peculiar genome haplotype ancestrally 
before the formation of the hybrid. I hypothesize that the Alu-like region 
might predispose to genomic rearrangements, similarly to previously reported data for 
Alu repeats in other genetic diseases229.  
Western Blot (WB) experiments document that the FHR31-4-FHR49 hybrid protein is 
produced and secreted in the serum of the DDDCFHR31-5-CFHR410 patient and her 
unaffected son. Hebecker and Jozsi showed that FHR4 protein serves as platform to 
assembly the AP C3 convertase through its C-terminal region which contains the C3b 
binding sites235. In addition,  SCR1-3 of  FHR3 show a high sequence similarity with 
the FH domains (SCR6-8) involved in the binding to heparin and other surface ligands9. 
On these basis, the hypothesis is that FHR31-4-FHR49 hybrid protein through its N-
terminal domains (deriving from SCR1-3 of FHR3) binds to heparin, 
glycosaminoglycans, sialic acid molecules on cell surfaces and the glomerular basement 
membrane (GBM) while through its C-terminal domain (deriving from SCR9 of FHR4) 
binds C3b fragments and favors the activation of the AP C3 convertase.  
However, the CFHR31-5-CFHR410 hybrid gene may not be the main responsible of 
DDD in the patient #1678. Indeed, the DDD patient with the FHR31-4-FHR49 hybrid 
protein has a general deficiency of FHR proteins: 1) a reduced FHR2 protein (caused by 
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p.Q211X variant) 2) total deficiency of FHR1; 3) a FHR3 involved in a novel hybrid 
protein with FHR4. Since FHRs are circulating proteins, the abnormalities in this patient 
could not be corrected by kidney transplant, which is consistent with the clinical history 
of the patient who manifested relapsing disease in two kidney grafts. Although further 
studies are necessary to understand the effect of the FHR abnormalities identified in the 
DDD patient #1678,  the data obtained from this study suggest that the CFHR31-5-
CFHR410 hybrid gene may be present in patients with other genetic or acquired factors 
and that the specific combination of the hybrid gene with other complement 
abnormalities may determine the disease phenotype resulting in aHUS or DDD.   
The study of the FH/FHRs molecular pattern in DDD patients allowed identifying FHR 
abnormalities in 30% of them. Among them, only the patient #1549 showed abnormal 
copy numbers (represented by CFHR1-CFHR4dupl described above) identified by 
MLPA, which may explain the abnormal bands observed in the WB analysis. DDD 
patients with a unexplained abnormal FHR molecular pattern on WB have been selected 
for deep sequencing of the entire CFH-CFHR genomic region by a new technique 
(Single Molecule Real-time sequencing, SMRT) that uses a DNA sequencing long-read 
approach thus overcoming the problem of read-mapping ambiguity of this genomic 
region. Bioinformatic analyses are still ongoing. I expect to identify new 
rearrangements and or new intronic and intergenic variants accounting for expression of 
the altered proteins. The combined molecular and genetic approach may represent a 
valuable tool to discover and characterize at genetic and protein levels new 
abnormalities in the FH-FHR proteins. Results will deepen the knowledge on the 
pathogenetic mechanisms underlying DDD and may contribute to identify new 
molecular targets for complement inhibitory therapies.
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5. CONCLUSIONS 
In the past decade new insights in the pathogenic mechanisms have changed our 
understanding and the classification of membranoproliferative glomerulonephritis 
(MPGN). The current classification distinguishes C3 Glomerulopathy (C3G), including 
Dense Deposit Disease (DDD) and C3 glomerulonephritis (C3GN), characterized by 
strong glomerular C3 deposition, from immune-complex-mediated MPGN (IC-MPGN), 
characterized by a predominant deposition of immune-complexes. 
In this thesis, a well characterized Italian cohort of patients with IC-MPGN, DDD and 
C3GN was studied (Chapter 2). Genetic and biochemical data obtained from this study 
were correlated with histological features, complement profile, clinical phenotype and 
outcome to examine the pathogenetic mechanisms underlying these glomerular 
diseases. About 75% of patients showed low C3 and normal C4, indicating an activation 
of the alternative pathway (AP) of complement. Likely pathogenetic variants (LPVs) in 
C3, CFB, CFH, CFI and CD46 genes were present both in IC-MPGN and C3G patients. 
In patients with C3G we also identified two LPVs in the THBD gene. These variants 
were previously described in patients with atypical haemolytic uremic syndrome 
(aHUS) and in vitro functional studies showed that the mutant THBD proteins impaired 
complement regulation through FI-mediated C3b inactivation22 supporting their 
involvement in the pathogenesis of C3G. However, complement LPVs carriers ranged 
only from 15 to 24% across the three histological groups. Biochemical studies revealed 
that C3NeF, identified in 40% of IC-MPGN and C3GN patients and in 79% of patients 
with DDD, is associated with low C3 levels in all three histology groups. Our study on 
complement profiles suggested two different mechanisms. C3NeF mainly affected the 
C3 convertase in patients with DDD, whereas it appeared to act predominantly on 
terminal pathway in patients with IC-MPGN and C3GN.  
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However, this study did not disclose genetic or acquired abnormalities in 17% of DDD 
patients although they showed low circulating C3 levels, suggesting that other 
abnormalities in unknown factors are involved in AP complement regulation in patients 
with DDD.   
Another important finding from this study is the evident involvement of AP 
dysregulation in patients with IC-MPGN, as documented by low C3 and normal C4 (in 
70% of patients) and the presence of complement LPVs and/or C3NeF (in 49% of 
patients). These data are not consistent with the current MPGN classification that 
considers the IC-MPGN mediated by the activation of the complement classical 
pathway and indicate that further studies were needed to better classify patients on the 
basis of the underlying pathogenetic mechanisms185.   
 
The risk to develop end stage renal disease (ESRD) was similar among the three 
histology groups. However, patients without genetic and or acquired abnormalities 
showed a higher risk to develop ESRD in comparison to those patients carrying LPVs 
and or C3NeF indicating that another mechanism is also involved in the progression of 
renal disease in IC-MPGN/C3G patients. 
 
To make a step forward into the classification of IC-MPGN and C3G patients based on 
pathophysiologic mechanisms, five parameters (presence of LPVs, presence of C3NeF, 
serum C3≤50mg/dl, serum C3> 50 & <90 mg/dl, presence of intramembranous highly 
electron-dense deposits) were used to create a three-step algorithm2 that was used to 
classify patients from our Italian cohort of IC-MPGN/C3G patients. The analysis 
divided patients with abnormal AP complement profile and carrying genetic and/or 
acquired abnormalities (cluster 1-3) from patients with normal complement profile and 
low frequency of LPVs and or C3NeF (cluster 4).  Cluster 1 and 2 were characterized 
Conclusions 
 
 
173 
 
by very high SC5b-9 levels suggesting a strong complement activation until the 
terminal pathway. Notably, cluster 2, mainly composed by IC-MPGN patients and few 
C3GN patients, was also characterized by strong deposition of IgG, IgM and C1q and 
abnormal C4 levels (24%) suggesting also an involvement of the classical pathway.  
Cluster 3 included all DDD patients and few IC-MPGN patients, showing low serum C3 
and normal or mildly increased plasma SC5b-9 levels indicating a prevalent activation 
of the C3 convertase in fluid-phase. 
Cluster 4 is different from the others 3 groups because of the normal complement 
profile and the low prevalence of genetic and acquired complement abnormalities. The 
strong glomerular C3 deposition, the normal complement profile and the development 
of thrombotic microangiopathy in 11% of them suggest the presence of unknown 
factors that cause local glomerular activation in subgroups of IC-MPGN and C3GN 
patients.  
Cluster analysis confirmed our published data and separated patients with fluid-phase 
complement activation from patients with solid-phase complement activation. Among 
patients with AP activation in fluid phase, cluster analysis allowing us to identify 
distinct pathogenetic patterns separating patients with terminal complement activation 
from patients with a predominant C3 convertase activity. 
 
The above mentioned study evidenced that: 
 - The majority of C3GN patients and some IC-MPGN patients are characterized by 
fluid phase complement activation of the terminal pathway (complement LPVs and/or 
C3NeFs are often present).  
 - The majority of IC-MPGN and few C3GN patients are characterized by the activation 
of both alternative and classical pathways (complement LPVs and/or C3NeFs are often 
present) 
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- A consistent number of patients with IC-MPGN and C3GN are characterized by a 
local glomerular activation (in absence of known complement LPVs and/or C3NeFs); 
-  Few IC-MPGN patients are characterized by fluid phase complement activation 
predominantly at C3 convertase level; 
 - The majority of DDD patients are characterized by fluid phase complement activation 
predominantly at C3 convertase level, usually in association with the presence of 
C3NeFs; 
-  Some DDD patients are characterized by fluid phase complement activation 
predominantly at C3 convertase level because of the presence of unknown genetic and 
or acquired factors. 
 
In order to identify new genetic abnormalities, 17 of 26 DDD patients included in this 
study were analyzed by a wide NGS panel including 85 complement and coagulation 
genes (Chapter 3). Although likely deleterious variants in new complement genes (like 
PTX3, ITGAM, C4BPA, C5aR1, C5aR2 and others) were identified in combination with 
one or two additional complement variants,  the most interesting finding was 
represented by the 60% of variants in complement regulators/activators genes, including 
CFH and CFHR genes, that require further investigation. 
 
The study of CFH-CFHR family in patients from our cohort (Chapter 4) revealed the 
presence of unknown copy number abnormalities involving the CFHR4 gene both in 
C3G and IC-MPGN patients. Although functional studies are necessary to understand 
their functional effects, these data suggest that analysis of copy number variations 
(CNVs) in CFH-CFHR genes should also be extended to patients with IC-MPGN. 
Furthermore, the CFHR4 gene, not commonly analyzed, should be included in the study 
of CFH-CFHR CNVs.  
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In addition Western Blot study in DDD patients disclosed abnormal molecular patterns 
of FHRs in patients with normal CNVs.  Since the homologies within CFH-CFHRs 
represent a strong limitation for both the read alignment step in NGS techniques that 
produce reads of few hundred base pairs, and for designing probes for CNV techniques, 
we planned a combined genetic and molecular approach to disclose new abnormalities 
in the FH-FHR family. Indeed, patients with abnormal molecular pattern and normal 
CNV were selected to be analyzed by Single Molecule Real Time (SMRT), a new 
sequencing technique based on long-read sequencing. We expect that this new 
technique, coupled with target enrichment capture method, will enable us to avoid the 
problem of read-mapping ambiguity of the CFH-CFHR region, and will disclose new 
genomic rearrangements or intronic/intergenic variants accounting the abnormal 
molecular pattern observed in patients with DDD. 
Altogether the above reported data indicate that: 
- functional studies are required to understand the effect of C3, CFB, CFH, CFI LPVs 
identified in our cohort on complement activation; 
- we have to verify whether autoantibodies here identified as C3NeFs, also include other 
nephritic factors (C4NeF or C5NeF);  
- the presence of other acquired factors (anti-factor H, anti-factor B autoantibodies) in 
all patients should be verifed; 
-  genetic studies in other cohorts of  DDD patients are required to confirm the 
involvement of new identified complement genes (PTX3, ITGAM, C4BPA, C5aR1, 
C5aR2 and others); 
- functional studies on CFHR variants identified in patients with DDD are required to 
understand their role in the pathogenesis of disease; 
- genetic abnormalities in new complement genes (Exome Sequencing) should be 
searched. 
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In summary, in this study the correlation of genetic and biochemical abnormalities with 
clinical and histological parameters allowed us to deepen the knowledge on the 
pathogenetic mechanisms underlying IC-MPGN, DDD and C3G that may contribute to 
identify new molecular targets for complement inhibitory therapies. 
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